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Cancer is one of the leading causes of mortality and morbidity in the Western world. The 
anguish caused by cancer is exacerbated by current chemotherapeutic treatments as severe 
adverse effects can be caused by off-target cytotoxicity against some healthy tissues. This limits 
the patients these drugs can be used in and importantly the doses that can be used, impacting 
on therapeutic efficacy. Therefore, tumour specific delivery of cytotoxic agents by 
environmentally sensitive nanoparticles to minimise off-target effects may be an effective 
strategy. 
 
Another approach to treat cancer would be to utilise a patient’s immune system to more 
naturally treat cancer. However such immunotherapies have struggled to produce effective 
results as a comprehensive review of cancer vaccines demonstrated an overall response rate (as 
defined as the shrinkage of the tumour) of 3.6% (1). One of the challenges with cancer vaccines 
is the inefficient and ill-defined process of ‘cross-presentation’ which occurs rarely in antigen 
presenting cells. As cross-presentation is involved in the production of anti-cancer cytotoxic T 
cell responses, the delivery of antigen directly to the cytoplasm to bypass cross-presentation 
has been suggested as a strategy to improve vaccine efficacy. 
 
Two strategies and nanoparticle formulations were investigated in this thesis where the release 
of therapeutic agents in acidic conditions was desired. In the first strategy, a formulation of pH 
responsive polymeric nanoparticles using PDMS-b-PDMAEMA was examined. This polymer 
was previously reported by Car et al. (2) due to the pH dependent ionisation of PDMAEMA. 
This ionisation is hypothesised to destabilise the nanoparticle in acidic conditions to release 
ii 
 
loaded chemotherapy agents, such as doxorubicin (DOX), in the acidic tumour 
microenvironment for tumour specific DOX release. 
 
Secondly, liposomes modified with polyethyleneimine (PEI) and cyclodextrin based ion 
channels were developed. PEI confers pH responsive release from liposomes due to the ‘proton 
sponge effect’. The effect occurs when liposomes are internalised within the acidic endosomes 
of cells, and the buffering effect of PEI leads to an increase in counterion concentration within 
the liposomes and endosomes. This increase in ion concentration results in osmotic lysis of 
endosomes and liposomes resulting in release of actives into the cytoplasm. Cyclodextrin ion 
channels, previously reported by Chui et al. (3), were included in the formulation to facilitate 
the movement of ions across the liposomal membrane to allow the effect to occur. Delivery of 
DOX and an immunotherapeutic vaccine combined with an immunostimulant, 5,6-
dimethylxanthenone-4-acetic acid (DMXAA) was examined.  
 
Both types of nanoparticles were produced by the thin film hydration method. Uptake and 
release in vitro was determined using a light scattering based assay. Cell culture with murine 
melanoma cells and an in vivo murine melanoma model were utilised to assess biological 
activity. 
 
PDMS-b-PDMAEMA nanoparticles demonstrated enhanced DOX release in acidic endosomal 
conditions. However, it was found to be incompatible with the model protein OVA preventing 
its use in vaccines. Whereas, modified liposomes demonstrated acid specific lysis which was 
then associated with improved cytoplasmic delivery in dendritic cells. In vitro dendritic cell 
stimulation, T cell proliferation assays, and an in vivo murine melanoma experiment established 
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The simplest definition of cancer is: a group of diseases categorised by the uncontrolled 
division of cells. The difficulty of treating cancer is reflected by the etymology of the term 
‘cancer’ as it is derived from the Latin word for ‘crab’, as tumours behave similarly to the 
tenacious grip of a crab (4). The effect of cancer in modern society is still felt today, as cancer 
was responsible for approximately 1 in 3 deaths in New Zealand in 2014 and was therefore one 




The uncontrolled growth of malignant cells is responsible for the high mortality rate of cancer 
(6). These malignant cells may metastasise into healthy organs, which are commonly the bones, 
lungs, non-draining lymph nodes, liver, and pleura (7). A combination of theories explains the 
formation of metastatic sites. Firstly, the vasculature of the organ may trap metastatic cells in 
circulation. The pulmonary circulation most effectively demonstrates this concept as 
pulmonary capillaries narrow to 4 µm which may trap tumour cells that are 20 µm in diameter 
(8).  Another theory to explain the non-random distribution of metastasis is referred to as 
Paget’s ‘soil and seed’ theory where the tissue (the soil) must be conducive to the growth of 
metastatic cells (the seeds). The bone is a good example of this theory due to the high 
concentration of growth factors in addition to the hypoxic and acidic environment that is 
favourable for tumour growth (9). Historically, these theories have been presented as 
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The aetiology of cancer is complex as genetic and environmental factors are responsible for the 
conversion of healthy cells into malignant cells. Due to high public interest, many factors 
responsible for carcinogenesis have been identified and publicised. For example, the link 
between processed meat products and colorectal cancer (Risk Ratio of 1.23) (10). Thus, only 
the most pertinent factors will be discussed in this section (Figure 1.1.1). 
 
 
Figure 1.1.1: Factors which contribute to the aetiology of cancer 
1.1.2.1 Genetic factors 
 
Genes pertaining to the aetiology of cancer may be divided into oncogenes and tumour 
suppressor genes. The activation of oncogenes is associated with the proliferation of tumours, 
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while growth is opposed by tumour suppressor genes. Thus, mutations in these genes caused 
by hereditary or environmental factors is associated with cancer (11). 
 
Oncogenes may originate from proto-oncogenes found in healthy cells where the expression of 
the gene is normally tightly regulated. One example is the expression of growth factor receptors 
for tissue maintenance. A proto-oncogene becomes an oncogene once its expression is greatly 
increased. For example, HER2 is an epithelial growth factor receptor which is frequently 
overexpressed in breast cancer (12). Due to this prevalence, anti-HER2 antibodies 
(trastuzumab) are effective in limiting the growth of HER2 positive cancers in clinical settings 
(13). 
 
Tumour suppressor genes are responsible for the repair, senescence, or apoptosis of damaged 
cells. The key suppressive proteins that have been identified are p53, Bcl2, Bax, and 
cytochrome c (cyt c) (14). The master regulator of the intrinsic tumour suppressors is p53 and 
its synthesis and degradation is tightly controlled in cells. In healthy cells, the activity of p53 
is limited by Mdm2, which binds to and assists with the degradation of p53 (15). However, 
once DNA damage is detected by genotoxic sensors such as ATM kinase, p53 is phosphorylated 
reducing its degradation and increasing its activity (16). High p53 activity results in the 
activation of DNA repair pathways and the expression of cell cycle arresting proteins such as 
p21 to prevent the proliferation of damaged cells (17). 
 
In addition to the pro-repair and anti-proliferative effects of p53, the expression of Bax is 
increased by p53. Bax, in conjunction with Bcl2 and cyt c, is responsible for inducing apoptosis 
in damaged cells. The ratio of Bax to Bcl2 controls the permeability of the mitochondrial 
membrane, and in healthy cells with high Bcl2 expression the cyt c is safely sequestered within 
4 
 
mitochondria. However, in damaged cells where p53 expression is elevated, the Bax/Bcl2 ratio 
becomes skewed towards Bax resulting in increased mitochondrial permeability, allowing cyt 
c release to trigger apoptosis (18, 19). 
 
1.1.2.2 Environmental factors 
 
Many oncogenic environmental factors (also termed carcinogens), have been identified. 
However, they may be simplified into three broad categories: biological, chemical and physical 
carcinogens. Despite their differences many carcinogens share a common mechanism of action 
through damage or alterations to DNA. This is due to the potential of inactivating tumour 




Biological carcinogens are pathological processes which result in cancer. This may occur due 
to direct changes to DNA by viruses, where the insertion of the viral genome into the host’s 
genome may introduce oncogenes or inactivate suppressor genes. For example, infection with 
the Human Papilloma Virus (HPV) leads to the production of a viral protein, E6, which binds 
to and inactivates p53. Therefore, HPV infection is a high risk factor for cervical cancer (21). 
 
In contrast to direct changes in host DNA, other viruses such as Hepatitis C (22), or non-
pathogenic conditions such as gastric reflux (23) may cause chronic tissue damage and 
inflammation. The chronic inflammation is associated with oncogenic effects such as increased 
production of reactive oxygen species (ROS) to damage DNA. Additionally, the secretion of 






Many compounds have been identified that can damage DNA and contribute towards 
oncogenesis. Chemical carcinogens are capable of inflicting direct or indirect DNA damage. 
For example, methylcholanthrene (MCA) has been utilised to induce tumours in rodent models. 
The binding of MCA to the aryl hydrocarbon receptor induces CYP1A1, which causes ROS 
production with subsequent DNA damage and oncogenesis (25). 
 
Interestingly, a distinction may be drawn between carcinogens and mutagens. Mutagens are 
compounds capable of inducing mutations, but not all mutagens are carcinogenic and vice 
versa. Zeiger (26) explains this discrepancy is primarily due to the differences in screening 
models where mutagenicity is screened using strains of Salmonella, which may not share the 
same biochemical pathways as eukaryotes. Therefore, the generation of carcinogenic products 
may be different. However, Zeiger emphasises that in the majority of cases, mutagens are 




Lastly, physical factors are primarily attributed to the action of high energy waves or particles. 
Ionising radiation, such as X-rays, and non-ionising radiation, such as lower energy UV 
radiation may cause direct damage to DNA (27). For example, exposure to UV radiation causes 
a photochemical reaction between thymine bases to form dimers to alter the structure of the 
double stranded helix (28). The carcinogenic effect of UV is demonstrated most clearly in 
countries such as New Zealand as the rate of melanoma is disproportionally high in contrast to 
the rest of the world (29). This may be attributed to the depletion of UV-absorbing ozone from 
the atmosphere in the southern hemisphere (30). 
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 Current chemotherapy 
 
Chemotherapy is one of the main modes of treatment currently available, alongside surgery and 
radiotherapy. While the latter two treatments are effective in the removal of detectable tumours, 
chemotherapy is effective as an additional therapy to target metastatic sites to improve survival 
(31). Despite the existence of many classes of chemotherapeutic agents, a common mechanism 
of action is to prevent the replication of cells. Examples include the inhibition of the 
cytoskeleton with vinca alkaloids (32), prevention of DNA replication with false metabolites 
(33), or damage to DNA by alkylating agents (34). 
 
The earliest form of cancer chemotherapy was derived from nefarious intentions. Sulphur and 
nitrogen mustards or ‘mustard gas’ were utilised during the First World War as chemical 
weapons. Serendipitously, the cytotoxic effects of these agents were discovered that led to their 
use in the early treatment of malignancies (35). From this discovery, safer compounds in this 
class of alkylating agents were discovered such as cyclophosphamide, which is a mustard 
prodrug (36) that is metabolised into an active nitrogen mustard by the liver (37). 
 
Another commonly used chemotherapeutic agent is doxorubicin (DOX). It is an anthracycline 
compound that was first reported in 1969, when it was isolated from a mutated strain of 
Streptomyces peucetius (38). While the precise mechanism of action of DOX is unclear, it is 
thought to inhibit topoisomerase IV to halt DNA replication, as well as catalysing the 
production of free radicals to cause cellular damage (39). Regardless of the mechanism of 
action, it is currently utilised against a range of cancer types including solid tumours, leukaemia 




The largest drawback of chemotherapy is the severe adverse effects which can accompany 
treatment. From a clinical perspective, the adverse events are dose-limiting that may prevent 
the use of an otherwise efficacious drug. For example, cumulative exposure to DOX is 
associated with cardiotoxicity due to oxidative stress (41). The adverse effects of chemotherapy 
from a patient’s perspective are equally dire, with DOX being referred to as ‘the red death’ due 
to its deep red colour and unpleasant adverse effects (42). 
 
The adverse effects are due to the similarity between tumour cells and healthy cells, as both 
cells are derived from the same host. While there may be some differences in tumour cells with 
respect to the underlying biochemistry, the enzymes and the raw materials required for 
synthesis (such as nucleic acids) remain the same. This is in contrast to antibiotics that 
demonstrate mild adverse effects as pathogens have unique biochemical pathways that may be 
exploited, such as the de-novo folate synthesis pathway (43). However toxicity is often limited 
to cells that are rapidly dividing, due to the mechanism of action of these drugs on the cell 
cycle. Unfortunately this includes healthy tissues, such as the gastrointestinal system, leading 
to stomatitis and ulceration (44). 
 
Despite the issues with current chemotherapy, they remain a staple of treatment which is 
reflected by market data for cancer treatments. Data available for non-small cell lung cancer, 
which is representative of cancer due to its high frequency, showed that sales of 
chemotherapeutic agents was responsible for 55% of the non-small cell lung cancer market in 
six countries in 2014 (45). Thus, there is a need to improve the delivery of current 




1.2 Nanoparticle enhanced delivery 
 
Nanoparticles are well suited for the delivery of chemotherapeutic agents due to the potential 
for tumour specific release, which reduces the delivery of cytotoxic compounds to healthy 
tissues to minimise adverse effects. The mechanisms for this will be discussed in Section 2.2. 
 
 Nanoparticle formulations – a review 
 
Given the wide breadth of nanoparticles which have been reported in the literature, a review 
was conducted to establish the varieties and functionalities of nanoparticles to identify possible 
knowledge gaps. Articles published in 2017 were retrieved using a Web of Science search using 
the terms “Chemotherapy AND nanoparticles”. However, due to the large interest in the field 
of nanoparticle-based delivery systems (328 references), the scope of this review was further 
limited to formulations delivering doxorubicin. This is likely to be a representative sample of  
nanoparticles, due to its use as a model drug (46), which is also reflected by the number of 
citations (109 publications from 328). From these 109 publications, 61 were reviewed as the 
doxorubicin keyword was not successful in limiting results to formulations delivering DOX. 
Figure 1.2.1 summarises the 61 formulations that have been categorised based on the material 












Figure 1.2.1: Distribution of nanoparticle publications published in 2017 categorised by type 
of formulation 
 Liposomes and hybrid lipid nanoparticles 
 
An unexpected finding was the low number of publications on liposomes reported in 2017, with 
only one article by Sarfraz et al. reporting the use of liposomes (47), contrary to their current 
dominance in the clinic (included in ‘other’ in Figure 1.2.1). One reason for this is that 
liposomes may have been superseded by ‘hybrid’ nanoparticles which have been used for 
newer functionalised delivery systems (see Section 1.2.8).  Hybrid nanoparticles are solid 
nanoparticles that incorporate a layer of lipids to prevent leakage of drug. Yao et al. reported 
that DOX loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles coated in lethicin and a 
light sensitive polyethylene glycol (PEG) linker demonstrated remarkably low release without 
light (<10%) in comparison to triggered release (>70% in 48 hours), suggesting the lipid layer 
may be beneficial in preventing the leakage of DOX (48). Additionally, Liu et al. produced 
particles with and without a lipid bilayer coating and discovered the leakage of DOX in non-
triggered conditions was halved in comparison to uncoated particles (~30% versus ~15% 
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release). However, this was not a universally successful strategy, as Wu et al. reported 
nanoparticles coated with lethicin and a redox sensitive PEG linker that showed >70% DOX 
release in the absence of trigger at 48 hours (49). One possible reason for this discrepancy in 
stability is the nanoparticles reported by Wu et al. are considerably more complex due to the 
incorporation of additional components including a gadolinium contrast agent and folate 
targeting moiety at the lipid surface. As no stability data was reported, these additional 
components may have produced an unstable particle or coating resulting in DOX release. 
 
 Micelles and core-shell nanoparticles 
 
Historically, micelles have been described as small aggregates which result when amphiphiles 
are dispersed within an aqueous phase above the critical micelle concentration (50). However, 
this definition does not appear to be rigid, as some micelles have been reported as core-shell 
nanoparticles (51) and vice versa (52). This may be due to the similarity between these two 
systems. While standard micelles are aggregates that form a hydrophobic core and hydrophilic 
corona, core-shell systems are more varied in composition and physical properties as they are 
loosely defined as any particle incorporating two distinct phases (53). 
 
Nanoparticles with multiple phases, such as micelles, core-shell nanoparticles, and liposomes 
can accommodate multiple agents. This is advantageous as monotherapy in cancer is ill advised 
as the selection pressure of treatment leads to resistance in surviving tumour cells (54). 
However, the reviewed core-shell nanoparticles did not utilise this strategy, as multiple adjunct 
chemotherapies, such as curcumin and gefitinib, were co-located with DOX in the core of 




An example of a successful core-shell or micellar system was reported by Zeng et al. (51). 
Despite the inaccurate classification as noted above (a micelle identified as core-shell 
nanoparticle), the system demonstrates the advantages of micelles and core-shell nanoparticles. 
The nanoparticle was self-assembled from a polymer consisting of PEG conjugated to 
ibuprofen via a linker and DOX was loaded into the core via hydrophobic interactions. The use 
of ibuprofen in this system was interesting as it formed the hydrophobic core of the 
nanoparticle, while conferring anti-metastatic effects through cyclooxygenase-2 (COX-2) 
inhibition. In vitro performance of the system was marginal, as unformulated DOX was more 
cytotoxic in comparison to the nanoparticles against B16 melanoma cells (IC50 of 0.315 and 
0.638 μg mL−1 respectively), which was explained by the slow release of DOX over 120 hours. 
However, the in vivo results truly demonstrated the efficacy of this system as the inhibition of 
COX-2 in conjunction with enhanced DOX delivery was effective in reducing tumour volume 
and metastasis, which cannot be measured in vitro. 
 
 Mesoporous nanoparticles 
 
Mesoporous materials are characterised by the presence of pores ranging from 2 to 50 nm in 
diameter (57). Therefore, these materials exhibit a very large surface area available for loading 
where an improvement in the order of 103 was measured in comparison to liposomes (58). 
 
Overwhelmingly, silicon dioxide was the most common material for mesoporous delivery 
systems due to its biocompatibility, ease of chemical modification, and tuning of pore size (59). 
To take advantage of the well understood surface chemistry, a common modification was the 
addition of environmentally sensitive ‘gates’ to the entrances of the mesopores. These gates 
consist of degradable linkages to the surface of the particles to control release. Examples 
include hydrazone (60), imide (61), or disulphide bonds (62). This gating strategy was effective 
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in preventing the leakage of DOX, as <10% release at 48h in non-triggered conditions was 
observed in comparison to 60% when triggered (62). 
 
As with liposomes, micelles and core-shell nanoparticles, mesoporous nanoparticles for drug 
delivery have been reported previously (63). Thus, to maintain novelty a common strategy was 
to incorporate mesoporous silica into other nanoparticles, such as core-shell assemblies. Chen 
et al. reported the production of lanthanide core and mesoporous silica shell nanoparticles, as 
the lanthanide core confers light sensitivity. The delivery system demonstrated good stability 
and release, with 10% release without trigger and 80% release when triggered (64). 
 
 Inorganic nanoparticles 
 
Solid nanoparticles may be produced using a range of inorganic materials which may be 
metallic, such as gold, or minerals such as calcium carbonate. Non-organic nanoparticles have 
been utilised since antiquity with the use of colloidal gold and silver to create stained glass. 
Such nanoparticles have been recently repurposed for drug delivery (65).  
 
Gold and iron nanoparticle based systems were commonly reported, due to their ease of 
synthesis and favourable surface chemistry, which allows for DOX loading and the conjugation 
of polymers (66). They may also be incorporated into other systems, such as covalent bonding 
to mesoporous silica as gates (67). Additionally, the high density of metal is ideal as a contrast 
agent for radiography, conferring thernostic properties. For example, tantalum oxide containing 
nanoparticles are visible in vivo (68) with computed tomography (CT). 
 
Long term toxicity is a concern for inorganic nanoparticles. While the biocompatibility of gold 
nanoparticles was demonstrated by some authors such as Yang et al. with short-term in vitro 
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cell viability assays (67), long term in vivo murine experiments demonstrated severe toxicity 
and lethality after 21 days when gold nanoparticles of 8 to 37 nm in diameter were administered 
(69). As Yang et al. did not report in vivo data, this toxicity may present an issue for future 
studies. 
 
 Polymeric nanoparticles 
 
While the other nanoparticles included in this review have defined structures, polymeric 
nanoparticles may be loosely defined as aggregates formed from polymers. Although this 
definition covers many other nanoparticles in this review, such as micelles and core-shell 
nanoparticles; for the purpose of this review, ill-defined polymeric aggregates were classified 
as polymeric nanoparticles. 
 
An interesting example from this category were the nanoparticles reported by Wang et al. (70), 
as it was the most functionalised of all the nanoparticles in this review. The nanoparticles were 
self-assembled from two polymers, a block-copolymer of PEG, poly(2-(hexamethyleneimino) 
ethyl methacrylate (PHMA) and chlorin(e6) (Ce6); and a second polymer consisting of 
Arginine-Glycine-Aspartate peptide (RGD), Pluronic P85 and DOX. While the mechanism of 
action will be explained in Section 1.2.10.1, PEG prevents non-specific uptake, PHMA confers 
pH sensitivity, Ce6 is reactive to near infrared light with therapeutic and diagnostic modalities, 
RGD is a targeting ligand, and Pluronic P85 inhibits efflux of DOX. This nanoparticle 
demonstrated excellent in vivo performance in a murine model, in comparison to DOX and 




 Enhanced delivery - Passive targeting: The Enhanced Permeation and 
Retention Effect (EPR effect) 
 
The enhanced permeation and retention effect (EPR effect) was first reported in 1986 by 
Matsumura and Maeda (71). In their experiment, proteins ranging from 12 to 160 kDa were 
labelled with 51Cr and administered intravenously in mice. Proteins above 69 kDa were retained 
at the tumour in contrast to low molecular weight proteins. Additionally, Evan’s dye conjugated 
to albumin with a molecular weight of 69 kDa was retained at the tumour site for 72 hours in 
contrast to unconjugated dye to visually confirm the effect. 
 
Matsumura and Maeda attributed the effect to the malformed vasculature of solid tumours. As 
tumour angiogenesis is mediated by the pathological secretion of vascular endothelial growth 
factor (VEGF), tumour vasculature is highly torose with sinusoidal cavities. These features 
allow nanoparticles to escape the vasculature and enter the tumour bed (72). Additionally, the 
lymphatic drainage present in healthy tissue is often absent in tumours, which prevents the 
drainage of nanoparticles from the tumour bed. Thus, nanoparticles are retained at the tumour 
for extended periods allowing for tumour specific release of actives (73).  
 
Current nanoparticle based chemotherapies are liposomal doxorubicin (Doxil), daunorubicin 
(Daunoxome) and paclitaxel (Taxol). These liposomal products take advantage of the EPR 
effect to reduce adverse effects. For example, Doxil is associated with reduced cardiotoxicity 
in comparison to unformulated DOX as reported in a meta-analysis by Lee (74). However, as 
Doxil does not improve overall survival in comparison to unformulated DOX (74), further 





The lack of any increased efficacy of Doxil over unformulated doxorubicin is concerning, given 
that much faith was placed in nanoparticles after the discovery of the EPR effect three decades 
ago. An article by Jain (75) clearly articulates the limitations of the EPR effect, primarily due 
to low perfusion and high interstitial pressure within the centre of tumours that may limit 
nanoparticle access to the periphery of tumours. In addition inter-tumour variability is another 
concern as not all tumour lines are susceptible to the EPR effect, especially in clinical settings 
(76). Therefore, as the EPR effect is not uniform it becomes a selection pressure that favours 
the survival of resistant tumours (77). 
 
 Enhanced delivery - Functionalised nanoparticles  
 
Currently as passively targeted chemotherapies have had limited success in improving 
therapeutic efficacy,(76) an overwhelming majority of the nanoparticle publications in 2017 
utilised particles functionalised with environmental sensitivity or active targeting to improve 
tumour specific release (Figure 1.2.2). A significant number of delivery systems utilised 
multiple factors to increase efficacy or decrease toxicity. Due to the high frequency of 
multifunctional systems, the overall number of references recorded in Figure 1.2.3 exceeds the 




Figure 1.2.2: Categorisation of reported functions per nanoparticle 
 
 





 Tumour specific targeting 
 
Active targeting ligands were utilised extensively by the nanoparticles in this review. This is 
where targeting ligands are attached to the surface of nanoparticles to improve tumour specific 
delivery. Non-receptor mediated endocytosis is essentially random as particles on the surface 
will be internalised by chance. However, with receptor mediated endocytosis the binding of the 
targeting ligand to the cognate receptor on the cell will trigger endocytosis to improve uptake 
(78). For example, transferrin is a glycoprotein that binds iron for safe transport, as unbound 
iron catalyses production of free radicals (79). As iron is required by rapidly dividing cells such 
as tumour cells, transferrin based targeting of nanoparticles leads to improved uptake (80). 
Polymeric nanoparticles developed by Kim et al. demonstrated this theory using transferrin 
modified polymeric nanoparticles. Using in vitro cytotoxicity assays with L929 cells (which do 
not overexpress transferrin) and HCT119 and KB cell lines (which overexpress transferrin), the 
transferrin modified nanoparticles were less cytotoxic for L929 cells in comparison to DOX 
and transferrin-free nanoparticles. Additionally, the transferrin containing nanoparticles were 
more cytotoxic in HCT119 and KB cell lines. While this report supported prior literature for 
transferrin based targeting, the absence of statistical analysis or curve fitting for the 
cytotoxicity, and the lack of in vivo studies weakened the claims of efficacy made by the 
authors. 
 
An interesting alternative targeting strategy was utilised by Liu et al. with their core-shell 
nanoparticles (81). Methotrexate is a folate false metabolite used to inhibit DNA synthesis, 
which was also utilised as a targeting moiety in addition to its chemotherapeutic function. Due 
to its similarity to folate, it was recognised by the folate receptor to improve the uptake of 
nanoparticles. The improved uptake was verified by confocal microscopy and fluorescence 
activated cell sorting (FACS). However, in an in vivo murine melanoma model, no improved 
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targeting was observed with folate targeting alone as the addition of magnetic targeting was 
required for folate to have an effect. This suggests the methotrexate based targeting was not 
completely successful for this nanoparticle. 
 
 Tumour specific release - Intrinsic triggers 
 
Due to the pathological conditions of the tumour microenvironment (TME), the physiological 
conditions of the tumour are dissimilar to healthy tissue. Thus, nanoparticles that are sensitive 
to these differences may allow for tumour specific release. Some specific examples, such as 





It is well-known that tumour beds are acidic primarily due to the production of lactic acid as a 
result of aerobic glycolysis, termed the Warburg effect (82). While the purpose of the effect is 
not yet fully understood, it is thought to allow tumour cells to outcompete healthy cells for an 
energy source (i.e. glucose), as well as establishing an acidic environment that is beneficial to 
the growth of the tumour (83). This pH difference can be targeted to facilitate tumour specific 
release.  
 
The degradation of acid-labile functional groups allows moieties within molecules to become 
separated in acidic conditions. As noted with mesoporous particles, this is an effective 
technique in gating the release of DOX from mesopores with pH sensitive hydrazone (60) and 
imide (61) bonds. In other systems, such as core-shell nanoparticles, the degradation of a pH 
sensitive linker allows for the release of DOX from a polymer. This was demonstrated by Gao 
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et al. (55) where pH 5 DOX release was measured to be 80% after 60 hours in comparison to 
30% at pH 7.4. Despite this favourable in vitro release profile, results from their in vitro cell 
viability assays did not reflect the success of this system. While the authors claimed their drug 
delivery system was capable of improving cytotoxicity against MCF-7 (a breast cancer cell 
line) while protecting non-cancerous MCF-10A cells, the inhibition curve fitting for their 
experiments was dubious due to the very narrow range of concentrations tested. Additionally, 
without an in vivo tumour model experiment to demonstrate tumour specific targeting, the 
overall efficacy of the system is unknown.  
 
Other systems use the change in pH for the ionisation of functional groups, commonly amine 
(positively charged) or carboxylate (negatively charged) groups. The polymeric nanoparticles 
reported by Wang et al. (70) (introduced in Section 1.2.6) demonstrates this concept most 
effectively. The PHMA of the PEG-PHMA-Ce6 polymer is unionised and hydrophobic at 
physiological pH that anchors the polymer into the hydrophobic core of the nanoparticle. Due 
to its pKa of 6.9, PHMA becomes increasingly ionised in acidic conditions, converting into a 
hydrophilic group and triggering the ejection of the polymer from the nanoparticle. 
 
One issue with pH sensitive systems is the in vitro release of DOX was frequently examined 
against an acidic pH of 5 to demonstrate tumour specific, acid sensitive release. While reports 
of extracellular pH measurements show great variability, a pH of 5 is too acidic for the TME. 
For example, a pH of 6.70 ± 0.08 was recorded in a MCF-7 tumour (84), while melanomas 
were found to have a neutral pH of 7.36 ± 0.1 (85). While a pH of 5 is too acidic to represent 
the TME, nanoparticles that have been internalised by tumour cells may still be exposed to pH 
5 conditions within endosomes. Nanoparticles internalised via endocytosis are located within 
endosomes, which mature to reduce the internal pH to 4.8-6 (late endosomes). Additionally, 
20 
 
the pH may be further reduced to pH 4.5 upon endosome–lysosome fusion (86). While most 
authors acknowledged that pH 5 release is due to endosomal conditions, some authors 
erroneously attributed pH 5 release to the TME (87, 88).  
 
Some systems, such as the nanoparticles developed by Wang et al. (70) specifically target the 
TME as they demonstrate pH sensitivity at pH 6.8. Another system that was sensitive to the 
conditions of the TME were micelles reported by Huang et al. (89). The micelles were self-
assembled from DOX, Zn2+ ions, and a polymer consisting of elastin-like polypeptides (ELP), 
which were modified with histidine residues and conjugated with PEG. The system 
demonstrated exceptional pH sensitivity, with 90% DOX release at pH 5.6 for endosomal 
release, whereas less than 10% was released at pH 7.4. However, the most interesting aspect of 
the system occurs at pH 6.8, as the histidine residues of the ELP become positively ionised, 
which improved the adhesion of the nanoparticles to negatively charged cells resulting in 
enhanced uptake. The uptake was validated by confocal microscopy and FACS, comparing 
complete formulations with histidine-free controls. The in vitro performance translated to 
prolonged survival in an in vivo tumour model, demonstrating the efficacy of the nanoparticles.  
 
While the acidic pH found in mature endosomes is useful in the delivery of chemotherapies, it 
can also be used to activate cancer vaccines. Strategies utilising the acidic environment of the 




The environment within tumour cells is reductive compared to healthy tissues due to the 
increased concentration of reducing agents such as glutathione (GSH). GSH production 
protects tumour cells against damage caused by ROS produced by pathological processes in 
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tumour cells (90). Elevated concentration of GSH may be targeted with a reducible linker, such 
as a disulphide bond. In the case of polymeric nanoparticles reported by Nehate et al. (91), the 
polymer contained a disulphide bond which demonstrated GSH sensitivity with in vitro release 
studies. The release studies showed the GSH-free pH 7.4 release was only 10% after 72 hours, 
while nanoparticles at pH 5 in the presence of 10 mmol of GSH demonstrated 60% release. 
 
1.2.10.3 Reactive oxygen species (ROS) 
 
While elevated concentrations of GSH in response to ROS production may be targeted by 
reducible groups, the increased ROS concentration may also be directly targeted with a novel 
ROS sensitive mechanism. A mesoporous silica based nanoparticle reported by Hu et al. (92) 
was gated with a ROS sensitive thioketal functional group. As the concentration of ROS in 
tumour cells is too low for reliable drug release (93), the nanoparticles were also loaded with 
α-tocopheryl succinate (α-TC) which generates ROS via mitochondrial disruption. The uptake 
of these nanoparticles by tumour cells triggered the release of α-TC. The α-TC-induced ROS 
production initiated a positive feedback loop of ROS production, allowing for further release 
of DOX from the mesopores. In vitro cell viability assays with cancerous MCF-7 cells and non-
cancerous 293T cells demonstrated specific cytotoxicity against MCF-7 cells, while showing 
low toxicity against 293T cells. The in vitro results were supplemented with an in vivo murine 
tumour model with excellent results. 
 
 Tumour specific release - extrinsic triggers 
 
In contrast to intrinsic triggers, extrinsic triggers such as light and magnetism may allow for 
more specific release as they are not naturally generated in the body. Additionally, the intensity 
may be tuned in comparison to the fixed mild physiological conditions of the tumour (e.g. pH 
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6.5 for the TME). However, an issue that is inherent to most of the externally triggered systems 
reviewed here is the location of the tumour must be known to direct the trigger. Many metastatic 
sites are difficult to detect, which is an important issue as treatment resistant metastasis are the 
leading cause of mortality in cancer cases (6). To demonstrate the challenge of detecting 
metastatic sites, Coumans et al. (94) identified that 95% of currently detected masses are 5mm 
or larger resulting in metastases in 9.6% of breast cancer patients. To reduce the frequency of 
metastases to 1%, the metastatic masses must be detectable at a size of 2.7 ± 1.6 mm, which 
requires a 15-fold improvement in current detection limits. 
 
1.2.11.1 Near infrared (NIR) and other phototherapies 
 
Light sensitive nanoparticles contain a photosensitizer, which is capable of absorbing light to 
trigger the release of drug. Near infrared (NIR) light based photosensitisers were the most 
commonly utilised, as NIR is known to penetrate tissues more effectively compared to other 
wavelengths of light (95). Examples of photosensitising compounds include Ce6 (96), or 
metals, such as titanium dioxide coated iron oxide nanoparticles (97). 
 
The absorption of light by photosensitisers has two effects at the tumour. The first effect is 
termed photodynamic therapy which is the destruction of tumour tissues in response to 
photosensitiser-induced production of ROS (98). The second effect is localised hyperthermia 
termed photothermal therapy. While photothermal therapy is capable of causing direct damage 
to tumour tissues, additional functions such as increased sensitivity of tumour cells to 





An example of an NIR sensitive system are the mesoporous carbon nanotubes reported by Li 
et al. (100). The carbon nanotubes were beneficial for three reasons. Firstly, the mesoporous 
structure allowed the loading of DOX that was gated with a DNA based targeting aptamer. 
Secondly, the sp2 hybridised carbon utilised in the nanoparticle innately functions as a 
photosensitiser for photothermal and photodynamic effects. Lastly, due to its action as a 
photosensitiser, light is absorbed rendering the nanoparticles optically opaque. This last 
function is interesting as loaded DOX does not fluoresce, in contrast to released DOX which is 
fluorescent. Thus, these nanoparticles have theranostic functions as DOX release at tumours is 
detectable with fluorescence due to a 10-fold increase in fluorescence intensity at the tumour. 
However, as the in vitro or in vivo effects of photothermal or photodynamic therapy were not 
yet reported by the authors, the overall efficacy of the system is yet to be proven. 
 
Despite the improved tissue penetration of NIR light, it is still attenuated by light scattering due 
to lipids and water. Therefore, a shallow penetration depth of 8.530 ± 1.907 mm was recorded 
in vivo using human neonatal heads (101). While NIR may be appropriate for superficial 
tumours such as melanoma, deeper tumours (such as colorectal, prostate, and lung cancer) will 




Magnetic fields have been utilised in the treatment of cancer for imaging purposes, for example 
magnetic resonance imaging (MRI). In addition to imaging, magnetism has been used in 
targeting as paramagnetic particles will align with a magnetic field (102). Additionally, the 
penetration depth of magnetic fields is much greater in tissues in comparison to NIR, as 
evidenced by MRI where whole body scans are possible. To demonstrate this concept, Liu et 
al. (81) incorporated a core of magnetic iron oxide in nanoparticles that was utilised to 
24 
 
magnetically retain nanoparticles at the tumour with an externally applied magnet. The efficacy 
of the system was verified in an in vivo murine model. 
 
Magnetic nanoparticles may also be used for inducing local hyperthermia as rapidly fluctuating 
magnetic fields allows the particles to generate heat. Oh et al. (103) utilised cobalt iron oxide 
to generate heat and release DOX in response to a fluctuating magnetic field. However, this 
was examined in vitro only and in vivo efficacy is yet to be determined. 
 
Magnetic particles may also play a role in thernostics due to enhanced MRI contrast for 
visualisation. An example of this are the hybrid nanoparticles reported by Wu et al. (49) that 
incorporate a gadolinium based lipid as gadolinium is a MRI contrast agent (104). In vivo 
imaging demonstrated the system was capable of visualising tumours via MRI. However, as a 
lower limit of detection was not established, its efficacy in detecting metastatic sites is 
unknown. 
 
 A link between systems – interactions between chemotherapy and the 
immune system 
 
It is known the immune system is capable of controlling cancer and the presence of cytotoxic 
compounds may unintentionally undermine the immune response. This was demonstrated by 
Steinmetz’s group, where a potato virus was utilised for the delivery of DOX, as the virus is a 
biocompatible nanoparticle with simple manufacturing and loading. The filamentous shape of 
the virus was hypothesised to allow increased extravasation from tumour vasculature, resulting 
in improved tumour specific delivery. While the system demonstrated efficacy in nude 
immunodeficient mice (105), experiments with wild type C57BL/6 mice did not result in a 
survival benefit (106). The authors attributed these results to a decrease in availability of DOX 
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in tumour cells due the increased uptake of virus and DOX by tumour macrophages. However, 
this is unlikely to explain the results as macrophages in immunodeficient mice are more 
phagocytic (107), yet these mice demonstrated a survival benefit which directly contradicts this 
explanation. While the authors did not discuss this in depth, these results may be attributable 
to a decrease in immune function (i.e. formulation induced immunosuppression) due to toxicity 
against cells of the immune system. This explanation is supported by the strains of mice used 
for experiments as the formulation was effective in immunodeficient mice only, where 
formulation induced immunosuppression is not an issue as the immune function is already 
compromised. Whereas, the immunocompetent C57BL/6 mice experienced a decrease in 
cytokine concentrations (such as IFN-γ) in response to exposure to DOX loaded virus (106), 
which suggests the formulation disrupted the anti-cancer immune response. As the anti-cancer 
response was disrupted, no improvement in survival was observed. 
 
Although nanoparticle based chemotherapies may affect the immune system, the immune 
system may also affect nanoparticles. A common issue is the clearance of the nanoparticles by 
a component of the immune system, the reticuloendothelial system (RES), also known as the 
mononuclear phagocyte system (MPS) (108). The RES consists of phagocytic cells primarily 
concentrated in the liver and spleen. During circulation, nanoparticles may become opsonised 
by plasma proteins, which become effectively removed by the RES to reduce the circulation 
time and efficacy of the nanoparticles (109). Therefore, to avoid uptake by the RES the 
attachment of PEG as a steric shield has been shown to be effective in preventing the 
opsonisation of nanoparticles, which was demonstrated by the long circulation time of Doxil 
liposomes (110). This strategy of utilising the effects of PEG was shared by a number of 




Although the addition of PEG allows for improved pharmacokinetics due to reduced RES 
clearance, this strategy is also associated with reduced efficacy as the uptake of nanoparticles 
is inhibited by PEG, which has been termed the ‘PEG dilemma’ (111). The nanoparticles 
reported by Wang et al. (70) (Section 1.2.6) solves this issue as the acidic pH of the TME causes 
PEG to be shed from the nanoparticles, restoring the uptake of nanoparticles in tumour cells. 
 
An interesting alternative strategy to solve the issue of RES uptake without the use of PEG was 
reported by Yu et al. (112). The delivery of unloaded hydroxyethyl starch-g-polylactide 
nanoparticles 1.5 hours prior to the delivery of DOX loaded nanoparticles was successful in 
saturating RES binding and uptake to prevent the uptake of DOX loaded nanoparticles. 
Saturation of the RES system elicited multiple improvements such as the increase in circulation 
time, improved distribution of DOX to the tumour, and improved in vivo anti-tumour efficacy 




While targeted chemotherapies show promise in improving treatment, immunotherapy is 
another mode of treatment which has attracted interest. In the simplest definition 
immunotherapies are therapies that improve the action of the immune system.  The utilisation 
of the patient’s own immune system is desirable as it allows for a powerful and highly specific 
response against cancer.  
 
The effect of the immune system against malignant cells is visually demonstrated by iatrogenic 
Kaposi’s sarcoma. This condition presents as skin lesions secondary to immunosuppressive 
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treatments, such as corticosteroids or methotrexate. This unusual cancer is reversible in some 
cases with the withdrawal or reduction of immunosuppressants (113). 
 
 Immune responses against cancer 
 
The immune system may be separated into the innate and adaptive responses based on 
functional differences. Innate responses occur as a first response against a threat, thus the 
response is rapid but non-specific. In contrast, the adaptive response represents a specialised 
and highly specific response to the original threat. Despite these differences the two systems 
are linked, as the innate immune response stimulates and supports the adaptive response (Figure 
1.3.1). 
 
Figure 1.3.1: Overall summary of the immune system. The innate immune system 
(represented by dendritic cells, DCs) is responsible for the activation of the acquired immune 
system via Signal 1 and 2 interactions. During the activation of T helper cells (Th cells), they 
become polarised to Th1 to stimulate a cytotoxic T lymphocyte (CTL) response or become 
polarised to Th2 to stimulate an antibody response. 
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The specificity of the acquired immune response is due to the unique recognisable elements of 
pathogens and cancers termed ‘antigens’. The antigens of primary importance in cancer are 
peptides derived from proteins expressed by tumours. Tumour proteins may be antigenic if they 
are mutant proteins produced by genetic instability; or are germline proteins which are not 
expressed by normal healthy cells; or if they are overexpressed in comparison to healthy cells 
(114). 
 
 Cells of the immune response 
 
Cytotoxic CD8+ T cells (also known as cytotoxic lymphocytes, CTLs) have been the focus of 
anti-cancer immunotherapies due to their ability to recognise and destroy tumour cells. 
However, as CTLs are cells of the acquired immune system, several steps are required for 
activation. The first step requires the activation of antigen presenting cells (APCs) such as 
dendritic cells (DCs). DCs are phagocytic cells of the innate immune system which are highly 
effective in processing and presenting tumour antigens to CD4+ T helper (Th) cells to begin the 
adaptive response (115) (Figure 1.3.1, left). 
 
Two signals are required for CD4+ Th cell activation by DCs (116). Firstly, ‘Signal 1’ is the 
antigen presented by DCs on Major Histocompatibility Complex- II (MHC-II), which must be 
recognised by the Th cell through its T cell receptor (TCR). Each T cell possesses a unique 
TCR, therefore only T cells that recognise the tumour antigen are activated through Signal 1. 
The second signal (Signal 2) is a co-stimulatory signal from the DC.  This second signal is 
required to prevent inappropriate immune activation (for example autoimmunity) in the 
absence of infection or cancer (117). Thus, co-stimulatory signals may be referred to as ‘danger 
signals’, confirming the presence of cellular damage or a pathogen. Danger or threat is detected 
by DCs through Toll-like receptors (TLRs) binding with pathogen-associated or damage-
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associated molecular patterns (DAMPs and PAMPs respectively). For example, high mobility 
group box 1 (HMGB1) is a protein that is normally bound to DNA. However, it is released 
during apoptosis and inflammation, binding to TLR4 to activate DCs (118). TLR ligation 
upregulates expression of co-stimulatory molecules such as CD80 and CD86 (119).  
 
CD4+ T helper adaptive responses may be further divided into cellular (Th1) or humoral (Th2) 
responses (Figure 1.3.1, middle). For Th1 cellular responses, the T helper cells recruit and 
support the development of CTLs. For antibody mediated responses B cells are recruited by 
Th2 polarised T helper cells and mature into antibody secreting plasma cells (120). As CTLs 
are part of the Th1 response, it is widely accepted that the Th1 polarised immune response is 
important for anti-cancer therapies. 
 
Once Th cells are activated and polarised towards Th1, they assist in the activation of CTLs by 
APCs (Figure 1.3.2). They do this by producing soluble immune stimulatory factors (cytokines) 
and by expressing co-stimulatory ligands that supports activation of both CTLs and APCs (also 
known as DC licensing) (121, 122). CTLs also require 2 signals for activation, but unlike Th2 
cells, signal 1 is presented on MHC-I as opposed to MHC-II for Th2 cells. This is an effective 
strategy as all nucleated cells constitutively process and express antigens on MHC-I, in 
comparison to MHC-II which is only expressed on APCs. Therefore, CTLs are capable of 
examining all nucleated cells in the body for cells that may be producing cancer antigen. Once 
the CTL has been activated by a DC via signal 1 and 2 interactions, it can then kill any target 
cells expressing that same antigen through the release of cytotoxic granules. These granules 




Figure 1.3.2: Danger signals in the form of DAMPs or PAMPs are required for signal 2 
interactions between DCs and T cells. Danger signals are detected by pattern recognition 
receptors such as the TLRs, when triggered results in the upregulation of CD80 and CD86, as 
well as the production of cytokines. 
Despite the prominence of CTLs in cancer research, other cells are also capable of eliminating 
cancer cells. Natural killer (NK) cells are innate immune cells which do not require activation 
to kill tumour cells as NK cells are by default activated to destroy cells (124). This is not an 
issue for healthy cells as the cytotoxic ability of NK cells is inhibited by the presence of MHC-
I on the target cell. As one strategy utilised by viruses and tumour cells to evade CTL detection 
is to downregulate the expression of MHC-I, the intrinsic cytotoxic activity of NK cells allows 






 Major Th1 cytokines 
 
An important factor for the generation of an anti-tumour immune response is the secretion of 
cytokines by Th1 cells. Although there are many cytokines involved in the anti-cancer 
response, interferon gamma (IFN-γ) is considered to be the hallmark Th1 cytokine (126). The 
importance of IFN-γ was demonstrated by experiments where disruption in the production or 
signalling of IFN-γ resulted in weaker anti-cancer immune function in murine models (127, 
128). The initial secretion of IFN-γ from innate immune cells, such as NK cells (129) or APCs 
such as DCs and macrophages (130), is important for establishing a Th1 response as the Th2 
response is inhibited by the presence of IFN-γ (131). Once activated Th1 cells secrete IFN-γ to 
support CTL activity. 
 
Interleukin-12 (IL-12) is another important Th1 cytokine. In conjunction with the early release 
of IFN-γ, the secretion of IL-12 by APCs is a powerful inducer of IFN-γ production (132) and 
Th1 polarisation (133). Furthermore, the secretion of IL-12 also has an effect on the innate 
immune system, as it is a potent activator of NK cells to further increase the production of IFN-
γ (134). 
 
 Antibody dependent cell mediated cytotoxicity (ADCC) 
 
Antibody dependent cell mediated cytotoxicity (ADCC) occurs when malignant cells coated 
with tumour-specific antibodies are destroyed by NK cells. Although the binding region of 
antibodies is diverse, the Fc fragment or the ‘stalk’ of the antibodies is consistent, which may 
be recognised by NK cells via the FcγRIIIA receptor. Activation of the FcγRIIIA triggers the 





Interest in ADCC has been low due to its association with Th2 responses as they have been 
reported to interfere with Th1 CTL responses (136). However, recent interest in ADCC was 
ignited by the introduction of antibodies, such as trastuzumab (anti-HER2 antibody), as 
‘biologic’ treatments with widespread clinical use. In the case of trastuzumab, the original 
intention of the antibody was to prevent the activation of the growth factor receptor HER2 to 
prevent further growth of malignant cells (13). However, it was also discovered that the 
administration of trastuzumab was associated with ADCC mediated anti-cancer activity, 
suggesting these biological treatments may also play a role in immunotherapy (137). 
 
 The immunoediting model 
 
Despite the anti-tumour activity of the immune system, it is evident by the high incidence of 
cancer that the immune system is not capable of reacting against all malignant cells. Therefore, 
the immunoediting hypothesis or model is the currently accepted model of cancer, where the 
balance between pro-cancer and anti-cancer immune activities contributes to the clinical 
outcome (138). The immunoediting model describes the progression of cancer in three stages, 
elimination, equilibrium, and escape (Figure 1.3.3). 
 
The term was originally coined by Shankaran et al. in a landmark study that unambiguously 
demonstrated the immune system is capable of suppressing tumour growth (139). During 
experiments to determine the effect of the immune system in tumour rejection, prior studies 
were confounded by the use of athymic (nude) mice as immunodeficient controls as these mice 
retained residual T cell activity. As these control athymic mice were able to reject tumours, the 
effect of the immune system in immunocompetent wild type (WT) mice was not detectable 
(140). To rectify this issue, Shankaran et al. utilised recombination activating gene 2 (RAG2) 
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knockout mice to produce truly immunodeficient mice. These mice served as a more 
appropriate comparison to WT mice to conclusively demonstrate that the acquired immune 
system was responsible for spontaneous tumour rejection (139). 
 
1.3.5.1 Elimination, Equilibrium, and Escape 
 
In the first stage of the model (Figure 1.3.3), elimination, the immune system is capable of 
overwhelming malignant cells. This is primarily due to the high immunogenicity of early 
malignant cells due to the high expression of pro-apoptotic receptors such as calreticulin. 
Calreticulin is expressed on the surface of cells in response to endoplasmic stress, which marks 
tumour cells for swift immune destruction mediated by CTLs (141). Also, the expression of 
MHC-I and antigen on tumour cells is unhindered, allowing for the activation and proliferation 
of CTLs that is supported by the abundant secretion of IFN-γ and IL-12 by immune cells (142). 
 
The next stage is equilibrium. This stage is characterised by increasing resistance of tumour 
cells as the remaining cells have undergone positive selection due to the activities of the 
immune system (143). However, Mittal states the exact factors contributing to the conversion 
from elimination to equilibrium are unknown due to the difficulty of modelling this state in 





Figure 1.3.3: The immunoediting model of cancer consists of three phases, elimination, 
equilibrium, and escape. Pro-immune effects such as the secretion of IFN-γ and IL-12, or the 
expression of pro-apoptotic factors such as calreticulin diminishes over time. Conversely, 
pro-tumour effects, such as the infiltration of regulatory cells and the secretion of anti-
inflammatory cytokines inhibits the immune response. 
 
Despite the difficulty in detecting the equilibrium state, a major study by Koebel et al. (144) 
demonstrated its existence. WT mice with functional immune systems were implanted with 
tumours sourced from WT and immunocompromised (RAG2 knockout) mice. Tumours from 
RAG2 knockout mice were rejected more readily compared to WT donors, as the 
immunoediting of tumours from WT donors with functional immune systems became less 




In the final stage, escape, malignant cells are no longer restrained by the immune system, 
leading to the clinical presentation of cancer. Several factors that are responsible for tumour 
escape will be discussed below. 
 
 Immunosuppressive cells 
 
Immunosuppression is an essential component of the immune response and is important for 
regulating inappropriate immune activation. Reactivity against self-antigen must be controlled 
as it may result in significant damage to the host. However, in the case of cancer 
immunosuppression is pathological as it enables the tumour to escape (145). 
 
The primary immunosuppressive cells are the regulatory T cells (Treg). Treg cells, as do all T 
cells, possess a TCR. However, unlike helper or cytotoxic T cells the TCR of Treg cells is 
capable of recognising self-antigen, which is utilised to recognise and prevent the activation of 
self-reactive T cells (146). Once a self-reactive T cell is recognised by a Treg, signalling 
through direct contact or through the secretion of cytokines, such as transforming growth 
factor-β (TGF-β), induces anergy in the target T cell to prevent its activation (147). Due to their 
immunosuppressive properties, the infiltration of Treg cells within tumours is associated with 
poor prognosis in many, but not all, cancers (148). 
 
Another group of cells that have been identified with immunosuppressive properties are the 
myeloid derived suppressor cells (MDSCs). One of the major immunosuppressive mechanisms 
utilised by MDSCs, and also by malignant cells, is the expression of indoleamine-2,3-
dioxygenase (IDO). IDO is a key enzyme for the conversion of tryptophan to kynurenine and 
is commonly active in MDSCs (149). IDO activity leads to immunosuppression through two 
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mechanisms as kynurenine (the product) is an activator of MDSCs (150), while the depletion 
of tryptophan (the precursor) causes anergy in effector T cells (151). 
 
In addition to IDO, NADPH oxidase activity in MDSCs produces ROS (152). A well-studied 
product formed from the generation of ROS is peroxynitrite (PNT), which is generated from 
the spontaneous reaction between superoxide (O2-) and nitric oxide. The PNT reacts with amino 
acid residues such as cysteine, methionine, and tryptophan (153), leading to non-specific 
addition of steric bulk to MHC-I and TCR. These PNT modified receptors show marked 
reductions in affinity that impedes the ability of the CTL to recognise and destroy tumour cells 
(154). 
 
1.3.6.1 Immune Checkpoints 
 
The term ‘immune checkpoint’ is derived from the cancer immunity cycle as the maintenance 
of the immune response against cancer is modelled as a repeated cycle, where the release of 
tumour antigen from CTL activity allows for the continuation of CTL activity (155). To limit 
the activity of this cycle, one important checkpoint is the expression of the negative regulator 
cytotoxic T-lymphocyte-associated protein 4 (CTLA-4, also known as CD152) by activated T 
cells. CTLA-4 binds to CD80 and CD86 on APCs outcompeting CD28 which is also used for 
T cell activation. Therefore, CTLA-4 expression dampens T cell activity and prevents over-
activation of the immune system (156). The importance of this molecule is demonstrated by its 
abrogation in mice, which causes lethal autoimmune effects within one month of birth (157). 
CTLA-4 has been shown to hinder the development of anti-tumour immune responses as 
evidenced by studies in mice that have shown the blockade of CTLA-4 improves anti-cancer 




Programmed cell death protein 1 (PD-1, also known as CD279) is another well-studied 
checkpoint inhibitor expressed by activated T cells. Unlike CTLA-4, ligands for PD-1, such as 
PD-L1 (also known as B7-H1 or CD274) may be expressed by tumour cells to directly dampen 
the anti-tumour immune response (159). Therefore, increased PD-L1 expression is associated 
with poor prognosis (160). 
 
 Available immunotherapies 
 
A limited selection of immunotherapies are now available for clinical use. This is remarkable, 
given the anti-cancer effect of the immune system was only confirmed in the early 2000s (139). 
Currently available therapies in the clinic will be discussed below (Figure 1.3.4), which 
includes checkpoint inhibitors, CAR T cells, and cancer vaccines. 
 
 
Figure 1.3.4: Overview of current immunotherapies. Therapies may relieve the inhibition of 
the immune system with checkpoint blockade, or improve the strength of the anticancer 
response with vaccines. Alternatively, genetically modified immune cells to target tumour 
cells may be infused into the patient, such as chimeric antigen receptor (CAR) T cells. 
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1.3.7.1 Anti-checkpoint inhibitors 
 
As checkpoint inhibitors are capable of reducing CTL activity, antibodies have been developed 
to relieve checkpoint inhibition. CTLA-4 blockade with ipilimumab is indicated for use in 
advanced metastatic melanoma in New Zealand (40). PD-1 blockade therapies are also 
available in New Zealand with pembrolizumab recently being funded by Pharmac (40).  
Investigations into the relative efficacies of the two therapies have reported PD-1 blockade as 
being more effective than CTLA-4 blockade (47.3% versus 26.5% six month progression free 
survival in pembrolizumab and ipilimumab respectively) (161). Additionally, PD-1 blockade 
is associated with a reduced incidence of Grade III/IV adverse effects (8% for 
pembrolizumab/nivolumab versus 35% ipilimumab) (162). Due to the success of these 
treatments, checkpoint inhibitors are projected to contribute the largest share of market value 
of non-small cell lung cancer treatments in 2024 (45). 
 
Although checkpoint blockades are generally effective, some patients do not respond due to 
‘immune quiescence’. This is where both the PD-L1 expression and tumour infiltration by 
CTLs is low, thus the blockade of negative regulators is unlikely to improve clinical outcomes 
due to the lack of pre-existing immune activity (163). Therefore, the administration of a vaccine 
in conjunction with checkpoint inhibitors may be an effective strategy in improving CTL 
infiltration and activity (163). However, a study examining the combination of a gp100 
melanoma vaccine with anti-PD1 did not show a clinical benefit (164), suggesting current 
vaccines are not capable in generating a sufficient immune response to demonstrate this 
synergy. 
 
Another issue is the high incidence of autoimmune related adverse effects associated with 
checkpoint inhibitors. The concurrent use of PD-1 and CTLA-4 blockade is effective in 
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improving anticancer responses. However,  the combination is associated with higher incidence 
of toxicity, especially hepatotoxicity requiring glucocorticoids or treatment withdrawal (165). 
To solve this issue, the co-administration of a vaccine may allow for a specific immune 
response to be generated without needing to suppress checkpoint inhibition to the point of 
causing autoimmune reactions (166).  
 
1.3.7.2 Ex vivo cellular therapies 
 
Ex vivo cellular therapies are focused on the generation of effector T cells or APCs ex vivo to 
bolster the patient’s immune response. Current treatments are autologous to prevent graft 
versus host disease where infused non-autologous immune cells recognise the new host as 
foreign tissue, which leads to skin, liver, and gastrointestinal symptoms (167). 
 
Chimeric Antigen Receptor (CAR) T cell therapy involves the infusion of T cells that have 
been genetically modified to express a CAR. The binding region of a CAR is derived from an 
antibody to allow the T cell to recognise antigen regardless of MHC-I expression on the target 
cell (168). Additionally, multiple co-stimulatory domains may be included in the CAR, which 
further improves anti-tumour activity (169). Recently, the Food and Drug Administration of 
America (FDA) approved Tisagenlecleucel (Kymriah), an anti-CD19 CAR T cell treatment for 
B cell lymphomas (170). Tisagenlecleucel demonstrated high efficacy in the treatment of end-
stage B cell lymphoma with an 81% remission rate within three months of treatment (171). 
 
Another ex vivo cellular therapy available in the clinic is Sipuleucel-T (Provenge). While it is 
approved and marketed as the first cancer vaccine, activated APCs are generated ex vivo and 
must be infused into the patient. Sipuleucel-T itself is a recombinant protein consisting of 
prostatic acid phosphatase (PAP) fused to granulocyte macrophage colony stimulating factor 
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(GM-CSF) to generate activated APCs ex vivo (172). Improvement in overall survival in 
patients with advanced prostate cancer was modest (4.1 months) (173). 
 
The disadvantage of cell based therapies is exemplified by the costly production processes of 
CAR T cells outlined by Levine et al. (174). The production of CAR T cells requires aseptic 
techniques and rigorous quality control from all steps during treatment, such as the collection 
of blood from the patient, the production of the transfecting lentivirus and the materials used 
during cell culture. Therefore, the high price of CAR T treatment, US$475,000 (170), is a 
barrier to utilization of this therapy in the clinic. 
 
 Cancer vaccines 
 
Vaccines are treatments where the immune response against an antigen is stimulated through 
the administration of antigen. Although the concept of vaccination may be traced to Jenner’s 
work with pox virus (175), research into cancer vaccines has been a more recent development. 
 
Cancer vaccines have not achieved similar success in the clinic in comparison to currently 
available immunotherapies. A comprehensive review of 49 early phase cancer vaccines by 
Klebanoff et al. (1) determined the pooled response rate was just 3.6%. Thus, this is an area 
where many improvements may be made. Several barriers to producing a cancer vaccine have 




Figure 1.3.5: Summary of issues in the development of cancer vaccines. Poor delivery and 
antigen processing may lead to weak responses, while an inappropriate adjuvant may cause 
anergy and immune tolerance to the tumour antigen. 
1.3.8.1 Adjuvants 
 
APCs that are not activated by DAMPs or PAMPs (i.e. ‘danger signals’) will not express the 
necessary co-stimulatory molecules (CD80 or CD86) for T cell activation. Protein or peptide-
only vaccines (subunit vaccines) are poorly immunogenic, requiring an adjuvant to generate 
the necessary danger signals to produce an immune response and avoid anergy (176). 
Additionally, the selection of an appropriate adjuvant is required as the polarity of the immune 
response is determined by the adjuvant. For example, alum is a commonly used adjuvant in 
humans for prophylactic vaccines against viruses and bacteria. However, it generates a weak 
CTL response, thus it is less effective in the treatment of cancer (177). 
 
Not all adjuvants target APCs, for example, α-galactosylceramide (α-GalCer) targets Natural 
Killer T cells (NKT cells) which are a distinct subtype of NK cells that express a semi-invariant 
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T cell receptor. This allows them to recognise glycoprotein antigens such as α-GalCer. 
Activation of NKT cells results in strong IFN-γ secretion, which greatly improves the action of 
Th1 cells to increase survival in murine melanoma models (178, 179). Phase I/II clinical trials 
in humans demonstrated it was well tolerated (one Grade III event from 69 cycles of treatment) 
and seven from 21 patients had the progression of cancer stabilised (180). 
 
1.3.8.2 Antigen delivery 
 
DCs are able to internalise antigens with high efficiency due to specialised pathways such as 
receptor mediated endocytosis (181). However, further improvements in antigen delivery are 
possible through the association or incorporation of antigen with particles. Particles, 
particularly those that are below 500 nm in diameter are efficiently phagocytosed by DCs (182) 
thereby delivering a bolus of antigen to the APC. 
 
Another factor to consider for immune activation is the kinetics of delivery of antigen and 
adjuvant to the APC. For Th1 type responses, simultaneous delivery of antigen and adjuvant is 
required (183, 184). To illustrate this, linking OVA with CpG (a Th1 adjuvant) with a reducible 
linker resulted in superior responses in a murine melanoma survival model (9/10 responders in 
contrast to 1/10 in control) (185). Similarly, incorporation or association of antigen and 
adjuvant in a particle will ensure synchronous delivery to APC resulting in Th1 responses 
(184). 
 
1.3.8.3 Antigen processing and presentation 
 
An issue with antigen delivery with vaccines is that the antigen is processed as an exogenous 
molecule, taken up by the APC by endocytosis. Antigen processing and presentation through 
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the MHC-I pathway (which is required for CTL activation) is normally reserved for 
‘endogenous’ molecules (i.e. antigen produced by the cell itself and present in the cytoplasm). 
In contrast, exogenous antigens are normally expressed on MHC-II. Fortunately however the 
distinction between the two pathways is not absolute with some DCs being capable of ‘cross-
presentation’ where exogenous antigen is processed as endogenous antigen for MHC-I loading 
(176). 
 
While the mechanism behind cross-presentation is not yet fully understood, the endogenous 
MHC-I loading pathway has been fully elucidated. Endogenous proteins are processed in the 
cytoplasm by the proteasome to generate peptides. These peptides are then transported into the 
lumen of the ER by transporter associated with antigen processing (TAP) proteins, where they 
are loaded onto MHC-I and subsequently expressed on the surface of cells (186). It is theorised 
that exogenous antigen may gain access to the cytoplasm to utilise the endogenous pathway 
(cytosolic pathway), or may be loaded on MHC-I in endosomal compartments (vacuolar 
pathway) (187). 
 
As the exact mechanism of cross-presentation is unknown it has been hypothesized that 
enhancing the delivery of exogenous antigens to the cytoplasm of DCs may be beneficial. 
Cytoplasmic delivery allows antigens to be processed by the endogenous pathway improving 
cross-presentation and CTL responses (188). One technique that demonstrated improved 
cytoplasmic delivery was photochemical internalisation (PCI) where photosensitive 
compounds such as disulfonated tetraphenyl chlorin (TPCS2a) were delivered to the 
endosomes of target cells. The presence of light catalysed the degradation of TPCS2a 
generating free radical products causing the lysis of endosomes, with the subsequent release of 
antigen into the cytoplasm (189). 
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 Nanoparticles as vaccine carriers 
 
One solution to poor vaccine efficacy is to utilise nanoparticles for the delivery of vaccines. 
While the same nanoparticles which were discussed earlier in this chapter (Section 1.2) may be 
used, immune stimulating complexes (ISCOMs) strongly demonstrate the potential 
nanoparticles hold for vaccine delivery. ISCOMs are cage-like structures that are produced 
when antigen is combined with QuilA, a saponin extracted from the Quillaja saponaria tree 
(190). These complexes are 40 nm in diameter (191, 192), which are likely to be endocytosed 
efficiently by DCs (182, 193). The poor adjuvancy of subunit vaccines is solved with ISCOMs 
as QuilA is a potent adjuvant capable of producing a robust CTL response against cancer in 
murine models (194, 195). Additionally, as the adjuvant and antigen are present in the same 
nanoparticle, synchronicity of delivery is unlikely to be an issue. Lastly, saponins are known 
to stabilise pores in biological membranes (196). Thus, it is theorised the improved cytoplasmic 
delivery of antigen mediated by QuilA contributes to the generation of a strong CTL response 
(197). ISCOMs have also been used clinically in an Phase II study where patients with 
advanced melanoma were immunised against NY-ESO-1, a commonly expressed 
immunogenic cancer antigen (198). While the immunisation improved antibody responses, the 
efficacy was dampened by the strong activity of Treg cells. Adjuvant therapy with 
cyclophosphamide to deplete Treg cells produced a modest effect of increasing NY-ESO-1 
specific CD4+ T cell responses in five out of 14 patients, however only one patient in 14 
developed a vaccine induced CTL response (199). 
 
The most significant drawback of ISCOMs is low antigen loading due to its open cage-like 
structure, which is exacerbated by the lack of easily exploitable loading techniques. 
Hydrophobic interactions between antigen and ISCOMs may allow for high loading, but may 
result in the loss of immunogenicity if the shape of the antigen or carrier is affected (200). 
45 
 
Meanwhile, the chemical conjugation of antigen to ISCOMs is also possible, but difficult as 
the reaction is restricted by steric hindrance. Attempting more powerful coupling reactions to 
improve loading is not an appropriate solution, as this results in the polymerisation and 
inactivation of antigen or ISCOMs (201).  
 
1.4 Overall aims 
 
The overall aim of this thesis was to develop a nanoparticle that was capable of targeted 
delivery of chemotherapeutic agents or of antigen. This would allow for the testing of our 
hypothesis that the use of pH sensitive nanoparticles would improve the efficacy of cancer 
chemo- or immunotherapy, while decreasing the off-target adverse effects of chemotherapy 
 
To achieve this, two nanoparticle systems were examined: polymeric nanoparticles (PDMS-b-
PDMAEMA) for pH sensitive release at the tumour, and modified liposomes (PEI + 
cyclodextrin channel liposomes) for cytoplasmic delivery of actives. 
 
The aim for the first experimental chapter was to produce polymeric nanoparticles and 
liposomes with acceptable quality parameters such as size, loading, and stability. Therefore, 
this chapter details the methods that were optimised for the production and characterisation of 
nanoparticles. Additionally, the synthesis of compounds that were not commercially available 
is also reported in this chapter. It was hypothesised that the thin film hydration method would 
be suitable for producing polymeric nanoparticles from PDMS-b-PDMAEMA and liposomes 




In the second experimental chapter the pH responsive properties of the nanoparticles fabricated 
in the previous chapter was evaluated. The in vitro release of actives was measured after the 
development and validation of assays. The hypothesis investigated in this chapter was that 
polymeric nanoparticles would release doxorubicin in acidic conditions, whereas the modified 
liposomes would be capable of delivering actives to the cytoplasm of cells via acidic 
endosomes. 
 
The aim of the last experimental chapter was to develop a vaccine carrier utilising the 
nanoparticles fabricated earlier. The in vitro and in vivo performance was evaluated using a 
murine melanoma cell lines and mouse models. It was hypothesised that the immunisation of 
tumour bearing mice with complete vaccine formulation (with antigen, channels, PEI, and 




Chapter 2 : Development and 
characterisation of nanoparticles for 




The central hypothesis of this thesis is that targeted delivery of actives (drugs or vaccines) in 
responsive nanoparticles will increase efficacy and decrease adverse effects. In this chapter the 
design, synthesis, and characterisation of two nanoparticle formulations will be examined. 
Specific responsiveness of the nanoparticles to triggers will be examined in the next chapter.  
 
As discussed in Chapter 1, pH was chosen as a trigger to take advantage of the acidic tumour 
bed and endosome without the need for external stimuli. Polymeric nanoparticles were 
produced from polydimethylsiloxane-block-poly(2-dimethylaminoethyl methacrylate), 
(PDMS-b-PDMAEMA), an amphiphilic block co-polymer synthesised and kindly provided by 
Car et al. (2). The amphiphilicity of the polymer is due to PDMS forming the hydrophobic 
region while PDMAEMA with positively charged amine groups is the hydrophilic region. As 
it is amphiphilic, the polymer is able to self-assemble to form nanoparticles. PDMS will form 
a hydrophobic core while the PDMAEMA forms a hydrophilic corona (Figure 2.1.1, left).  The 
pH responsiveness of this formulation is mediated by a change in charge associated with a 





Figure 2.1.1: Diagram demonstrating the two formulations in this thesis. The PDMS-b-
PDMAEMA polymeric nanoparticles (left), and modified liposomes (right) 
The liposomal formulation was composed of three major components (Figure 2.1.1, right). 
Dipalmitoylphosphatidylcholine (DPPC) is a zwitterionic phospholipid isolated from lung 
surfactants, and was selected as the base component as it is a natural phospholipid that is 
generally regarded as safe (GRAS) in biological systems (202). As DPPC does not exhibit pH 
sensitivity two substituents were added, cyclodextrin ion channels and polyethyleneimine 
(PEI). 
 
Cyclodextrin ion channels (3) were incorporated into the liposomes to permit the transport of 
ions into the interior of the particle. This is an unconventional use of cyclodextrin as they were 
primarily developed as drug carriers due to their toroidal structure with an internal hydrophobic 
cavity and an external hydrophilic face. These properties are ideal for the solubilisation and 
transport of hydrophobic actives (203). However, in the case of cyclodextrin ion channels the 





Figure 2.1.2: Simplified diagram of cyclodextrin ion channels. The hydrophobic tails allow 
the self-insertion of channels into the membrane (right), where it mediates the transport of 
ions through the membrane. 
The overall structure of the channel consists of a beta-cyclodextrin with alkyl chains (‘tails’) 
attached to one face of the cyclodextrin (Figure 2.1.2). As the channels are amphiphilic due to 
the polar cyclodextrin group and non-polar tails, they are able to self-insert into membranes to 
disrupt to the membrane that permits the transport of charged ions (3). It was our hypothesis 
that inclusion of the channels in the liposome would facilitate pH responsiveness mediated by 
PEI. While the mechanism of action will be discussed in the next chapter, PEI is a cationic 
polymer that contains a high density of amine groups that when exposed to acidic conditions is 





2.2 Methods of Particle Preparation 
 
Numerous methods have been developed for the production of nanoparticles. These vary in 
their ease of use, their potential for scale up, and their capacity to produce consistent batches 
of formulations. The advantages and disadvantages of common formulation methods will be 
discussed.  
 
 Thin film hydration 
 
Since Bangham and Horne discovered the presence of vesicular structures after hydrating dried 
phospholipids (204), the preparation method of thin film hydration (205) has been prevalent in 
the field of vesicular nanoparticles.  The technique relies on the deposition of a thin, uniform 
film suitable for rehydration through the rapid evaporation of a solution containing 
lipids/polymers (206). To facilitate the formation of a good film a suitable solvent is required. 
Chloroform is an ideal solvent for this process for two reasons. Firstly, amphiphiles generally 
exhibit good solubility in chloroform, and secondly it is a volatile solvent allowing for quick 
and complete evaporation. Small volumes of methanol may be added without adverse effects 
to assist in the solubilisation of more polar compounds, while larger concentrations of methanol 
are to be avoided as methanol interacts strongly with polar head groups to hinder evaporation 
(207). Alternative solvents, such as dichloromethane, tertiary butanol, or cyclohexane may be 
used if chloroform is unsuitable (208). 
 
The next step of thin film hydration involves the addition of aqueous phase to the film (i.e. 
hydration). The prepared sheets of bilayers are hydrated and agitated for several hours to form 
particles. It is important to control time and temperature during this step. Adequate time (at 
least 1 hour (209)) and agitation must be applied to fully hydrate the film (206), while the 
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temperature must be kept above the phase transition temperature of the polymer or 
phospholipid to allow the formation of hydrated bilayers (210). This elevation of temperature 
above the phase transition temperature is critical as the water must penetrate into the dry lipids 
for hydration (211). Below the phase transition temperature the phospholipids are densely 
packed in the ‘trans’ conformation (Figure 2.2.1, left). Whereas, above the transition 
temperature the acyl chains adopts the ‘gauche’ conformation increasing water permeability 
for the hydration of bilayers (212) (Figure 2.2.1, right). 
 
Figure 2.2.1: Gel to liquid-crystalline phase transition and thin film hydration. Phospholipids 
below the phase transition temperature (left) are packed parallel in the ‘trans’ conformation, 
denying the access of water. Once heated above the phase transition temperature (right), the 
phospholipids are arranged into a ‘gauche’ conformation, allowing for greater permeability 
of water. Bilayer diagram adapted from (213). 
Hydrophilic actives, such as proteins, peptides, DNA, or PEI, may be incorporated during 
hydration as the aqueous phase becomes encapsulated within vesicles. Encapsulation 
efficiencies can be low with this production method but this may be improved through ‘passive’ 
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or ‘active’ methods (discussed below in Section 2.3.1). In contrast, hydrophobic actives are 
incorporated within the hydrophobic core of membranes or micelles. For example, paclitaxel 
is a lipophilic chemotherapeutic agent for the treatment of cancer that is currently administered 
as an emulsion due to its low aqueous solubility. Therefore, in liposomal formulations 
paclitaxel is dispersed within the liposomal membrane (214). 
 
The main advantage of this method is its simplicity as the original discoverer of the method, 
Alec Bangham, describes it as “exceedingly easy” with near-spontaneous formation of 
liposomes (211). However, this method is only suitable for laboratory or small scale clinical 
trials due to limited scalability as impractically large surfaces are required for the deposition of 
lipid films for industrial production (215). 
 
In addition to poor scalability, the hydration of phospholipid bilayers in this manner results in 
the formation of crude vesicles with large heterogenous diameters and multilamellar structures 
(207). These multi-lamellar vesicles (MLVs) are rarely used. One notable exception however, 
is amphotericin B where the high phospholipid content is ideal to solubilise the compound 
(216). To produce homogenous and unilamellar vesicles further processing is required to 
produce more pharmaceutically acceptable small unilamellar vesicles (SUVs, particles below 
100 nm) or large unilamellar vesicles (LUVs, particles that are 100-500 nm). This is thought to 
proceed through an intermediate structure termed oblate micelles (Figure 2.2.2, top right). 
These micelles are disks of phospholipids ablated from MLVs when energy is applied to the 
system, which due to the exposure of the hydrophobic tails to the aqueous environment will 
close into a vesicle (206). In addition to sonication, a number of methods have been used for 





Figure 2.2.2: Production of unilamellar vesicles with the thin film hydration method, where 
MLVs are produced then refined into unilamellar vesicles using sonication (middle) or 
extrusion (bottom). While extrusion results in the formation of LUV/SUV directly via budding, 
sonication and other ablative techniques form LUV/SUV through an intermediate structure of 
oblate micelles (top right). Oblate micelles may also be produced from phospholipid solutions 
(top) with the removal of detergents (dialysis) or from the mixing of solvents (solvent 
injection and microfluidics systems). 
2.2.1.1 Sonication 
 
Sonication of MLVs (in sonicating baths or with tip sonicators) uses high power sound waves 
to impart energy to MLVs and produce oblate micelles. However, several factors, such as 
temperature, sample positioning and the shedding of particulates from tip sonicators must be 
taken into consideration. 
 
The temperature during sonication must be controlled. While sonication must occur above the 
phase transition temperature of the lipid, the process also results in friction and high 
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temperatures, especially with tip sonicators. These conditions adversely affect lipids and 
polymers as oxidation and hydrolysis rates are increased (217, 218). Therefore, the increase in 
temperature may be controlled through the use of chilled baths and pulsed sonication to limit 
total exposure (219). 
 
The positioning of the sonicating tip or the sample within the sonicating bath is important. For 
sonicating probes, the tip must be positioned low in the liquid to avoid foaming (219). To 
complicate this, a stationary tip is associated with a focalised area of high temperature which 
may damage the formulation. Thus it is recommended to move the tip, which may cause 
foaming when the tip is not immersed sufficiently resulting in lower transduction of energy 
(220). Meanwhile, for sonicating baths the sample must be positioned carefully to take 
advantage of the areas of high cavitation energy in the bath as the distribution of sonication 
energy is not homogenous (221). However, as cavitation is associated with the production of 
lipid damaging ROS, care must be taken to limit exposure times (222). 
 
Lastly, in the case of tip sonicators, an important consideration is the shedding of metal particles 
from the probe. Therefore, samples prepared using a tip sonicator are centrifuged prior to use 
(207). This has a secondary effect of improving homogeneity of the particles as any remaining 
MLVs or aggregates are removed. However, this increases production cost due to the price and 




The extrusion of MLVs through polycarbonate membranes is another widely utilised method 
to produce LUVs. Smaller volumes of lipid or polymer dispersions may be processed by a hand 
extruder and larger samples with a high-pressure nitrogen gas extruder. As MLVs pass through 
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the polycarbonate membrane pores at temperatures above the phase transition temperature, 
LUVs are produced. Multiple extrusion passes, starting with larger pored membranes and 
followed by smaller pored membranes is recommended (208).  
 
Formation of UVs by this method does not involve the formulation of oblate micelles (as seen 
with sonication). Instead, when membranes are extruded through pores long cylindrical 
structures are formed. As these structure are inherently unstable, LUVs bud off due to the 
application of pressure (224). 
 
An advantage of this method is ease of use, as liposome extruders and polycarbonate 
membranes are commercially available as compact benchtop units. These units are able to 
produce very homogenous liposomes that do not require further processing (225). However, 
scaling up of extrusion is difficult due to the tendency of the filtration membrane to clog (226), 




High pressure homogenization may be used to produce LUVs from MLVs via expulsion 
through a small orifice at high pressures. The high shear forces during expulsion allow oblate 
micelles to form. High pressure homogenization represents a good opportunity to scale up 
liposomal production to an industrial scale due to its simplicity (228). However, due to the 
shedding of metal particles, similar to tip sonication, the liposomes must be centrifuged prior 





 Reverse phase evaporation 
 
Reverse phase evaporation, first reported by Szoka et al., is an alternative method of 
nanoparticle production that is associated with improved encapsulation efficiency (230). In 
contrast to the film rehydration method the lipid or polymer is in solution during the formation 
of vesicles. The organic solvent (for example diethyl or isopropyl ether) used to solubilise the 
lipids or polymer must be water immiscible and volatile. To this organic solution, a small 
volume of aqueous phase is added allowing for the formation of inverted micelles (230) (Figure 
2.2.3). 
 
Figure 2.2.3: Production of unilamellar vesicles (UVs) by reverse phase evaporation. 
Aqueous phase (blue) is dispersed within a volatile organic phase (yellow) with 
phospholipids to generate reverse micelles. Upon evaporation of the organic phase, micelles 
aggregate into a gel-like phase that collapses into UVs with further evaporation. 
The formation of inverted micelles is critical to this method as the aqueous phase within the 
inverted micelles will form the aqueous interior of the resulting liposomes. Therefore, a very 
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high entrapment volume is attained in contrast to thin film hydration (230), and high 
encapsulation efficiencies may be reached (231). 
 
Once the inverted micelles are formed, the organic phase is evaporated at a controlled rate to 
reduce foaming (207). Over time, a gel phase will form from the inverse micelles with the lipids 
arranged in an inverse hexagonal phase, as the distance between inverted micelles becomes 
smaller as the organic solvent is removed. With further evaporation, the gel collapses into a 
dispersion of unilamellar vesicles (230). 
 
One of the disadvantages of reverse phase evaporation is the retention of organic solvent in the 
final product, which restricts use of solvents to biocompatible alternatives such as ethanol and 
ethyl acetate (232). Additionally, industrial scale up is an issue as high shear mixing devices 
required to generate reverse micelles as a microemulsion at an industrial scale are not yet 
available (233). 
 
 Dialysis method 
 
While oblate micelles may be generated through ablation from MLVs, they may also be 
produced from solutions of phospholipids. Detergent dialysis involves the formation of mixed 
micelles consisting of phospholipids stabilised with an additional detergent. Once the detergent 
is removed by dialysis, the stability of the micelles becomes compromised and will form oblate 
micelles (234). The oblate micelles close up to form LUVs (206). 
 
The advantages and disadvantages of this method may be attributable to the process of dialysis. 
As dialysis is a straightforward process, no advanced equipment is required, simplifying 
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production. However, the rate of detergent removal is slow and inconsistent, leading to low 
reproducibility of liposomes (235). 
 
 Solvent mixing methods  
 
The solvent injection and microfluidics systems will be discussed together as the mechanisms 
behind both processes are similar (236, 237). Lipids are dissolved into a water miscible solvent, 
such as isopropyl alcohol or ethanol, which is then diluted in an aqueous phase. This dilution 
causes the lipids to precipitate out at the boundary between the alcohol and water. As the lipids 
are no longer solubilised, they begin to aggregate to form oblate micelles that are followed by 
LUVs (237, 238). 
 
In the case of the solvent injection method, the alcoholic lipid solution is simply injected at a 
constant rate into a turbulent flow of stirred aqueous phase (239). Whereas, in microfluidics 
systems a specialised ‘chip’ contains micrometer sized channels for fluid flow that improves 
control of the process by carefully controlling the rate and lamellarity of flow to produce 
homogenous liposomes (237). This may be scaled up to industrial quantities (240). An issue 
with solvent mixing is the concentrations of lipids (and subsequently liposomes) is low in 
comparison to currently available products (0.1 to 2.0 mM with microfluidics, versus 5 to 







2.3 Particle characterisation and physical stability 
 
Once the nanoparticles have been formed, they must be characterised. In contrast to current 
small molecule treatments, rigid regulatory requirements for nanoparticle delivery systems are 
yet to be developed. This is due to several properties of nanoparticles, such as encapsulation 
and particle stability that are exclusive to these systems (241). Therefore, a draft report 
outlining industry recommendations by the FDA has been published with suggested 
measurements of several parameters that are pertinent to efficacy and stability (241).  
 
 Encapsulation of actives 
 
Passive loading of hydrophilic actives occurs when a solution of active is encapsulated during 
vesicle preparation (Figure 2.3.1, top), and this may be low with some preparation techniques. 
Encapsulation of actives may be improved through the manipulation of two parameters (242). 
Firstly, the total volume that is entrapped (entrapment volume) may be improved by increasing 
the number of vesicles produced during hydration. This is achieved by increasing the 
concentration of lipids or polymers. Secondly, more active may be encapsulated within the 
same entrapment volume if the concentration of active is increased. 
 
Active loading does not require the active to be present during vesicle formation, as loading 
occurs after the formation of the particles (Figure 2.3.1, bottom). Active loading can utilise ion 
trapping (242) whereby weakly acidic or basic actives which are unionised outside vesicles 
may diffuse across the hydrophobic membrane to the aqueous interior of the vesicle. However, 
if the pH within the vesicle differs from the surrounding solution, the active may become 
ionised. As an ionised active is unable to diffuse across the membrane, it is retained within the 




Figure 2.3.1: Passive loading (top) involves the encapsulation of actives that were dispersed 
in solution during the formation of liposomes. In contrast, active loading (bottom) occurs 
with unloaded liposomes. However, the interior of these liposomes has an acidic or basic pH 
to facilitate the process of ion trapping. 
The methods utilised for the removal of unentrapped actives will be discussed further in 
Chapter 3 (Section 3.4.2). In brief, physical methods such as dialysis and centrifugation are 
capable of separating prepared liposomes from excess unencapsulated actives for both actively 
and passively loaded liposomes. 
 
2.3.1.1 Particle size 
 
Particle size is considered by Desai (244) to be critically important as the efficacy of 
nanoparticles is affected by size through several mechanisms. Firstly, the pharmacokinetics of 
nanoparticles are influenced by size as MLVs (micrometer sized) were more rapidly cleared in 
comparison to LUVs (100-200nm) and SUVs (30-50nm) (245, 246). This issue is compounded 
by the process of Ostwald ripening where smaller particles produce larger particles (247, 248), 
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which is driven by the reduction in surface energy by decreasing the interfacial surface area 
between liposomes and the aqueous phase (249). Thus, the homogeneity of the formulation, 
reported as the polydispersity index (PDI), is an important parameter to examine. 
 
Size has also been reported to affect the mechanism of action of particles. The EPR effect, 
discussed in the previous chapter (Section 1.2.7), is an example of passive targeting where size 
of the nanoparticles is important. Furthermore, the uptake of particles by phagocytosis is also 
affected by particle size as particles below 500 nm are known to be internalised more efficiently 
(182). 
 
Particle size is commonly measured using dynamic light scattering (DLS). DLS relies on the 
correlation of the light scattered by nanoparticles over time. To expand on this, smaller particles 
are expected to move around quickly as they are more affected by Brownian motion. Therefore, 
the pattern of scattered light may be correlated to the populations of nanoparticles that are 
present in solution (207). However, as this method does not directly measure particles it is 
susceptible to inaccurate measurements of polydisperse samples as larger particles are over-
represented (250-252).  
 
Due to these issues with DLS, electron microscopy (EM) is frequently used to confirm the size 
of the nanoparticles in solution(207). In addition to the size of nanoparticles, EM techniques 
such as cryo EM and transmission EM may be used to directly observe the morphology of 
particles. Despite these advantages, EM is not recommended for routine sizing of particles as 
it is an involved process. Firstly, the grids for sample preparation must be pristine to prevent 
artefacts necessitating the use of plasma cleaning (253). Once pristine slides are prepared, the 
low electron density of liposomes is not easily visible with electron microscopy. Therefore, a 
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contrast agent such as phosphotungstic acid as a negative contrast (254) or sputtering of a metal 
film (255) is required, which may also introduce artefacts. 
 
 Zeta potential 
 
Another parameter that is stated in the FDA report as being pertinent to efficacy and stability 
is the zeta potential as it provides electrostatic repulsion between colloidal particles to prevent 
aggregation (247). A commonly quoted threshold for stability is ± 30mV (251), as it is 
associated with sufficient electrostatic repulsion under the DLVO theory. However, particles 
below this threshold may still be stabilised by other factors such as steric hindrance from a 
coating of hydrophilic polymers (256). Although the stability may improve with high zeta 
potentials, care must be taken as charge may affect particle clearance through increased 
opsonisation and RES clearance (245) or inhibit cellular uptake as membranes are negatively 
charged (182). 
 
Zeta potential is commonly measured with benchtop units, which may also measure size, as 
both measurements may be carried out with the same optics. However, a separate cuvette with 
electrodes is required for zeta potential measurements, in comparison to the simple acrylic 
cuvettes used for sizing. The electrodes introduce a rapidly fluctuating electric field within the 
cuvette to allow the suspended nanoparticles to become mobile. The electrophoretic mobility 
can then be measured by the optics within the unit, which is converted into zeta potential based 





2.4 Chemical stability 
 
In addition to the physical stability, the chemical stability of nanoparticles must also be 
considered. Particles may be stored as a dehydrated formulation or, more commonly for pre-
clinical investigations, in aqueous suspension. Particles in an aqueous environment are 
inherently at risk of hydrolysis as many phospholipids contain an ester group (258), which are 




pH strongly influences the rate of hydrolysis due to acid or base catalysis of hydrolysis, 
showing a typical ‘V shape’ profile with higher rates of hydrolysis at the extreme pH conditions 
(218, 258). Therefore, any procedure altering pH such as pH dependent active loading may 
have an effect on the stability of liposomes. 
 
Hydrolysis may be limited by producing a dehydrated formulation. A common method is 
lyophilisation where the completed formulation is frozen in the presence of a lyoprotectant such 
as sucrose. The sucrose continues to interact with the polar head groups of the phospholipids 
to preserve the structure during the sublimation of water (207). Lyophilized liposomes may be 
redispersed into aqueous phase with minimal damage (259). While lyophilisation may be cost 
and time prohibitive (260), dehydrated formulations are preferred for commercial products due 
to increased stability without compromising release properties (261). 
 
If the size or homogeneity of the liposomes is not important, lipids may be stored in a solid 
state to make hand-shaken MLVs, such as amphotericin B (Section 2.2.1). An alternative 
method relies on the adsorption of phospholipids to the surface of a readily dispersible solid 
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substrate, such as sucrose. Once hydrated, the sucrose solubilises leaving behind large or giant 
unilamellar vesicles dispersed within an isotonic solution that is ready for injection (260). 




Oxygen is another factor that must be considered for chemical stability, as peroxidation of 
lipids and polymers may occur. Long acyl chains of lipids and polymers are vulnerable to attack 
from reactive oxygen species via a free radical mechanism. While the exact mechanisms are 
beyond the scope of this thesis, exposure to heat, oxygen and transitional metal ions (262, 263) 
will predispose lipid samples to oxidation. 
 
2.5 Chapter Aim 
 
The aim of this chapter is to develop and characterise two pH-responsive nanoparticle 
formulations, PDMS-b-PDMAEMA polymeric nanoparticles and modified liposomes. In the 
case of modified liposomes a variety of preparation techniques such as reverse phase 
evaporation, sonication, and extrusion were investigated. The size, homogeneity, loading and 
stability of the nanoparticles were characterised. 
 
2.6 Materials and methods 
 
2.6.1.1 Materials for formulation 
 
PDMS-b-PDMAEMA polymer (AB5) and the pH insensitive PMOXA variant was kindly 
provided by Dr. Anja Car (UNIBAS, Basel, Switzerland). DPPC was obtained from Avanti 
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Polar Lipids Inc. (USA). PBS tablets were sourced from Oxoid (UK). Cholesterol, FITC, and 
OVA were sourced from Sigma-Aldrich (USA). FITC and OVA were conjugated to form 
FITC-OVA (Appendix B). PEI (linear, 25 kDa) was sourced from Polysciences Inc. (USA). 
DOX was sourced from AKScientific (USA). 
 
2.6.1.2 Materials for synthesis 
 
All reagents were purchased with 97% or higher purity. Beta-cyclodextrin was sourced from 
AKScientific (USA). 5-hexyn-1-ol, perfluorobutyryl chloride, ascorbic acid, sodium 
methoxide solution, and copper sulphate were sourced from Sigma-Aldrich (USA). Solvents, 
such as chloroform, diisopropyl ether, methanol, DCM, hexane, and DMF (HPLC grade) were 
sourced from Merck (USA). 
 
 Synthesis of cyclodextrin channels 
 
The synthesis of per-6-iodo-beta-cyclodextrin and per-6-azido-beta-cyclodextrin was based on 
the method described by Ashton et al. (264).  
 
2.6.2.1 Synthesis of per-6-iodo-beta-cyclodextrin 
 
8.02 g of triphenylphosphine (30.6 mmol, 15 eq.) was dissolved in approximately 30 mL of 
anhydrous dimethylformamide (DMF) in a dry round bottom flask. 8.10 g of iodine crystals 
(32 mmol, 16 eq.) was added to the flask, resulting in a dark brown solution following an 
exothermic reaction. After 10 minutes of stirring, 2.32 g of dry beta-cyclodextrin (2.02 mmol, 
1 eq.) was added to the flask, and the temperature was raised to 70°C. The anhydrous conditions 




Following the overnight reaction, approximately half the volume of DMF was removed via 
rotary evaporation. After the removal of DMF, the flask was transferred to a chilled bath, and 
12 mL of 25% sodium methoxide solution in methanol (55.6 mmol, 25 eq.) was added slowly 
to the flask while stirring. The next step deviates from the methods of Ashton et al. (264), after 
30 minutes, the contents of the flask were precipitated with approximately 500 mL of ice cold 
distilled water, yielding a light brown precipitate. 
 
The precipitate was filtered and superficially dried. After drying, excess iodine was removed 
by Soxhlet extraction with methanol for up to 48 hours, until the filtrate became colourless. 
The resulting product was dried overnight at 400 mbar and 40°C. 1.76 g of cream coloured 
powder was obtained (46% yield), which was spectroscopically similar to that reported in the 
literature. 1H NMR (400 MHz, DMSO-d6) δ 7.64 – 7.56* (m, 13H), 7.56 – 7.49* (m, 9H), 6.07 
(d, J = 6.1 Hz, 7H), 5.99 (d, J = 2.2 Hz, 7H), 4.96 (d, J = 3.5 Hz, 7H), 3.82 – 3.72 (m, 7H), 3.59 
(dd, J = 21.4, 8.9 Hz, 14H), 3.46 – 3.31 (m, 14H), 3.26 (t, J = 9.1 Hz, 7H). Peaks denoted with 
an asterisk (*) were not reported by Ashton et al. (264), and can be attributed to remaining 
triphenylphosphine oxide, which is formed during the iodination step. 
 
2.6.2.2 Synthesis of per-6-azido-beta-cyclodextrin 
 
1.2 g of the previously synthesized per-6-iodo-beta-cyclodextrin (0.628 mmol, 1 eq.) was 
dissolved in 20 mL of anhydrous DMF in a dry round bottom flask. 0.4 g of sodium azide (6.16 
mmol, 10 eq.) was added to the flask, and the temperature was increased to 60°C. The reaction 




The next day, up to half of the DMF was removed by rotary evaporation and the product was 
precipitated in approximately 200 mL of ice cold distilled water. The precipitate was filtered 
and washed with additional ice cold water. The washed product was dried overnight at 400 
mbar at 40°C. White coloured powder weighing 0.807 g was obtained (98% yield), which was 
spectroscopically similar to that reported in the literature (264). 1H NMR (400 MHz, DMSO-
d6) δ 7.70 – 7.62* (m, 17H), 7.62 – 7.56* (m, 12H), 5.96 (d, J = 6.6 Hz, 7H), 5.84 – 5.76 (m, 
7H), 4.95 (d, J = 3.6 Hz, 7H), 3.87 – 3.73 (m, 14H), 3.64 (m, J = 11.5, 8.1, 4.3 Hz, 14H), 3.46 
– 3.37 (m, 14H). Peaks denoted with an asterisk were not reported by Ashton et al. (264), which 
is due to remaining triphenylphosphine oxide. 
 
2.6.2.3 Synthesis of alkyne 
 
The synthesis of cyclodextrin ion channels utilizing per-6-azido-beta-cyclodextrin was based 
on the method reported by Chui et al. (3). 1 g of 5-hexyn-1-ol (10.18 mmol, 1 eq.) and 2.2 g of 
anhydrous potassium carbonate (15.28 mmol, 1.5 eq.) was added to a round bottom flask. 
Approximately 2 mL of anhydrous tetrahydrofuran (THF) was added to the flask to produce a 
slurry. The slurry was chilled to 0°C in a chilled bath. 3.54 g of perfluorobutyryl chloride (15.28 
mmol, 1.5 eq.) was added dropwise under nitrogen to the rapidly stirred slurry. The flask was 
removed from the chilled bath and returned to room temperature and stirred for an additional 
two hours. 
 
The reaction was quenched with a small volume of methanol and the solution was filtered to 
remove potassium carbonate. The resulting filtrate was concentrated by gentle rotary 
evaporation to prevent the evaporation of product. The concentrate was purified with silica gel 
chromatography, using 1:5 ethyl acetate: hexane as an eluent. 0.731 g (18% yield) of a light 
yellow oil was eluted, which was similar to the spectrum previously reported (3) (note a 
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different NMR solvent was used in comparison to the published procedure as the compound is 
more freely soluble in DMSO) 1H NMR (400 MHz, DMSO-d6) δ 4.50 (t, J = 6.4 Hz, 2H), 2.82 
(t, J = 2.7 Hz, 1H), 2.25 (td, J = 7.0, 2.7Hz, 2H), 1.88 – 1.76 (m, 2H), 1.59 – 1.50 (m, 2H). 
 
2.6.2.4 Synthesis of channels 
 
160 mg of the previously synthesised alkyne (0.550 mmol, 12 eq.) was added to a round bottom 
flask in 1.5 mL DMSO. To the flask, 9.2 mg copper sulfate pentahydrate (0.0366 mmol, 0.8 
eq.), 29.4 mg sodium ascorbate (0.0367 mmol, 3.2 eq.), and 60 mg per-6-azido-beta-
cyclodextrin (0.0458 mmol, 1 eq.) was added and the light brown solution was stirred for 24 
hours at room temperature. The solution was then added to 10 mL of ice cold distilled water to 
precipitate a light green solid. The precipitate was filtered and washed with excess ice cold 
water. The precipitate was then superficially dried with a stream of air. 
 
The following steps deviate from the original method from Chui et al. (3). The dried precipitate 
was washed with chloroform to remove excess alkyne, followed with additional washing in 1:1 
chloroform: ethyl acetate to remove ascorbic acid. The resulting product was dried overnight 
at 400 mbar at 40°C. 84.3 mg of light green product was collected (60% yield). The peaks are 
similar to those reported by Chui et al. and differences will be discussed in Section 2.8.1 (3) 
1H NMR (400 MHz, Methanol-d4) δ 7.96 – 7.51 (m, 1H)*, 5.17 (s, 1H), 4.74 – 4.00 (m, 1H), 
3.99 – 3.71 (m, 1H), 3.65 – 3.39 (m, 4H), 2.60 (s, 2H), 1.91 – 1.42 (m, 3H). The peaks noted 






 Production of polymeric nanoparticles 
 
The thin film hydration method was adapted to produce nanoparticles, as described by Car et 
al. (2). In a round bottom flask, 900 µL of 10 mg/mL PDMAEMA or PMOXA polymer in 
chloroform solution was added with 2 mL chloroform (total 9 mg polymer). The chloroform 
was removed by rotary evaporation (Buchi, Switzerland) at 200 mbar until a film was observed. 
The film was dried by increasing the vacuum to 100 mbar for an additional 15 minutes and was 
then hydrated with 3 mL of aqueous phase (final concentration of 3 mg/mL polymer). For 
unloaded nanoparticles PBS was used for hydration, while 1 mg/mL DOX or FITC-OVA in 
PBS was used for loaded nanoparticles. The flask was briefly sonicated for 1 minute prior to 
transfer to a shaking water bath at 45°C for at least 2 hours to allow ample time for hydration. 
 
The resulting dispersion was then extruded through a 400 nm and 800 nm polycarbonate 
membrane stack (Millipore, USA) in a Lipex 10 mL extruder (Transferra Nanosciences Inc., 
Canada) under nitrogen (BOC, New Zealand). Formulations were extruded at least 10 times. 
The resulting nanoparticles were stored in the dark at room temperature until required. 
 
 Production of liposomes 
 
2.6.4.1 Reverse phase evaporation 
 
A modified method from Duzgunes was used (265). Briefly, 7.3 mg (10 µmol) of DPPC and 
1% channels (0.17 mg from 75.5 µL of a 2.26 mg/mL solution in methanol) were dissolved in 
diisopropyl ether to a volume of 1 mL. 0.33 mL of 2 mg/mL FITC-OVA in PBS was added and 
the resulting mixture was briefly sonicated at 50°C to form an emulsion of reverse micelles. 
After emulsification, the ether was removed over 30 minutes by rotary evaporation at 480-745 
70 
 
mbar at 45°C while controlling the rate of evaporation to reduce foaming. After the gel phase 
had broken to produce liposomes, 0.66 mL PBS was added to the flask, and the vacuum was 
increased to 200 mbar to allow residual ether to be removed. 
 
2.6.4.2 Thin film hydration 
 
The lipid film was produced by the addition of 1 mL of a 10 mg/mL DPPC in chloroform 
solution, 100 µL of 2.26 mg/mL ion channel in methanol solution, 20 µL of 10 mg/mL 
cholesterol in chloroform solution and 1 mL chloroform to a round bottom flask. For 
formulations where the inclusion of channels was not necessary, the channel solution was 
substituted with methanol. The solvents were removed by rotary evaporation at 200 mbar until 
a film was observed. The film was further dried by increasing the vacuum to 100 mbar for an 
additional 15 minutes. 
 
The hydration of the film was carried out with 500 µL of aqueous phase to give a DPPC 
concentration of 20 mg/mL. Unloaded liposomes were hydrated using 375 µL of PBS and 125 
µL of filtered 1 mg/mL PEI solution (Appendix A.4). For formulations that did not require PEI, 
PBS was substituted during hydration. Actives were added to the PBS to give a final 
concentration of 1 mg/mL DOX or FITC-OVA. 
 
In addition to the aqueous phase, five 2 mm glass beads were added to the flask, and the flask 
was transferred to a shaking water bath at 45°C for at least 2 hours for hydration. The bath was 
covered to exclude light. The resulting dispersion of MLVs were processed using sonication 






MLVs were sonicated in an Elmasonic S60 H sonicating water bath (Elma Schmidbauer 
GmbH, Germany). The temperature of the bath was set to 45°C, and samples were transferred 
aseptically from the round bottom flask to sterile 5 mL polypropylene tubes (Corning, USA) as 
glass flasks are likely to crack in these conditions. Importantly, the tubes were positioned at 
locations where the contents moved vigorously, indicative of an area of high energy transfer 
into the sample. Tubes were sonicated for 3 cycles of 5 minutes or until a clear dispersion was 
obtained. Formulations were allowed to rest in the dark overnight at room temperature prior to 




MLVs were initially extruded through 400 nm and 800 nm polycarbonate membranes, followed 
by extrusion through a single 200 nm membrane. Formulations were extruded at least 10 times. 
For formulations where an aseptic product was required, 70% ethanol was extruded and sprayed 
on the outlet hose before extrusion. Subsequently, the extruder was flushed twice with 1mL of 
PBS. Liposomes were stored in dark conditions at room temperature. 
 
  Analysis techniques 
 
2.6.5.1 Transmission Electron Microscopy (TEM) 
 
TEM samples were prepared by the addition of 10 µL of formulation onto plasma washed, 
carbon coated, 300 mesh copper grids. After one minute, 10 µL of 1% phosphotungstic acid 
was added as a negative stain. Excess moisture and sample were carefully blotted and images 
were obtained using a Philips CM100 microscope (Philips Electron Optics, Eindhoven, 
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Netherlands) operated at an accelerating voltage of 100 keV. Images were captured using a 
MegaView 3 camera (Soft Imaging System GmbH, Münster, Germany).  
 
2.6.5.2 DLS and zeta potential measurements 
 
DLS and zeta measurements were performed using a Malvern ZEN3600 Zetasizer (Malvern 
Corporation, USA). For DLS measurements 20-40 µL of formulation was diluted in 1 mL of 
PBS within a clear sided acrylic cuvette. The Zetasizer optic position and attenuator were 
automatically determined. Three measurements of ten runs were used to determine the size and 
PDI of the formulation. The measurements were repeated with three batches of formulation, 
and the mean and standard deviation were calculated. 
 
Zeta potential was measured using a Malvern ZEN3600 Zetasizer in conjunction with DTS1060 
zeta cuvettes (Malvern Corporation, USA) and dispersing up to 100 µL of formulation in 
distilled water. Voltages and the duration of measurements were automatically determined. 
Three measurements from one batch of liposomes were used to determine the zeta potential of 
the formulation. 
 
2.6.5.3 PEI-OVA aggregate characterisation 
 
PEI-OVA aggregates were produced from 1 mg/mL and 10 mg/mL OVA solutions and 
1mg/mL PEI solution in 10mM HEPES buffer (BDH Laboratory Supplies, UK). These stock 
solutions were combined in different ratios to give a range from 0-100% PEI compared to OVA. 





2.6.5.4 Measurement of encapsulation efficiency and loading 
 
To determine the encapsulation of FITC-OVA or PEI-FITC-OVA in formulations, unentrapped 
actives were separated by centrifugation using a PrismR benchtop microcentrifuge (Labnet 
International Inc, USA). Samples were centrifuged at 17,000 g for 90 minutes at 4°C. The 
supernatant was reserved and the fluorescence was measured using a POLARstar Omega plate 
reader (BMG LABTECH GmbH, Germany) at 485 nm excitation, 520 nm emission. 
Fluorescence was converted to concentration using standard curves prepared for FITC-OVA 
and PEI-FITC-OVA (Appendix D). 
Encapsulation efficiency (EE%) was calculated as: 
% = (1 −
  
  ) × 100 
For DOX or PEI-DOX containing formulations, unentrapped actives were removed by 
overnight dialysis against PBS in 100 kDa MWCO dialysis tubing (Spectrum Labs, USA) at a 
volumetric ratio of at least 1:300. The fluorescence of the formulation was measured at 485 nm 
excitation and 590 nm emission using a POLARstar Omega plate reader. Fluorescence was 
converted to concentration using standard curves prepared for DOX and PEI-DOX. 
Encapsulation efficiency (EE%) was calculated as: 
% =  
  
  × 100 
The loading was calculated with the following equation for all formulations: 
=  % × ℎ    
While this is not a conventional formula for the calculation of loading, the intention of this is 
to account for fluorescence quenching effects observed during this thesis. While a full 
discussion is available in the next chapter (Section 3.3.2.2), the absolute concentration values 
are affected by fluorescence quenching. Therefore, these values are unlikely to give an accurate 
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estimate of loading. Whereas, the encapsulation efficiency is a ratio that accounts for these 
quenching effects, thus is more likely to give a more accurate loading estimate. 
 
  Stability testing of liposomes 
 
The stability of liposomes was determined by incubating liposomes for 14 days at various 
temperatures. Varieties of formulations with or without PEI and channels were produced 
without loaded actives using the extrusion method outlined above. Aliquots of liposomes were 
incubated at room temperature, 4°C, and 37°C, and samples were taken on days 0, 1, 4, 7, and 
14 to measure the size and PDI of the liposomes using a Malvern ZEN3600 Zetasizer. 
 
2.7  Results and discussion 
 
While a range of techniques and materials were employed to produce the formulations in this 
chapter, the characterisation was similar between formulations with an emphasis on the particle 
size (as discussed in Section 2.3.1.1). In addition to size, other characteristics such as loading, 
zeta potential and stability were examined in conjunction with synthesis of non-commercially 
available compounds and method optimisation. 
 
 Characterisation of polymeric nanoparticles 
 
The first formulations produced and characterized were polymeric nanoparticles reported by 
Car et al. (2). A pH sensitive polymer, PDMS-b-PDMAEMA (PDMAEMA) and pH insensitive 
polymer, PDMS-b-PMOXA (PMOXA) were used in conjunction with the thin film hydration 
and extrusion methods to produce nanoparticles. As the formulations were previously reported 
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(2), the characterisation will be less extensive in comparison to the novel liposomes presented 




The sizes of polymeric nanoparticles produced from PDMS-b-PDMAEMA and the pH 
insensitive PDMS-b-PMOXA variant were investigated with DLS. 
 
Table 2.7.1: DLS size measurements for PDMAEMA nanoparticles with or without 
doxorubicin (DOX). A pH insensitive polymer (PMOXA) is included. Data are n=3 ± SD 
where indicated. 
 Z-average (nm) ± SD Peak size (nm) ± SD PDI ± SD 
PDMAEMA no DOX 185.7 ± 6.5 229.3 ± 30.3 0.193 ± 0.057 
PDMAEMA with DOX 223.0 ± 26.9 297.4 ± 67.8 0.291 ± 0.026 
PMOXA with DOX 198.2 279.5 0.258 
 
Figure 2.7.1: Representative size distribution of PDMAEMA polymeric nanoparticles when 
loaded with DOX. Data are n=3 measurements 
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The PDMAEMA nanoparticles without DOX were shown to have an average diameter of 185.7 
± 6.5nm and a peak diameter of 229.3 ± 30.3 nm (Table 2.7.1). The addition of DOX increased 
the average size to 223.0 ± 26.9 nm (Table 2.7.1, Figure 2.7.1). The  particles are similar in size 
to those made from PMOXA (198.2 nm), a polymer known to produce pH insensitive 
nanoparticles (2). The increase in size in PDMAEMA nanoparticles may have been due to the 
incorporation of DOX into the nanoparticle, as a DOX concentration of 132.5 ± 17.5 µg/mL 
and encapsulation efficiency of 14.00 ± 2.13% was measured (Table 2.7.2). 
 
Table 2.7.2: DOX loading into PDMAEMA, DOX was encapsulated at 1 mg/mL. Data are 
n=3 ± SD 
 DOX concentration (µg/mL) Encapsulation efficiency (%) 
PDMAEMA 
with DOX 
132.5 ± 17.5 14.00 ± 2.13 
 
The size data is similar to that published by Car et al. (186 nm compared to 150 nm), which 
suggests the formation of nanoparticles was successful. TEM images and further 
characterisation can be found in this reference (2) where it was shown the PDMAEMA forms 
micelles using TEM and Cryo-TEM. The pH responsiveness of the formulations is examined 
in Section 3.3.1. 
 
Interestingly, the sizing data suggests that vesicles were formed as the large size traditionally 
excludes micellar morphology. Conventional phospholipid micelles are ~50 nm in size (266), 
in comparison to the ~200 nm particles observed. However, it is important to note that particle 
size is strongly influenced by the size of the polymer or phospholipid (267). A phospholipid is 
smaller than many polymers, for example, DPPC has a molecular weight of 734 g.mol-1 while 
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the PDMS-b-PDMAEMA has a predicted molecular weight of ~7000 g.mol-1. Therefore, it is 
possible to form very large micelles using these polymers. 
 
PDMS-b-PDMAEMA was found to be completely incompatible with FITC-OVA, with loading 
below detectable levels and no nanoparticles were detected with DLS (data not shown). This is 
additional evidence suggesting the polymers do not form vesicles that can incorporate proteins 
into the aqueous compartment. Although micelles have been shown to deliver OVA (268), the 
OVA was adsorbed to the surface of pristine micelles. With PDMAEMA micelles, the addition 
of OVA during hydration may have disrupted the formation of micelles entirely, as the 
extrusion of polymer was not possible due to clogging of the polycarbonate membranes. This 
suggests the formation of very large aggregates or a gel-like substance. 
 
To discuss the mechanism behind the formation of micelles compared to vesicles, the shape of 
the subunit (i.e. phospholipid or polymer chain) must be described. Israelachvili’s theory on 
the self-assembly of micelles and vesicles (269) forms the basis for other theories (270), such 
as Discher’s theory for polymersome morphology (267). 
 
To summarise Israelachvili’s theory (Figure 2.7.2), the shape of the subunit (phospholipid or 
polymer), or the packing parameter, determines the overall shape and size of the nanoparticle. 
The packing parameter can be summarised as: 
 =  
  ℎ ℎ  ℎ
 ℎ    ×  ℎ   
Micelles with a small radius of curvature possess cone-like subunits, which are represented as 
a subunit with a large polar head group. Spherical micelles may form when the packing 
parameter is ~1/3. Whereas, with vesicles with a bilayer membrane the subunits must arrange 
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into a flat sheet. Therefore, the packing parameter must be closer to 1, which represents a well-
balanced cylindrical shape. 
 
 
Figure 2.7.2: A demonstration of the relationship between subunit shape and curvature and 
packing of lipids. Cylindrical subunits with a packing parameter close to 1 (top) are more 
likely to form vesicles, while cone-like subunits with a packing parameter of 1/3 are likely to 
form micelles (bottom). 
Discher’s theory for polymeric nanoparticle morphology simplifies Israelachvili’s theory to 
hydrophilic fraction, f, which describes the size of the hydrophilic chain in relation to the 
hydrophobic chain in amphiphilic polymers. It is thought that compounds with a hydrophilic 
fraction of ~35% form cylindrical subunits suitable for vesicle formation (267). Car et al. (2) 
reported that PDMAEMA (the hydrophilic moiety) contributed 13% mass to the overall PDMS-
b-PDMAEMA polymer. This is interesting, as this is too low for the predicted formation of 
vesicles and micelles, and inverted micelles are predicted (267). Therefore, surface specific 
techniques such as X-ray photoelectron spectroscopy may be used to determine the elements 
present at the surface (up to 10 nm depth) (271) to confirm the micellar structure of these 
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nanoparticles. If the nanoparticles are indeed micelles the surface of these nanoparticles is 
expected to be high in nitrogen (PDMAEMA) and low in silicon (PDMS). 
 
Ideally, PDMAEMA would have produced polymeric vesicles (polymersomes), as 
polymersomes exhibit several advantages compared to their lipid counterparts. Firstly, the size 
of a polymer chain can be considerably larger compared to phospholipids. Therefore, the 
membrane thickness of the vesicles is increased leading to more physically robust vesicles, as 
well as reduced rates of diffusion across the membrane leading to a more stable formulation 
(267). Furthermore, polymers are inherently easier to modify and functionalise compared to 
phospholipids as they may be synthesised de-novo, whereas as phospholipids are commonly 
purified from natural sources only allowing semi-synthetic approaches. This simplicity is most 
apparent when comparing pH sensitive polymers against the functionalised liposomes in this 
thesis. In comparison to PDMAEMA, liposomes require two additional components that adds 
complexity and cost to the formulation. 
 
2.8 Synthesis of ion channels for modified liposomes 
 
One of the components of the liposomal formulation are the beta-cyclodextrin based ion 
channels that were produced using the synthetic scheme reported by Chui et al. with 
modifications (Figure 2.8.1). Per-6-iodo-beta-cyclodextrin (1) was produced from beta-
cyclodextrin via an Appel-type iodination and this was subsequently converted to per-6-azido-
cyclodextrin (2) via nucleophilic substitution of the iodo groups with an azide (N3). In readiness 
for the 1,3-dipolar cycloaddition “click” reaction, 5-hexyn-1-ol was reacted with 
perfluorobutyrl chloride to produce ester (3). (2) and (3) were then reacted to give the final 
cyclodextrin product, (4). 
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 Synthesis of cyclodextrin based ion channels 
 
 
Figure 2.8.1: Synthetic scheme outlining the synthesis of cyclodextrin channels (4). 
Confirmation of structure for per-iodo (1) and per-azidocyclodextrin (2) was provided by 
comparing the proton NMR spectra with that reported in the literature. Figure 2.8.2 
demonstrates the successful conversion of beta-cyclodextrin to (1) via the disappearance of the 
6’-OH proton. Successful conversion of (1) to (2) was demonstrated by comparison with the 
literature and an observed change in the chemical shift of peaks in the 3.3-4.8 ppm region of 
the spectrum. The triplet at 4.49 ppm representing the proton of the hydroxyl group which was 
substituted with iodine is absent (Figure 2.8.2, red box B and C), while a shift from 5.76 ppm 
and 5.71 ppm to 6.13 ppm and 6.05 ppm was observed for the hydroxyl groups in the second 
and third positions respectively (Figure 2.8.2, blue box). However, during this step the 
production of oxidised triphenylphosphine (Ph3P=O) occurred, appearing as a multiplet from 
7.64 ppm to 7.56 ppm, despite purification of the sample via Soxhlet extraction with methanol 
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for 48 hours. Therefore, the oxidised triphenylphosphine was carried forward, and was only 
present in trace amounts in the final compound (Figure 2.8.5 A). The full spectra are available 
in Appendix C.  
 
Figure 2.8.2: 1H NMR spectra of (2), A; (1), B; and beta-cyclodextrin, C. The red box 
indicates the protons associated with the hydroxyl group at the 6th position of the hexose. The 
blue box corresponds to the hydroxyl groups at positions 2 and 3. Proton assignments were 














The synthesis of (3) was straightforward with the reaction between an acid chloride and alcohol 
resulting in the formation of an ester. The structure of (3) was confirmed by analysis of the 1H 
NMR spectrum (Figure 2.8.3) as the disappearance of the alcohol proton (4.4 ppm, Figure 
2.8.3A) and the significant downfield shift (from 3.41ppm in the Figure 2.8.3A to 4.48 ppm in 
Figure 2.8.3B) of the methylene (CH2) protons adjacent to the newly formed ester functional 
group. Additionally, (3) integrated to 9 protons while the starting 5-hexyn-1-ol integrated to 10 
protons demonstrating the loss of a proton during ester formation. While (3) was reported in 
literature (3), a direct comparison is not possible due to a difference in solvent systems (DMSO 
versus methanol). 
 











Lastly, compounds (2) and (3) were combined in a click reaction, resulting in the final product 
(4) (Figure 2.8.4 and Figure 2.8.5). Evidence for the success of this reaction is present in the 
stacked 1H NMR spectra (Figure 2.8.5), as the alkyne (2.80 ppm) in (3) was consumed and is 
no longer present in (4), while the formation of a broad triazoline peak, partially obscured by 
the remaining triphenylphosphine at 8.03 – 7.55ppm was observed in (4). When the 1H NMR 
spectrum was run in methanol-d4 the triazole proton peak was observed as a sharp singlet 
(Figure 2.8.4), which was more consistent with literature. 
 
 
Figure 2.8.4: 1H NMR spectrum for compound (4) in methanol. 
Although the synthesis of (4) was previously described, purification to remove excess copper 
and remaining triphenylphosphine oxide was a major challenge. One of the key issues was the 
polarity of the channel as it is soluble only in polar solvents such as DMSO and methanol. Chui 
et al. used silica gel chromatography to purify (4) where the eluent was 20% methanol in 
chloroform. However when this protocol was attempted, no compounds were recovered from 





Figure 2.8.5: 1H NMR spectra of (4), A; (2), B; and (3), C (spectra in DMSO). The red box 
indicates the proton peak associated with an alkyne, while the blue box indicates the broad 
triazoline peak that was partially obscured by triphenylphosphine. Peak assignments were 
reported by Chui et al. (3). 
Fortunately, the polarity of (4) provided an opportunity for partial purification. As (4) is 
insoluble in non-polar hexane, non-polar impurities, such as (3), were removed by washing 
with hexane and 1:1 hexane: ethyl acetate. After several washes a reasonably pure compound 
was obtained, as shown by 1H NMR spectroscopy (Figure 2.8.5A). The product was dried to 













The light green colour of the final compound is likely due to residual copper, as washing with 
non-polar solvents does not remove ions. A chelating resin was trialled (Chelex-100, Sigma-
Aldrich, USA) to bind copper, where the crude product was dispersed in methanol to chelate 
copper to the resin. However, a precipitate was formed during this step and the final compound 
could not be recovered. 
 
The presence of residual copper in the final compound is unlikely to have significant effects in 
biological systems due to the concentrations at which the channel is used in the formulation (1 
mol% to lipids). This represents a copper concentration in the nanomolar range (0.446 mg/mL 
of channels in formulation is 196 nM of copper, assuming no loss in copper), which is far below 
the IC50 of 230 ± 20 µM reported for copper nitrate in mammalian cell lines (273). A potential 
cause for concern was the stability of liposomes as copper is a transitional metal that can lead 
to greater peroxidation of lipids (263). Therefore, the stability of the liposomes in the presence 
of channel was examined in Section 2.6.6. In addition to potential stability issues, another issue 
of copper is its effects on the quality of the 1H NMR spectrum of (4) (Figure 2.8.5) as it may 
explain the broadness of the peaks. 
 
2.9 Formation of PEI-OVA aggregates 
 
The second component required for the formulation of pH responsive liposomes is PEI. The 
rationale for the use of PEI comes from transfection studies where the positively charged PEI 
chains are able to form aggregates with negatively charged DNA. These aggregates, termed 
polyplexes, have been used extensively in transfection studies due to their ability to enter the 
cytoplasm and will be explained in the next chapter (Section 3.1.2). As OVA is also negatively 
charged an electrostatic interaction between OVA and PEI may be possible. Figure 2.9.1 shows 
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the change in zeta potential with increasing PEI concentration starting with -8.8 mV for pure 
OVA reaching a plateau of 7.7 mV at 10% PEI. This suggests the PEI is modifying the charge 
of the particles in solution, which is consistent with the formation of aggregates.  

















Figure 2.9.1: Changes in zeta potential when increasing the ratio of PEI to OVA. Data were 
collected using laser Doppler micro-electrophoresis. Data are n=2 ± range 
In addition to the change in zeta potential, a change in size with increasing PEI concentration 
was observed (Figure 2.9.2). An important trend is the increase in particle size with PEI ratios 
greater than 10% (0.1 mg/mL PEI) suggesting the adsorption of PEI continues past the plateau 
in zeta potential seen in Figure 2.9.1. Additionally, the combination of PEI and OVA at a ratio 
of 9:1 resulted in a particle size greater than the two starting constituents further adding 
evidence the PEI and OVA form aggregates. The small size of these aggregates, 14.2 nm in 
size, is unlikely to interfere with the formulation of liposomes compared to the large ~300 nm 
aggregates observed by Chen et al. (274). The size disparity between their results and the results 
presented here are likely due to the preparation of PEI, as large precipitates that formed during 
the production of PEI solution were removed by filtration. As the objective of Chen et al. was 




Figure 2.9.2: Relationship between particle size and fraction of PEI in PEI-OVA aggregates 
measured by DLS. Data are n=3 ± SD. 
Taking Figure 2.9.1 and Figure 2.9.2 together, the PEI concentration was selected to be 0.25 
mg/mL in formulations. The major impetus behind this decision was the plateau in zeta 
potential and the need for free PEI chains for the proton sponge effect to occur (this will be 
discussed further in Section 3.1.4). 0.25mg/mL PEI represents 25% (w/w) PEI versus OVA 
when formulated with 1mg/mL OVA. This is well above the 10% where the plateau in zeta 
potential occurs. As the charge of OVA is completely neutralised beyond 10%, it was assumed 
that some free chains of PEI were available at 25%. 
 
Transfection studies have shown that the ratio of nitrogen from PEI and phosphorus from DNA 
(termed the N:P ratio) is important for optimal DNA delivery (275, 276). While DNA 
transfection studies are unlikely to translate directly to antigen delivery, Chen et al. also 
observed a relationship between antigen delivery and PEI:OVA ratios (274). They concluded 
an optimal ratio exists where higher amounts of PEI improved antigen delivery, but this was 
constrained by the cytotoxicity of PEI at higher ratios. However, as they formed solid 























formulation in this thesis. As the PEI-OVA is entrapped in the interior of the liposome, this 
may reduce toxicity. The toxicity of these formulations is examined in Chapter 4 (Section 
4.3.9). 
 
2.10  Production and characterisation of liposomes 
 
Due to the novelty of this formulation, many techniques such as reverse phase evaporation, 
extrusion, and sonication were investigated and optimised in order to produce small 
homogeneous nanoparticles with a high loading capacity. As indicated earlier, the liposomes 
consist of DPPC liposomes containing cyclodextrin ion channels and PEI-OVA aggregates. 
 
 Size characterisation and optimization 
 
As size is a salient factor for nanoparticles, method development was guided by the size and 
size distribution of particles. Ideally, the formulation will have a size below 500 nm and a PDI 
below 0.3 which indicates a homogenous population of particles.  
 
2.10.1.1 Reverse phase evaporation 
 
The first method that was utilised was reverse phase evaporation. It was chosen based on the 
benefits of having high encapsulation efficiency without the need for further processing, as is 
required with the thin film hydration method (for example, extrusion). The size and size 
distribution summarized in Figure 2.10.1 suggests while the size is acceptable (212.5 nm) the 
formulation was heterogeneous with a PDI of 0.451 and three distinct populations, thus it is 
inappropriate to suggest the z-average size of 212.5 nm is representative of this sample. One 
possible explanation for these results is that the formation of the w/o emulsion followed by the 
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gel phase was not successful. This was supported by experiments where after leaving the 
emulsion to stand for 30 minutes the two phases separated. One possible reason for the failure 
of the emulsion to form is due to the addition of channels as their inclusion may have interfered 
with the emulsion. Israelachvili’s theory suggests that the bulky polar cyclodextrin headgroup 
of the channels is not suitable for the formation of inverse micelles as a small headgroup is 
more favourable for the production of inverse micelles (Section 2.7.1.1) (277). 
 
Figure 2.10.1: Representative average size, and distribution of a PEI-OVA + 1% channel 
liposome dispersion produced using reverse phase evaporation. 
Another issue with this method is the relatively high reliance on visual cues and prior 
knowledge required to complete the process. For example, the formation of an acceptable 
emulsion where the correct rate of evaporation of ether and the successful formation of a gel 
require understanding visual cues (207). From many attempts, very few formulations yielded 
nanoparticles. While extrusion would likely have reduced particle size and increased 
homogeneity, encapsulation efficiency would have decreased (278) negating a major advantage 
for this technique. If extrusion is required, the thin film hydration method is a more simple 





















2.10.1.2 Thin film hydration and sonication 
 
As reverse phase evaporation was not suitable for the production of liposomes, thin film 
hydration was used to produce MLVs. MLVs were refined into unilamellar vesicles by 
sonication, which was achieved using a bath sonicator. The bath sonicator was selected as it 
does not cause the release of metallic nanoparticles compared to a probe sonicator and 
formulations can be prepared in aseptic conditions.  Compared to extrusion, sonication does 
not suffer from the drawback of potential loss of lipids or actives during size reduction (279, 
280). In addition, actives such as DOX adsorb to the surface of the extruder, necessitating 
complete disassembly and replacement of polytetrafluoroethylene containing components. 
 
Initial attempts at producing sonicated liposomes were not successful, as the size and 
homogeneity was not suitable for vaccine or drug delivery (Figure 2.10.2, blue).  
  
Figure 2.10.2: Representative average size, and distribution of a PEI + 1% channel liposome 






















However, by using the highly reactive points (anti-nodal points) within the bath, much more 
sonication energy was delivered to the MLVs. Thus, pharmaceutically acceptable liposomes 
were able to be produced (Figure 2.10.2, orange), even when actives are encapsulated, which 
is summarised in Table 2.10.1. Interestingly, a small population of particles approximately 50 
nm in size was also observed. These smaller particles may be SUVs, as it is unlikely that these 
particles are PEI-OVA aggregates, which are closer to 10 nm in size (Figure 2.9.2). 
 
Table 2.10.1: Size and homogeneity measurements for loaded and unloaded sonicated PEI + 
1% channel liposomes acquired using DLS. Data are n=3, except for FITC-OVA loaded 
liposomes (n=2). 
 Z-average (nm) ± SD Peak size (nm) ± SD PDI ± SD 
No actives 90.1 ± 1.0 116.9 ± 0.9 0.260 ± 0.006 
FITC-OVA (1 mg/mL) 123.7 ± 7.9 198.4 ±18.6 0.379 ± 0.002 
DOX (1 mg/mL) 134.9 ± 10.6 152.7 ± 11.3 0.386 ± 0.058 
 
The addition of FITC-OVA or DOX caused the size distribution of particles to become more 
heterogeneous (Table 2.10.1) as the PDI is above 0.3 with both actives. However, this is 
unlikely to be an issue as closer examination of the particle size distribution (Figure 2.10.3) 
shows a major peak (95%) of particles at 100 nm. While smaller populations of larger particles 
are present, it is likely these are aggregates formed due to the addition of actives. In the case of 
OVA, it is known to cause aggregation of liposomes at a protein to lipid ratio above 0.03 (here 
it was 0.05) due to electrostatic attraction between negatively charged OVA and positively 
charged liposomes, or hydrophobic interactions between OVA and lipid tails (281). However, 
DOX was not expected to induce aggregation in neutral DPPC liposomes (282), which suggests 




Figure 2.10.3: Representative size distribution of DOX loaded, sonicated PEI + 1% CHAN 
liposomes. 
2.10.1.3 Thin film hydration and extrusion 
 
Although there are drawbacks to extrusion as mentioned above, there are also benefits such as 
limiting the exposure of liposomes to high temperatures and ROS production associated with 
sonication. MLVs were extruded through polycarbonate membranes to form liposomes (Figure 
2.10.4 and Table 2.10.2) with acceptable size (179.5 ± 2.8 nm) and homogeneity (PDI of 0.219 
± 0.013).  
 
TEM images showed spherical particles with morphologies that are consistent with liposomes. 
Particle size was variable, however measurement of 10 particles gave a mean particle size of 
219.39 ± 106.67 nm (Figure 2.10.5), which is in agreement with sizes observed with DLS 




















Figure 2.10.4: Representative size distribution of extruded, 1% channel, DOX-PEI loaded 
liposomes. 
 
Figure 2.10.5: TEM images of 1% PEI-OVA liposomes at 33,000× magnification, 
counterstained with phosphotungstic acid. Scale bar is 200 nm. 
Compared to sonicated liposomes, the size of the extruded particles is larger (179.5 ± 2.8 nm 




















liposomes), which is due to the pore size of the membrane used for extrusion (200 nm). 
However, both formulations are likely to be taken up effectively by dendritic cells (182, 283).  
 
The improved PDI for extruded liposomes with DOX in comparison to sonicated liposomes 
(0.219 ± 0.013 for extruded liposomes compared to 0.386 ± 0.058 for sonicated liposomes) is 
interesting. While this increase in homogeneity may be attributed to the process of extrusion 
(227) as the pore diameter of the membrane is tightly controlled by the manufacturer, this is 
also an indication that PEI and DOX may be forming a different compound during sonication 
due to high temperatures (discussed further in Section 3.4.2.5). As extruded liposomes are not 
exposed to high temperatures they do not appear to form this product and the liposomes do not 
aggregate, which is consistent with literature (282). 
 
Table 2.10.2: Size and homogeneity measurements for extruded FITC-OVA or DOX 
encapsulated PEI + 1% channel liposomes acquired using DLS. Data are n=3 ± SD 
 Z-average (nm)  Peak size (nm)  PDI 
FITC-OVA (1 mg/ml) 250.0 ± 83.2 158.8 ± 4.6 (48.2%) 
1081.0 ± 287.1 (50.9%) 
0.481 ± 0.041 
DOX (0.5 mg/mL) 179.5 ± 2.8 218.8 ± 15.7 0.219 ± 0.013 
 
For OVA based formulations, the liposomes were found to be very heterogeneous with two 
observed populations (158.8 ± 4.6 nm and 1081.0 ± 287.1nm) suggesting the PEI-OVA 
aggregates have a negative effect on the homogeneity of extruded liposomes. This may be an 
issue for uptake due to the large population of large liposomes (Table 2.10.2). However, as 
sonicated liposomes are also polydisperse (0.379 ± 0.002), OVA induced aggregation explains 
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the high PDI in both the extruded and sonicated formulations, and may require the reduction in 
the OVA:lipid ratio to improve homogeneity in the future (281). 
 
 Optimisation of channels 
 
In the original report by Chui et al., channels were added to lipids at 1% concentration to 
demonstrate their permeability (3). Therefore, the effect of the addition of 0.5%, 1%, and 4% 
channels on liposome size and formulation homogeneity was examined for liposomes prepared 
by thin lipid film hydration with sonication (Figure 2.10.6, Table 2.10.3). The 4% channel 
demonstrates the effect of a large excess of channels, as a fine precipitate was observed 
suggesting the channels were no longer incorporated into liposomes at this concentration. 
 
 
Figure 2.10.6: Representative particle size distribution of sonicated liposomes with varying 
concentrations of channels (mol% compared to DPPC). Data were collected by DLS. 
From this data, there appears to be little impact of channel concentration on particle size as the 
average diameter at 0.5% channels is 109.3 ± 1.0 nm, which decreases to 90.0 ± 1.0 nm at 1%, 
followed with an increase to 127.1 ± 0.2 nm at 4%. This was unexpected as cyclodextrins were 








expected to affect the packing of the lipids, as the interfacial area of the channel is larger than 
that of phospholipids due to the size of the cyclodextrin polar head group. Thus the presence of 
channels should force more strain on the bilayer forcing a smaller vesicle size (284). Some 
evidence for this hypothesis exists as there are size decreases between 0.5% and 1% sonicated 
channel liposomes (Figure 2.10.6), and also extruded liposomes (Figure 2.13.1, 194.9 ± 1.4 nm 
for 0% channels, 171.8 ± 0.3 nm for 1% channels). The increase in size at 4% may be an outlier 
due to the formation of precipitates that may explain the lack of a general trend. However, more 
experiments are required to draw a firm conclusion. 
 
Table 2.10.3: Particle size (Z-average and peak) and PDI of sonicated PEI + channel 
liposomes with varying concentrations of channels (mol% compared to DPPC). Data are n=3 
± SD 
 Z-average (nm)  Peak size (nm)  PDI  
0.5% channels 109.3 ± 1.0 148.0 ± 12.0 0.281 ± 0.009 
1% channels 90.0 ± 1.0 116.9 ± 0.9 0.260 ± 0.006 
4% channels 127.1 ± 0.2 140.6 ± 1.6 0.106 ± 0.013 
 
 Detection of channels in liposomes 
 
A number of methods were investigated to provide confirmation that the channels were 
inserting into the liposome bilayer. However, this was challenging as the channels are present 
at a low concentration (1% compared to lipids) and have a small size (1.54 nm outer diameter 
(285), which prevents detection by electron microscopy. Additionally, the channels are in a 
complex formulation containing phospholipids, polymers, and protein that makes the use of 
detection methods such as NMR unfeasible. Although attempts were made to isolate the 
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channels via chromatography (Sephadex LH-20), the low concentrations at which the channels 
were present prevented recovery.  
 
Therefore, a strategy involving amantadine was developed to detect the presence of channels. 
While it is known for its anti-viral effects (286), the cage-like structure of carbon in amandatine 
is also an excellent guest for the hydrophobic cavity of cyclodextrin (287). It was our hypothesis 
that positively charged amantadine may be able to provide information about the presence of 
channels, as the adsorption of amantadine through host-guest effects would increase the 
positive charge of liposomes. The addition of amantadine to liposomes without channels 
resulted in a change of zeta potential from a negative value to a positive value (-2.11 ± 0.50 
mV to +2.43 ± 0.67 mV). However, the addition of channels at 0.5 and 1% did not have a 
significant effect on the zeta potential (+2.91 ± 0.25 mV for 0.5% CHAN and +3.58 ± 0.36 mV 
for 1% CHAN, p = 0.0599), suggesting this assay lacked sufficient sensitivity to detect the low 
concentration of channels added to the formulation. 
 
Formulations were dialysed overnight after exposure to amantadine to remove non-specifically 
adsorbed amantadine from the surface of liposomes in the hope of improving sensitivity (Figure 
2.10.7). However, instead the zeta potentials were indistinguishable from those of liposomes 
without amantadine (-0.89 ± 1.29 mV for 0% CHAN, +0.27 ± 0.50 mV for 0.5% CHAN, and 
-0.10 ± 0.40 mV for 1% CHAN, p= 0.3334). One possible explanation for this may be that all 
amantadine was removed by dialysis, including the amantadine within the channels. While 
specific data on amantadine release from cyclodextrin was not available, the release of 
aceclofenac and diltiazem from beta-cyclodextrin derivatives suggests the release of guests 
from the cyclodextrin cavity may occur within 1-2 hours (288, 289). Therefore, faster 



















































Figure 2.10.7: Zeta potential of liposomes containing 0%, 0.5% or 1% channels (without 
PEI). The addition of amantadine was expected to increase the positive charge of liposomes 
in relationship to the channel concentration. Liposomes exposed to amantadine were dialysed 
overnight to remove amantadine. Data are n=3 ± SD of 3 measurements. 
 
Another explanation for these results is the amount of channels may be too small to show a 
detectable change in zeta potential, given the channel is present at 1% concentration. Therefore, 
synthesising an amantadine derivative with a fluorescent moiety would perhaps increase the 






2.11 Loading efficiencies of liposomes 
 
The loading and encapsulation efficiencies of the liposomes prepared using the thin film 
hydration and either sonication or extrusion was examined. Overall, the liposomes encapsulated 
both DOX and FITC-OVA successfully making them suitable carriers for both small drugs for 
chemotherapy and large proteins for vaccine delivery (Table 2.11.1). 
 
For DOX, the small volumes used during hydration resulted in high passive loading mirroring 
the efficiencies achievable with reverse phase evaporation (30.83 ± 12.47% for extruded 
liposomes and 67.6 ± 16.6% for sonicated liposomes) (278). It is to be noted that the 
encapsulation efficiency for sonicated DOX loaded liposomes was unusually high for passive 
loading (67.6 ± 16.6%) with an encapsulation efficiency of 80% being observed in one batch 
of liposomes. This is a further indication that a reaction between PEI and DOX during 
sonication is occurring, as it appears the PEI and DOX are forming a product that can adhere 
to liposomes. This would result in increased encapsulation as well as explaining the increased 
aggregation as reported earlier (Section 2.10.1.3). 
 
OVA encapsulation efficiency was lower in comparison to DOX (13.71 ± 3.05% for extruded 
liposomes, and 21.7 ± 19.0% for sonicated liposomes). While the difficulty of encapsulating 
large hydrophilic proteins such as OVA is known (290), no straightforward explanation is 
available in literature. One possible explanation is the encapsulation of protein in liposomes is 
primarily due to the adsorption of protein to liposomal membranes via non-covalent 
interactions (291) or direct insertion into membranes (292). Therefore, the loading of proteins 
is low as it is restricted to the liposomal membrane area, in comparison to DOX which may be 
loaded into the aqueous interior in addition to adsorbing to the membrane. However, as higher 
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OVA loading has been previously reported in the literature (47.9% ± 8.9%, (231)), perhaps the 
addition of PEI may have had a negative effect on loading. 
 
The encapsulation of OVA was highly variable for sonicated liposomes, which may be 
indicative of inconsistent conditions during sonication. The delivery of a constant amount of 
ultrasonic energy was difficult as the location of the high-energy antinodal points within the 
sonicating bath was irregular with large inter-day variability. As the loading of OVA was more 
consistent with extrusion in comparison to sonication all further studies were carried out using 
extruded liposomes only. 
 
Table 2.11.1: Loading of extruded or sonicated PEI + 1% channel liposomes with DOX (0.5 
mg/mL) or FITC-OVA (1 mg/mL). Data are n=3 ± SD, except for sonicated FITC-OVA 
liposomes (n=2 ± SD) 
 Loading (µg/mL) Encapsulation efficiency (%) 
   
Extruded liposomes   
DOX  154.2 ± 62.4 30.83 ± 12.47 
FITC-OVA  137.1 ± 30.5 13.71 ± 3.05 
   
Sonicated liposomes   
DOX  338.0 ± 83.1 67.6 ± 16.6 





2.12 Zeta potential of loaded liposomes 
 
As discussed earlier (Section 2.3.2), the zeta potential may have an effect on the stability of 
liposomal formulations and values above +30 mV or below -30 mV are desirable. The 1% 
CHAN + PEI liposomes were measured with a zeta potential of 12.5 ± 0.2 mV (Figure 2.12.1). 
The zeta potential of the liposomes with PEI and without channels (PEI) was 11.7 ± 0.8 mV 
and 6.5 ± 0.5 mV for liposomes with 1% channels without PEI (1% CHAN). This suggests the 
PEI has an effect on increasing the zeta potential and is likely adsorbed to the surface, whereas 
channels do not appear to have an effect. This is consistent with the positively charged amines 

























Figure 2.12.1: Zeta potential of liposomes with 1% channels (1% CHAN), PEI, or both (1% 
CHAN + PEI) in PBS. Data are n=3 ± SD. 
Given these formulations are below the +30 mV threshold, the stability of the liposomes for 
two weeks in these conditions were examined. The low zeta potential of the liposomes is likely 
due to the high ionic strength of the PBS buffer which reorients the zwitterionic heads of DPPC 
to reduce the zeta potential of the liposomes (293). 
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2.13  Stability of liposomes 
 
Extruded OVA-loaded liposomes with and without channels and PEI were produced and the 
size and PDI were recorded on days 0, 1, 4, 7, and 14 following storage at room temperature, 
4°C and 37°C (Figure 2.13.1). 
 
Figure 2.13.1: Liposome size (Z-average, left) and PDI (right) measured by DLS for 14 days 
at room temperature (A), 37°C (B), and 4°C (C) of OVA encapsulated, extruded liposomes 
(liposomes only), liposomes with 1%  channels (+ CHAN), liposomes with OVA-PEI (+ PEI),  
liposomes with 1% channels and  OVA-PEI (PEI + CHAN). Data are n=3 ± SD. N.B. the size 
data for PEI + CHAN is almost identical to +CHAN and is therefore not clearly visible. 
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At room temperature, all formulations were found to be stable for two weeks as very little 
fluctuation in particle size and PDI was observed (Figure 2.13.1A). This trend was repeated 
with liposomes incubated at 37°C (Figure 2.13.1B). However, there was an exception between 
day 0 and 1 for unmodified liposomes and liposomes with PEI where a minor reduction in 
particle size was observed (194.9 ± 1.4 nm to 176.4 ± 1.1 nm for unmodified liposomes, and 
199.0 ± 3.3 nm to 179.2 ± 1.1 nm for PEI modified liposomes). The same decrease in size was 
not observed for channel containing liposomes suggesting the addition of channels was 
protective against this unexpected observation. Traditional sources of instability such as 
aggregation predicts an increase in particle size, thus the significance of resisting this decrease 
in particle size is unknown. 
 
The results at 4°C most clearly demonstrates the stabilising effects of the channels at low 
temperature (Figure 2.13.1C) as DPPC liposomes undergo fusion at 4°C. At higher 
temperatures (i.e. RT and 37°C) the deaggregation rate of liposomes is high, whereas at 4°C 
the rate of deaggregation is low (294). This causes aggregation and subsequent fusion of 
liposomes as predicted by the DLVO theory (295). Interestingly, the two formulations 
containing channels (1% channel modified liposomes and 1% channel + PEI modified 
liposomes) demonstrated exceptional stability, where the differences in particle size between 
these two groups was indistinguishable (Figure 2.13.1). This suggests the channels may have a 
cholesterol-like effect on membrane rigidity, as high concentrations (50%) of cholesterol 
stabilises the membrane to prevent fusion at 4°C (294). The improved stability and near-
identical sizes of channel-containing liposomes adds further evidence the channels are indeed 
present within the formulations. Although the low concentration of channels appears to exert 
an usually large effect, the theoretical area each channel can affect may be as large as 3nm in 
diameter, as the alkyne tails of the channels may be spread out within the membrane. Assuming 
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an average liposome size of 200nm, only 8 600 channels are required in comparison to 
approximately 4 000 000 DPPC molecules within the liposome, or 0.22 mol% (see Appendix 
D for calculations). Therefore, it is theoretically plausible for the 1% channels to provide a 
strong stabilising effect. 
 
The enhanced stability observed with channel modified liposomes is in contrast to initial 
expectations. As stated in Section 2.8.1, residual copper ions from channel synthesis were 
theorised to assist in the oxidation of phospholipids disrupting liposomes and impacting on  size 
measurements (296). However, it may be possible the damage from copper ions was not able 
to be observed within this short experiment and longer experiments may be required to fully 
assess oxidative damage. 
 
The major limitation of this experiment is the stability has been assessed by measuring size and 
homogeneity of formulations without the measurement of loading or encapsulation efficiency. 
While a more in-depth discussion of this will be presented in the next chapter (Section 3.3.2.2), 
the measurement of actives via fluorescence was not found to be reliable. Therefore, to avoid 
drawing false conclusions, stability was assessed by DLS measurements only. 
 
2.14  Conclusion 
 
In conclusion, nanoparticles were produced from polymers and lipids. In the case of PDMS-b-
PDMAEMA polymer, utilising the thin film hydration method in conjunction with extrusion 
produced nanoparticles capable of loading DOX but not OVA. DPPC liposomes were 
functionalised using synthesised cyclodextrin based channels and PEI by utilising sonication 
and extrusion techniques to produce liposomes, which was successful in encapsulating DOX 
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and FITC-OVA. Although the liposomal formulations showed minor issues such as 
heterogeneity in size and a low zeta potential, no issues were detected in stability studies, where 
the addition of channels imparted protection against cold induced fusion and aggregation of 
liposomes. 
 
In the next chapter, the pH sensitivity of the prepared formulations will be evaluated with in 








Chapter 3 : Release characteristics of 





pH sensitive nanoparticles have long been recognised as a potential approach by which the 
release of actives can be delivered more effectively to the tumour. Thus, the formulations that 
were successfully created in Chapter 2 were analysed for pH sensitivity in this chapter. The 
aims for this chapter were to determine the suitability of assays used to measure the release of 
actives from polymeric nanoparticles and liposomes. Following the assessment of assays, the 
acid-specific release properties were examined. 
 
While a plethora of pH sensitive release mechanisms have been examined in literature and were 
reviewed in Chapter 1 (Section 1.2.1), only two mechanisms are important to this thesis. Firstly, 
changes in subunit shape will be discussed as the polymeric nanoparticles are likely to undergo 
a change in subunit shape in response to acidification. Secondly, the ‘proton sponge effect’ 
allows modified liposomes to take advantage of the acidic endosomal conditions to improve 
cytoplasmic delivery of vaccines or cytotoxic drugs.  
 
 Changes in subunit shape 
 
Israelachvili’s (277) and Discher’s (267) theories on particle morphology state more conic 
subunits with a larger interfacial area are likely to form micelles while cylindrical subunits with 
a balanced size between hydrophobic and hydrophilic regions form vesicles (Section 2.7.1.1). 
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These theories can be exploited to cause the collapse of vesicles by influencing the shape of 
cylindrical subunits in situ. 
 
One of the simplest causes of in situ modification of subunit shape is the presence of ionisable 
weak acids or bases in polar regions of amphiphilic subunits. To illustrate this, cholesteryl 
hemisuccinate (CHEMS) and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) 
liposomes are stable at physiological pH due to the complementary conic shapes of the two 
substituents (Figure 3.1.1). However, CHEMS contains a carboxylic acid group that is ionised 
in physiological conditions. When exposed to acidic conditions the carboxylic acid 
deprotonates and deionises, causing a decrease in interfacial area. This effects a change in 
subunit shape, which is no longer able to stabilise the bilayer leading to rapid disassembly of 
the vesicle (297). 
 
The formulation of nanoparticles composed of PDMS-b-PDMAEMA seeks to exploit a change 
in subunit shape through Discher’s theory (267), where the hydrophilic fraction of the 
amphiphile (ƒ) determines the shape of the subunit and subsequently the particle morphology. 
The hydrophilic PDMAEMA domain of the polymer is polycationic with the presence of 
tertiary amine groups, which become positively charged in acidic conditions. Therefore, with 
a decrease in pH  PDMAEMA becomes more ionised, increasing ƒ and causing the collapse of 
vesicles (267). However, as the PDMS-b-PDMAEMA nanoparticles are micelles (Section 
2.6.3), Car et al. (2) suggests the increased strain from an increase in ƒ allows actives to escape 
from the hydrophobic core. The PMOXA-b-PDMS control nanoparticles do not contain an 
ionisable group. Therefore, no changes in ƒ, and subsequently particle morphology are 






Figure 3.1.1: Depiction of CHEMS: DOPE liposomal bilayer and mechanism of action. 
CHEMS and DOPE have complimentary shapes to stabilize bilayer formation (left and top), 
but when acidified, CHEMS becomes deprotonated and loses its conical shape, leading to the 
destabilisation of the bilayer (bottom). 
 Proton sponge effect 
 
The proton sponge effect does not rely on changes to subunit shape. Instead, the presence of a 
buffering agent (the ‘proton sponge’) inside the vesicle is necessary. To summarise (298), a 
decrease in pH causes the protonation of the proton sponge that causes the local proton 
concentration to decrease. This prompts the influx of more protons into the vesicle to 
compensate. However, during this process counterions will accompany the movement of 
protons, and the increase in ion concentration will cause osmotic stress inside the vesicle to 




Originally, the proton sponge effect was observed with DNA-PEI complexes (polyplexes) 
escaping from endosomes due to the activity of the V-type ATPase (subsequently will be 
referred to as ATPase). ATPase actively symports protons and chloride counterions into the 
endosome during acidification for lysis to occur (299). For this thesis it is hypothesised the 
osmotic lysis of liposomes may be triggered through the same effect to allow the release of 
actives from both the liposomes and endosomes to achieve cytoplasmic delivery, as previously 
seen with liposomal polyplexes (lipopolyplexes) (275). 
 
 
Figure 3.1.2: Simplified diagram showing the mechanism of the proton sponge effect in 
liposomes modified with channels and encapsulated PEI. At physiological pH the proton 
sponge, PEI, exists in a partially unionised state (left). However, when exposed to acidic 
conditions, it begins to protonate, buffering the solution (middle). The increase in counterion 
concentration increases the osmotic pressure until lysis occurs (right). 
Both polymers used in this thesis, PEI and PDMAEMA of PDMS-b-PDMAEMA can form 
polyplexes for the delivery of generic material during transfection studies (300, 301). These 
polymers possess a large amount of amines, which are thought to provide significant buffering 




Although PEI has been extensively used for transfection studies, the exact mechanism of action 
remains disputed. A summary of the factors influencing the activity of PEI will be discussed 
below. 
 
 pH, counterions, and lysis 
 
Despite the effect’s reliance on a low pH environment, there has been confusion regarding the 
effect PEI has on endosomal pH. Initially, it was thought the PEI buffers against acidification, 
causing the endosomes to be more neutral. The evidence for this comes from studies where co-
incubation with compounds intended to prevent the acidification of endosomes, such as 
bafilomycin, was found to attenuate the effects of PEI (299). Flow cytometry based assays 
developed to estimate the average pH also discovered that the DNA delivered by PEI was 
exposed to an average pH of 6.1 (303). As this higher than the expected pH of 4.5, this result 
may be due to the release of DNA into the neutral cytoplasm, or the buffering of endosomes 
against acidification. However, more recent imaging of endosomes utilising pH sensitive dyes 
has revealed the pH of the endosomes remains acidic, which was attributed to continued 
ATPase activity (304). Therefore the release of DNA into the cytoplasm is likely to explain the 
previously recorded average pH of 6.1 (303).  
 
The concentration of counterions that accompanies a change in pH required for lysis was a 
concern.  Won et al. (305) argued using theoretical PEI delivery and counterion concentrations, 
the osmotic pressure generated is not sufficient for lysis. Direct measurements of PEI 
concentration by Benjaminsen et al. (304) supported this view and they agreed that the osmotic 
lysis of endosomes is unlikely, noting that sufficient concentrations of counterions may occur 
in less than 1% of endosomes. This frequency however, is similar to direct observations by 
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Rehman et al. (306) as they observed 1 to 5 endosomes lysing per cell. Therefore, the low 
occurrence of lysis capable endosomes does not disprove the proton sponge effect. 
 
An alternative theory is that the PEI may cause disruption to the endosomal membrane to 
facilitate cytoplasmic delivery without lysis of the endosome. Bieber et al. (307) observed 
damage to the endosomal membrane in contact with PEI complexes using electron microscopy 
and suggested the damage caused by PEI allows for endosomal escape without acidification of 
higher molecular weight PEI complexes. However, the authors acknowledged the images were 
not sufficient to disprove the proton sponge effect. Therefore, more work is required to clarify 
the effects of pH and counterions in the proton sponge effect. 
 
 Presence of free PEI chains 
 
The presence of free PEI chains is required for the proton sponge effect to occur. In transfection 
studies the transfection efficiency correlates with higher PEI ratios (308), while removal of free 
PEI by chromatography attenuates transfection (308, 309). However, care must be taken as free 
chains are also associated with higher cytotoxicity (309). Additionally, it is thought the free 
cationic chains of PEI are responsible for the activity of PEI through interactions with 
negatively charged membrane proteins causing disruptions in the endosomal membrane to 
allow for release from the endosome (276). 
 
 PEI size and form 
 
PEI may be synthesised to different molecular weights as a linear or branched form. Therefore, 
many different sizes and forms have been utilised in the literature. Generally, high molecular 
weight PEI is correlated with higher transfection efficiency (310, 311) and cytotoxicity (312). 
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However, purified low molecular weight linear PEI has shown improved delivery at lower 
cytotoxicity (313), showing this trend is not absolute. The effect of branched or linear form on 
free polyplexes show branched PEI has greater effect and cytotoxicity, likely due to higher 
uptake (308). However, in the case of lipopolyplexes, the opposite was observed (314). 
 
In two published studies where PEI was utilised for the delivery of antigen, branched PEI was 
used (274, 315). Interestingly, for antigen delivery, it was found the form and size was not 
important in generating IgG titres in vivo (315) 
 
3.2 Chapter aim 
 
The aim of this chapter is to observe the release characteristics of the polymeric nanoparticles 
and modified liposomal formulations produced in the previous chapter. The PDMS-b-
PDMAEMA nanoparticles are theorised to show pH sensitivity, whereas the pH insensitive 
PMOXA nanoparticles should not. For the modified liposomes, it is hypothesised the extent of 
lysis and subsequent release of actives in acidic conditions is mediated by the addition of both 
PEI and channels.  
 
Release was assessed directly in cell-free conditions and indirectly by assessing biological 
activity (cell killing and activation) using mouse primary cells and cell lines. When traditional 
methods (such as dialysis) could not be used to assess release directly, alternative methods were 







 Polymeric nanoparticles 
 
DOX loaded PDMS-b-PMDAEMA and PMOXA nanoparticles were produced as described in 
the previous chapter (Section 2.2). A 1 mg/mL DOX solution in PBS was used for hydration 
of polymeric films. Nanoparticles were dialysed in 100 kDa MWCO dialysis tubes (Spectrum 
Labs, USA) against stirred PBS overnight at room temperature at a ratio of 1:300 to remove 
unencapsulated DOX. 
 
3.3.1.1 Dialysis release 
 
A 1 mL sample of dialysed nanoparticles was transferred to Float-a-lyzer 100 kDa MWCO 
dialysis devices (Spectrum Labs, USA) and was dialysed against at least 200 mL of 
magnetically stirred pH 7.4 PBS (Oxoid, UK) or 20 mM citrate, 150 mM NaCl, pH 5.5 citric 
acid buffer (BDH Lab Supply Inc., UK). A 100 µL sample was withdrawn from the contents 
of the dialysis device at 2 h, 24 h, 48 h, and 72 h for analysis, and was lysed with Triton X-100 
(Sigma-Aldrich, USA) at a final concentration of 1%. Absorbance was measured at 590 nm 
using a PolarStar Omega plate reader and was compared against a DOX standard curve in PBS 
(Appendix D) to determine concentration. Buffers were replaced at each time point to maintain 
sink conditions. 
Release was calculated as follows: 
 % =  
 





3.3.1.2 Cell viability 
 
Dialysed DOX loaded nanoparticles were assayed for DOX entrapment via the measurement 
of absorbance as described above and were then diluted with PBS to achieve DOX 
concentration parity. An aliquot of DOX loaded nanoparticles or DOX in solution was then 
transferred to pH 7.4 PBS or pH 6.5 or pH 5.5 citrate buffer for incubation at a DOX 
concentration of 6 µg/mL. At 24 h, 48 h, and 72 h timepoints 20 µL samples of incubated 
nanoparticles or DOX solution were transferred in quadruplicate to adherent 7.5x103 B16.OVA 
cells in 96 well plates (Corning, USA) with 80 µL RPMI (Appendix A.1) for a total volume of 
100 µL per well. The addition of formulations to cells did not involve separation techniques, 
such as dialysis, thus the samples contained both released DOX and nanoparticles. The 
formulations and cells were then incubated for 48 h at 37°C, 5% CO2. Freshly prepared and 
filtered (0.22 µm) 5 mg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) dye (Sigma-Aldrich, USA) in sterile PBS was added to the plates that were returned to 
the incubator for 4 h. The supernatant was then carefully removed and replaced with 100 µL 
DMSO. Absorbance was measured at 570 nm for signal and 690 nm for background in a 
PolarStar Omega plate reader. 
 
Cell viability was normalised against cells only (100%) and cell free controls (0%), data were 




Liposomes were produced through the hydration of a thin film containing DPPC, cholesterol, 
and channels as described in the previous chapter (Section 2.2). Subsequent steps will be 
described in each sub-section. 
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3.3.2.1 Dialysis release assay  
 
Liposomes were produced by the hydration of the film with 2 mg/mL FITC-OVA with or 
without complexation with PEI. PEI complexes were produced by substituting one quarter of 
volume in the OVA in PBS solution with 1 mg/mL filtered PEI solution. Larger aggregates 
between FITC-OVA and PEI were removed by brief (~10 second) centrifugation in a benchtop 
centrifuge at 17,000 g  
 
The hydrated films were sonicated for 15 minutes at 45°C and were dialysed overnight against 
PBS at a ratio of at least 1:300 excess of PBS in 100 kDa MWCO dialysis tubing (Spectrum 
Labs, USA) to remove unentrapped FITC-OVA or PEI-FITC-OVA.  
 
Liposomes were then incubated in pH 4.5 or pH 5.5 citrate buffer or pH 7.4 PBS for 30 minutes 
in the dark at room temperature, as imaging by Rehman et al. (306) showed release occurring 
in cells within 30-35 minutes. As the liposomes were directly transferred to altered pH 
conditions in this experiment, they were expected to lyse within 30 minutes as uptake and 
endosomal trafficking do not need to take place. 
 
After incubation, liposomes were dialysed overnight, against PBS at a ratio of at least 1:300 in 
100 kDa MWCO dialysis tubing to remove any released active. Fluorescence of the dialysed 
formulation was measured using a PolarStar Omega plate reader at 485 nm excitation and 520 
nm emission, after the addition of 1% Triton X-100. PEI-FITC-OVA and FITC-OVA standard 
curves were also prepared at different pH conditions to determine FITC-OVA concentration 
(Appendix D). Release was calculated as: 
 % =  
  
   × 100 
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3.3.2.2 Investigation of fluorescence quenching 
 
The quenching and antiquenching of FITC-OVA fluorescence was also investigated in order to 
validate the fluorescence results. Liposomes containing 0%, 0.5%, and 1% channels were 
produced in the absence of PEI and FITC-OVA by hydrating lipid films with PBS. Aliquots of 
liposomes were diluted 1 in 10 with PBS, with an additional aliquot of 1% channel liposomes 
diluted 1 in 10 with 0.04579 mg/mL amantadine in PBS solution (10 equivalence of channels) 
as a competitive guest molecule. 
 
In a 96 well flat bottom plate, FITC-OVA was serially diluted 1 in 2 with PBS from a starting 
concentration of 100 µg/mL in triplicate, which is representative of the concentration of pre-
dialysed FITC-OVA liposomes. 100 µL of the diluted liposomal dispersions were added to 
each well to determine if FITC-OVA fluorescence becomes antiquenched at lower 
concentrations. 
 
The quenching effects of the cyclodextrin channels in isolation (not in liposomes) was also 
examined. Beta-cyclodextrin (0.2 mg/mL) and cyclodextrin channel (0.2 mg/mL) solutions 
were serially diluted 1 in 2 in a 96 flat well plate in triplicate. All wells were diluted 1 in 2 with 
100 µg/mL FITC-OVA solution to give an equal concentration of FITC-OVA per well to 
standardise the expected fluorescence per well. The fluorescence was measured at 485 nm 







3.3.2.3 Centrifugation assay 
 
Liposomes were produced by the hydration of the film with 1mg/mL DOX or DOX-PEI 
solution, followed by sonication (Section 2.2). They were subsequently dialysed overnight in 
100 kDa MWCO dialysis tubing against PBS at a ratio of at least 1:300 in excess of buffer. 
 
Liposomes were incubated in pH 4.5 citrate buffer or pH 7.4 PBS for 4h at room temperature 
in the dark in triplicate. The incubation time was extended compared to the dialysis study in 
the event the lysis and release was incomplete, and to standardise the incubation time with 
future experiments. 
 
Liposomes were then centrifuged at 17,000 g for 90 minutes at 4°C in a PrismR benchtop 
centrifuge. The pellet was resuspended at an equal volume also containing 1% Triton X-100 
and fluorescence was measured using a PolarStar Omega plate reader at 485 nm excitation and 
590 nm emission. Fluorescence was compared against DOX and DOX-PEI standard curves to 
determine concentration (Appendix D). 
Release was calculated as: 
 % =  
   
  × 100 
3.3.2.4 Dynamic Light Scattering (DLS) assay  
 
Latex calibration beads (220 nm and 1 µm) were obtained from Malvern (Malvern Instruments, 
UK) and 30 µL of 220 nm beads were transferred to 1 mL filtered PBS (0.22 µm filter) to use 
as a reference sample of a homogenous population of beads. A mixed population of beads was 
created by diluting 15 µL of 220 nm beads with 15 µL of 1 µm beads in 1 mL of filtered PBS. 
These dispersions were created fresh daily. As the initial concentration of the calibration beads 
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is unknown, concentrations was normalised to the starting dispersion for the validation of this 
assay. 
 
All DLS measurements were carried out with a Malvern ZEN3600 Zetasizer (Malvern 
Instruments, UK), with the optics locked once an optimal configuration was found (optic 
position 1.25 mm, attenuator 7). The refractive index was 1.59, as recommended by the 
manufacturer for polystyrene beads. Beads were transferred to filtered PBS in an acrylic 
cuvette. The largest bead dispersion volume was 100 µL, the smallest volume was 20 µL, and 
the filtered PBS volume was adjusted to 1 mL. The derived count rate was measured in triplicate 
with 10 runs of 10 seconds, and three samples per concentration. The mean and standard 
deviation were calculated from three batches of liposomes. 
 
Liposomes were incubated in freshly filtered (0.22 µm) pH 4.5 and pH 7.4 HEPES buffer for 
4 hours. Equal aliquots of liposomes were transferred to 1 mL filtered PBS in an acrylic cuvette, 
and the derived count rate was measured in triplicate, with three samples per liposomal 
dispersion. The % lysis was determined to be: 
%  =
    7.4 −     5.5
    7.4 × 100 
DLS assay validation data were analysed in GraphPad Prism for linear regression and 
coefficient of variance (CV%). Two-way ANOVA, with Sidak’s multiple comparisons was 
used to calculate statistical significance in derived count rate between liposomes incubated in 






3.3.2.5 Calcein release 
 
Calcein liposomes were prepared by hydrating the lipid film with 50 mM calcein (Sigma-
Aldrich, USA) and 0.5 mg/mL Alexa Fluor 647 10 kDa dextran (Life Technologies, USA) 
solution. The liposomal dispersion was dialysed overnight against PBS at a ratio of at least 
1:300 in excess of buffer. The loading of the calcein into liposomes was analysed using a 
PolarStar Omega plate reader at 485 nm excitation and 520 nm emission. Different 
formulations were diluted using sterile PBS to achieve parity in calcein concentration. Alexa 
Fluor 647 loading was not determined. The absolute concentration of Alexa Fluor 647 was less 
important compared to calcein, as it was used to gate cells that have taken up the formulation. 
 
Murine bone marrow derived dendritic cells (BMDCs) were prepared by flushing murine 
hindleg femurs and tibias for marrow using a fine gauge needle. Ethical approval was obtained 
from the Animal Ethics Committee at the University of Otago (Approval number: AEC 15/14) 
for this experiment. Marrow was filtered through a coarse mesh to remove debris. Red blood 
cells (RBC) were lysed for 10 minutes at room temperature using 5 mL RBC lysis buffer (see 
Appendix A.3) per mouse. Post RBC lysis, remaining cells were washed and pelleted at 330 g 
for 8 minutes in a Heraeus Multifuge 3 (Germany). Cells were filtered through a coarse mesh 
and resuspended in 20 ng/mL GM-CSF supplemented RPMI at a concentration of 1x106 
cells/mL in 6 well plates (up to 5 mL per well). Four days later, non-adherent cells were 
removed in 3 mL, and the media was replaced with fresh 10 ng/mL GM-CSF supplemented 
RPMI. Cells were harvested six days post-flushing by the application of ice-cold sterile PBS 
and light scraping. 
 
Harvested dendritic cells were plated at 5x105 cells in 1 mL in a 24 well plate, and 100 µL of 
liposomes were added to each well in triplicate. Plates were returned to the incubator. Thirty 
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minutes later, Brefeldin A (Sigma Aldrich, USA) was added to wells designated as controls. 
Dendritic cells were incubated for 4 hours in total with formulations and were washed twice 
using warm PBS to remove formulations. 
 
Dendritic cells were analysed by fluorescence microscopy on an Olympus (USA) IX53 
microscope equipped with a DP73 sensor and an X-Cite 120Q (Lumen dynamics, Canada) 
xenon lamp for fluorescence. Images were taken with bright field, FITC, and TXRED filters, 
and analysed using OlyVIA software (Olympus, USA) 
 
Dendritic cells (unbleached by fluorescence microscopy) were stained for flow cytometry with 
violet live/dead detection reagent (Life technologies, USA) for 30 minutes in the dark, washed 
with PBS, and pelleted at 330 g for 8 minutes in a Heraeus Multifuge 3. Stained cells were 
analysed with a FACSanto II flow cytometer (Becton Dickinson, USA), measuring for calcein 
and Alexa Fluor 647 fluorescence live cells. 
 
Data were analysed in GraphPad Prism with one way ANOVA and Tukey’s multiple 
comparisons was used to determine statistical significance between groups. 
 
3.3.2.6 Cell viability 
 
Liposomes were prepared with 0.5 mg/mL DOX or DOX-PEI solution as described above. 
Initially the liposomes were sonicated, but were later prepared using extrusion through 800 nm, 
400 nm, and 200 nm membranes as described (Section 2.2). Loading was determined through 
the measurement of fluorescence at 485 nm excitation, and 520 nm emission using a PolarStar 





Liposomes were serially diluted 1 in 2 with sterile PBS, and 20 µL of diluted liposomes were 
transferred in triplicate to 7.5x103 B16.OVA cells in 100 µL of RPMI. The highest 
concentration of DOX added to the cells was 15 µg/mL. After 48 h of incubation of 
formulations with cells, 10 µL Vita-blue viability reagent (Bio-tool, USA) was added to cells, 
and the plates were further incubated for 2 hours. 
 
Fluorescence was measured using a PolarStar Omega plate reader at 544 nm excitation and 590 
nm emission, with 100% cell viability and 0% cell viability normalised against cell-only and 
cell-free controls respectively. 
 
Data were analysed in GraphPad Prism for the calculation of IC50 and inhibition curves. One 
way ANOVA with Tukey’s multiple comparisons was used to determine statistical significance 
between groups. 
 
3.4 Results and Discussion 
 
 Polymeric nanoparticles 
 
Car et al., the collaborators who synthesized the polymers, reported PDMS-b-PDMAEMA 
nanoparticles to be pH sensitive (2). The assays used to show this included fluorescence 
microscopy, dialysis release and cell viability assays. Here, DOX-loaded PDMAEMA and 
control PMOXA nanoparticles produced in Chapter 2 were analysed using dialysis release and 




3.4.1.1 Dialysis release: 
 
The nanoparticles were stable in pH 7.4 buffer with no release detected over 72 hours (Figure 
3.4.1A). No pH induced release of DOX from nanoparticles incubated at pH 5.5 was observed 
after 72 hours (Figure 3.4.1B). However, technical issues were encountered with the 
measurement of release in the pH 5.5 conditions as evidenced by the negative release values 
indicating an increase in concentration of active above the initial concentration. Additionally, 
large variability in the data was recorded.  
 
The negative release values indicates that the absorbance of DOX is increasing over time. As 
absorbance is determined by the Beer-Lambert law, the concentration and the molar attenuation 
coefficient are the only determinants of absorbance given a fixed path length. Therefore, 
changes in the molar attenuation coefficient are likely to be responsible for the observations in 
this experiment. In the literature, including the work carried out by Car et al., a single molar 
extinction coefficient value is used regardless of pH. On closer examination, PBS was used for 
both acidic and neutral conditions for their experiment. As the pKa values of PBS are 
approximately 2, 7, and 12, PBS is not expected to perform as a suitable buffer at pH 5.5 
conditions. Therefore, citrate (pKa 6.4) was selected as a more appropriate buffer salt in this 
thesis. The use of citrate buffer is likely to have caused the issues, as the buffer salt and ionic 
strength influences the molar attenuation coefficient of DOX (316). Some evidence for this 
effect is evident in Figure 3.4.1, as only the pH 5.5 samples are affected. Therefore, from this 











Figure 3.4.1: Release of DOX over 72h when PDMAEMA micelles (PDMAEMA), PMOXA 
micelles (PMOXA) or DOX in solution (DOX) were dialysed against pH 7.4 buffer (A) or pH 
5.5 buffer (B). Data are normalised means of 2 experiments ± range for pH 5.5, and one 





Comparing this experiment to the Car et al. performed dialysis experiment where pH sensitive 
release was observed, both experiments utilised 100kDa membranes and dialysis in pH fixed 
buffers. However one difference was temperature, as the experiment in this thesis was carried 
out at room temperature compared to 37°C. While dialysis rates are affected by temperature 
(317), the extent of dialysis is unlikely to be affected. It is possible the nanoparticles exhibit 
pH sensitive release only at elevated temperatures, as PDMAEMA is shown to be pH and 
temperature sensitive (318). 
 
Despite the negative release values measured, there was no increase in release from 
PDMAEMA nanoparticles incubated at pH 5.5 (Figure 3.4.1B), which does not support the 
theory that the PDMAEMA nanoparticles are pH sensitive. However, a cell viability assay was 
used as an alternative method to validate these initial findings. 
 
3.4.1.2 Cell viability assay (MTT) 
 
To study pH sensitive release, DOX loaded PDMAEMA nanoparticles were artificially 
triggered in pH 7.4, 6.5 or 5.5 buffers for 24, 48, and 72 hours prior to exposure to B16.OVA 
murine melanoma cells. Nanoparticles pre-incubated in pH 5.5 and 6.5 conditions were 
hypothesised to release more DOX resulting in increased cytotoxicity in vitro.  This method 
was developed to remove issues associated with damage to cells upon exposure to low pH 
conditions, which would impact on results. 
 
DOX loaded pH insensitive PMOXA nanoparticles, unloaded PDMAEMA nanoparticles, and 
PBS were used as negative controls for this experiment. The positive control of DOX solution 




The time points chosen for this experiment mirrors the release study above, and the previous 
work carried out by Car et al. In addition to the pH 5.5 and 7.4 conditions examined, the effects 
of the formulation at pH 6.5 was observed to determine if the release of DOX correlates with 
change in pH to strengthen the association between pH and release by providing an intermediate 
value. In addition to this, pH 6.5 represents a more accurate estimate of extracellular pH in the 
hypoxic tumour microenvironment compared to pH 5.5 (85). 
 
Cell viability was measured 24, 48, and 72h after the formulations were exposed to the cells 
using the MTT assay (Figure 3.4.2). This is consistent with other studies, as DOX begins to kill 
cells after a 3 hour lag period (319).  
 
While the PDMAEMA nanoparticles without DOX showed a statistically significant decrease 
in cell viability compared to PBS controls (Figure 3.4.2, p<0.0001 at all time points), the 
magnitude of this effect is minor. This suggests the toxicity of the polymer is low, and any 
additional cell killing observed with PDMAEMA nanoparticles loaded with DOX is mediated 


































































Figure 3.4.2: Cell viability of B16.OVA cells after 24h (A), 48h (B), and 72h (C) of 
incubation in varied pH conditions. Formulations were incubated at a ratio of 1 to 5 in pH 
fixed medium prior to exposure to cells with a further dilution of 1 in 5 with pH 7.4 RPMI. 
Data are n=4 ± SD, and is representative of 4 experiments. ns = p > 0.05, * = p ≤ 0.05, **** 
= p ≤ 0.0001. 
The pH responsiveness of PDMAEMA and PMOXA nanoparticles was examined (Figure 
3.4.2). As seen with Figure 3.4.2 B and C, exposure of cells to media containing formulations 
pre-incubated in buffers of different pH (i.e. ex vivo release) did not result in any consistent 
changes in cell viability. The lack of change in cell viability at lower pH conditions does not 
support the theory that PDMAEMA nanoparticles have released more DOX at low pH 
conditions. However, it is important to note that while the ex vivo release of PDMAEMA 
nanoparticles was not significant in acidic conditions, the decrease in cell viability in 
comparison to PMOXA control nanoparticles (p<0.0001 at all time points) suggests that 
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PDMAEMA nanoparticles are still capable of DOX release within acidic endosomes. This 
endosomal release of DOX has also been observed by Car et al. with fluorescence microscopy 
(2), suggesting a more acidic pH was required for release. This may be due to the endosomal 
pH, which may be as low as pH 4.5, in comparison to the lowest pH examined ex vivo (pH 5.5). 
For future studies, the inhibition of intracellular acidification using chloroquine (303) to 
prevent endosomal acidification and release will be required to conclusively determine the 
activity and mechanism of PDMAEMA nanoparticles. 
 
In summary, although PDMAEMA nanoparticles demonstrated release in endosomal 
conditions, they are unlikely to be of significant value for vaccine delivery as they form 
micelles opposed to vesicles (Section 2.7.1.1). This limited the ability to encapsulate OVA 




The second formulation developed in Chapter 2 were DPPC liposomes modified with 
cyclodextrin channels and the inclusion of PEI. It was determined that the optimal 
concentration of channels was 1 mol% (Section 2.10.2), with a PEI concentration of 0.25 
mg/mL (Section 2.9). 
 
The pH sensitive release of actives was measured using the fluorescent actives DOX and FITC-
OVA. Therefore, the preparation of liposomes via thin film hydration as described in Chapter 
2 (Section 2.2) was carried out with the inclusion of these actives. Overnight dialysis against 




3.4.2.1 Dialysis release and investigation of quenching 
 
Formulations were incubated in buffers at physiological pH (7.4) and at reduced pH (4.5 and 
5.5) for 30 minutes. Imaging studies by Rehman et al. show PEI can cause cytoplasmic release 
in 30 minutes after administration to cells (306). As liposomes were immediately exposed to 
an acidic environment, they are expected to release FITC-OVA within this time. 
 
The formulations tested included a liposome control, liposomes plus 1% channels, liposomes 
with 1% channels and PEI and liposomes with PEI. Size and entrapment data for the 
formulations is summarised in the previous chapter (Section 2.11).  
 
FITC-OVA loaded liposomes incubated at physiological pH (Figure 3.4.3) for 30 min released 
35.2 ± 28.9% of the encapsulated protein, while incubation at pH 4.5 resulted in 36.7 ± 20.7% 
release. Therefore, non-functionalised DPPC liposomes do not show evidence of pH sensitivity. 
 
Incubation of PEI-FITC-OVA formulations without channels (liposomes + PEI) in pH 4.5 and 
5.5 had minimal impact on release, with 78.4 ± 12.4% and 55.6 ± 4.1% release respectively 
compared to 66.2 ± 21.9% in neutral conditions. The lack of pH sensitivity without channels is 
expected, as ions are unable to diffuse across the liposomal membrane (243) to interact with 





Figure 3.4.3: Release of FITC-OVA from liposomes after 30 minute incubation in fixed pH 
buffers. Unencapsulated FITC-OVA was then removed by dialysis overnight, and dialysis bag 
contents were measured by fluorescence. Data shown are from 2-4 replicate experiments plus 
the mean. 
High variability and negative release values such as -3.26 ± 64.0% for Liposomes + 1% CHAN 
+ PEI at pH 4.5, -50.2 ± 1.0% for Liposomes + 1% CHAN at pH 4.5 and -3.8% ± 50.8% at pH 
7.4 were observed for formulations containing channels that made it impossible to determine if 
they were pH sensitive. This may be attributed to variability in fluorescence and three potential 
issues that could impact fluorescence were identified: 
 
Firstly, the fluorescence of FITC is strongly influenced by pH (320). As different pH conditions 
were utilised in this experiment, the fluorescence of FITC may have been affected. However, 
this issue was expected and was mitigated through the use of standard curves for each pH 




Quenching of the fluorescence by PEI itself through static quenching has been reported (321), 
and this was confirmed experimentally (Figure 3.4.4A) by examining the fluorescence of 
unmodified FITC-OVA liposomes in comparison to PEI-FITC-OVA liposomes. Again, this 
was expected and a separate PEI-FITC-OVA standard curve was utilised to compensate for this 
quenching effect (Appendix D). This is shown in Figure 3.4.4B as the FITC-OVA 
concentration of PEI modified liposomes was observed to be close to the theoretical value 
(1059 ± 61.7 µg/mL experimental versus 1000 µg/mL theoretical) 
 
The third possibility, as the negative results were observed only when channels were included 
(Figure 3.4.4), is an interaction between the FITC-OVA and cyclodextrin. Initially, it was 
theorized FITC-OVA would not interact with cyclodextrin as the large disparity in size would 
reduce the probability of host-guest interactions. Several experiments were carried out to 
determine the quenching and antiquenching effects of cyclodextrin in order to explain the 
anomalous release data. Firstly, fixed concentrations of FITC-OVA were exposed to increasing 
concentrations of unmodified cyclodextrin, or the cyclodextrin channels (Figure 3.4.5). 
Interestingly, interaction between the unmodified cyclodextrin and FITC-OVA showed an 
antiquenching effect, while the cyclodextrin channels exhibited a strong quenching effect 
mirroring the quenching seen in formulations (Figure 3.4.4A and B). However, as the 
hydrophobic cavity of the cyclodextrin is present in both cases, a host-guest interaction is 







































































Figure 3.4.4: Representative FITC-OVA fluorescence (A) and concentration (B) in liposomes 
prior to dialysis. The dotted line in B shows the expected concentration (1000 µg/mL). Data 

















Figure 3.4.5: Quenching and antiquenching effects observed for FITC-OVA solution with 
varying concentrations of unmodified beta-cyclodextrin, or cyclodextrin channels. Data are 
n=3 ± SD 
To further investigate a host-guest interaction between FITC-OVA and the channels, liposomes 
were prepared with 0%, 0.5% and 1% channels in the absence of FITC-OVA. After hydration 
of the lipid film, liposomes were incubated with FITC-OVA (Figure 3.4.6). No changes in 
fluorescence was observed even when amandatine was added as a competitor for the 
cyclodextrin cavity. Therefore, it is very unlikely the quenching effects are due to host-guest 
interactions. 
 
The likely explanation for the quenching of FITC-OVA by cyclodextrin channels is due to 
interaction between FITC-OVA and free channels at the start of hydration. The evidence for 
this comes from Figure 3.4.6, where the quenching of FITC-OVA was not observed when 
FITC-OVA is added post-hydration, as the channels are no longer available due to 
incorporation into the liposome membrane. Whereas, in Figure 3.4.5 a solution of freely 
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available channels shows quenching of fluorescence, demonstrating that initial contact between 
channels and FITC-OVA is required.  
 
The negative release values observed in the release experiment are explained by quenching and 
antiquenching. For fluorescence based release studies it is assumed the fluorescence of each 
molecule does not change during release. As the liposomes containing channels are quenched 
prior to dialysis (Figure 3.4.4A) the removal of the quenching effect during dialysis will result 
in increased fluorescence. This leads to an apparent increase in concentration and negative 
release values. The exact mechanisms for this process is unknown. One explanation is the 
exposure of formulations to sink conditions overnight during dialysis may be responsible. The 
slow disassociation of FITC-OVA and channels by equilibrium with sink conditions may 
restore the original FITC fluorescence leading to a higher post-dialysis fluorescence with 
apparent negative release. 
 
Given the novelty of channel modified liposomes, little literature exists for comparison. 
However, the interaction between cyclodextrins and fluorophores has been studied. For 
example, dansyl cyclodextrins will fluoresce at different wavelengths due to the host-guest 
effect between the hydrophobic cavity of the cyclodextrin and a dansyl group attached to the 
cyclodextrin with a linking moiety (322). Although FITC-OVA and channels do not show a 
host-guest effect, perhaps the addition of an environmentally sensitive dye attached to the 
channel may provide an opportunity to produce theranostic liposomes in the future. 
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Figure 3.4.6: Fluorescence of FITC-OVA when incubated with liposomes with 0%, 0.5%, and 
1% channels with or without amantadine. Data is n=3 ± SE 
Due to quenching and antiquenching effects, the results in all subsequent experimental data 
was normalised to the starting concentration of the liposomes to account for these effects and 
alternative assays to measure release were investigated. 
 
3.4.2.2 Centrifugation method and quenching of DOX fluorescence 
 
As the dialysis data proved unsuitable for determination of release, centrifugation was selected 
as an alternative technique. This method can also be more easily up-scaled enabling more 
samples to be analysed concurrently to improve statistical power. FITC-OVA was substituted 
for DOX in an attempt to avoid issues with fluorescence described in the previous section. 
While the mechanism of quenching with FITC-OVA is unknown, it was theorised the smaller 




Figure 3.4.7: Release of DOX from liposomes after 4 hour incubation in pH fixed buffer. 
Unencapsulated actives were removed by centrifugation, and the fluorescence of the pellet 
was measured. Data are the means of 4 experiments ± SD, with 3 measurements per 
experiment. 
The variability in the data (Figure 3.4.7), while not as severe as the dialysis method, was still 
sufficiently high that pH sensitive release could not be observed. The mean release for 
liposomes with 1% CHAN + PEI was 62.7% at pH 4.5 and 66.1% at pH 7.4. The coefficient of 
variance (CV%) was 19.1% at pH 4.5 and 11.8% at pH 7.4. The CV% measured for this 
experiment is of concern due to the subtlety of the proton sponge effect (304, 306). Therefore, 
an alternative assay may be required to observe pH sensitivity of the liposomes. 
 
The quenching of DOX fluorescence by channels was also briefly investigated (Figure 3.4.8). 
A similar pattern of quenching and antiquenching of fluorescence by channels and unmodified 
137 
 
cyclodextrin mirrored previous experiments with FITC-OVA (Figure 3.4.5), where the addition 
of channels was associated with quenching while unmodified cyclodextrin caused 
antiquenching. Interestingly, there was also an increased fluorescence for PEI containing 
liposomes (Figure 3.4.9A). Despite accounting for the fluorescence modifying effects of PEI 
through the use of PEI-DOX standard curves, the concentration of DOX measured does not 
correlate to expected DOX concentrations (Figure 3.4.9B) due to this antiquenching. An exact 
explanation for this is outside the scope of this thesis as mechanistic studies are required to 
determine the effect of PEI on DOX fluorescence. However, some sources of interaction may 
be safely disregarded, such as electrostatic interaction between DOX and PEI, as both 
molecules are positively charged. 
 
Figure 3.4.8: Quenching and antiquenching effects of unmodified beta-cyclodextrin and 
completed cyclodextrin channels when concentration of the quenchant is varied while the 
concentration of DOX is fixed. Data are n=3 ± SD. 
The consequence of the quenching and antiquenching effects in this experiment were minimal 
compared to FITC-OVA as no negative release values were observed during this experiment. 
This may be due to the shorter time required for the separation of unencapsulated DOX from 
liposomes in comparison to dialysis (1.5 hours versus overnight). Therefore, the shorter time 
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may have prevented the disassociation of the channel-DOX complex to keep the fluorescence 
constant. 
 
It may be argued the relative centrifugal force used for this experiment was insufficient. The 
liposomes were centrifuged at 17,000g for 90 minutes. This is well below what is achievable 
with ultracentrifuges (>100,000g), which has been used for the near-complete pelletisation of 
liposomes (323, 324). However approximately 90% pelletisation was achieved (as measured 
by DLS count rate assay) and all liposomes were subject to the same relative centrifugal force, 
allowing for valid comparisons to be made.  
 
Due to the issues with quenching, the use of fluorescence based release assays were suspended. 




















Figure 3.4.9: Quenching and antiquenching effects observed for DOX in modified or 
unmodified liposomes with fluorescence (A) and calculated DOX concentration (B). 
Concentrations were calculated using standard curves comprised of the mixed individual 
components (Appendix D). The dotted line in B shows the expected concentration of DOX in 
the liposomes (500µg/mL). Data are n=3 ± SD 
140 
 
3.4.2.3 Dynamic Light Scattering (DLS) assay quantification and lysis assay 
 
Previous studies have shown the scattering of light by nanoparticles measured by DLS as count 
rate is well correlated to the concentration of particles present in solution (324). As we have 
hypothesized that a decrease in pH will result in the lysis of liposomes, we theorised that count 
rate could be used to evaluate a reduction in liposome numbers. 
 
Validation of this method was carried out using 220 nm polystyrene calibration beads (Figure 
3.4.10A). The robustness of the assay was evaluated by repeating measurements with a mixture 
of beads (220 nm and 1 µm at 1:1 ratio) to simulate a polydisperse formulation (Figure 
3.4.10B). Inter-day and intra-day variabilities were also calculated (Table 3.4.1 and Table 
3.4.2). As the exact concentration of beads is unknown, relative concentrations were used. 
 
The results indicate a good linear correlation between relative concentration and derived count 
rate. The lowest r2 observed was 0.9962 for homogenous beads and 0.9893 for heterogeneous 
beads (Table 3.4.1), showing the assay is likely to produce valid results even for heterogeneous 
































































Figure 3.4.10: Correlation between derived count rate and relative concentration of 220 nm 
(A), or a mixture of 220 nm and 1 µm (B) polystyrene calibration beads. Data are n=3 ± SD 
 
The intraday coefficient of variability (CV%) was found to be 0.60% to 2.28% for the 
homogenous population of beads, and 0.93% to 1.53% for heterogeneous beads (Table 3.4.1). 
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Given the low intra-day variability, the limiting factor is likely due to operator error, and 
improvements may be made through the use of automated pipetting systems. 
 
Table 3.4.1: Intra-day variability and simple linear regression analysis. Data are n=3 ± SE 
 Day 1 Day 2 Day 3 Day 4 
    
220nm beads only    
    
CV% 0.80 2.28 1.08 0.60 
r2 0.9977 0.9962 0.9962 0.9999 
Slope 941 ± 26.05 1032 ± 36.77 843.8 ± 30.14 869.1 ± 4.81 
Y-intercept 4133 ± 864 2166 ± 1220 4717 ± 999.8 3270 ± 159.5 
     
220nm + 1µm beads    
    
CV% 0.93 1.53 1.24 1.21 
r2 0.9893 0.9940 0.9967 0.9999 
Slope 449.8 ± 27.02 449.4 ± 20.18 593.7 ± 19.63 574.6 ± 3.833 
Y-intercept 4547 ± 896.2 3598 ± 669.4 2418 ± 650.9 1462 ± 127.1 
     
 
The inter-day CV% was 5.56% for homogenous beads and 7.51% for heterogeneous beads 
(Table 3.4.2). However, the inter-day variability is greater than the intra-day variability and a 
statistically significant difference could be detected between days (p<0.0001 for both 
homogenous and heterogeneous beads), which indicates that samples must be analysed on the 








Table 3.4.2: Inter-day variability. The average CV% represents the inter-day variability 
(n=4). 
 220nm only 
 
220nm + 1µm 
 Mean SD CV% 
 Mean SD CV% 
100% 49518.0 4021.3 8.12%  28343.6 2926.9 10.33% 
80% 40154.3 2067.1 5.15%  23906.6 1994.9 8.34% 
60% 31655.6 1824.6 5.76%  19111.6 1333.9 6.98% 
40% 22454.3 1267.2 5.64%  13501.8 794.9 5.89% 
20% 12295.1 384.3 3.13%  7701.7 464.3 6.03% 
Average   5.56% 
 
  7.51% 
 
In addition to measuring the correlation between count rate and particle concentration, the 
resolution of the assay was determined by varying the concentration of the particles by 1%, 
3%, or 5%. The resolution was found to be higher with a homogenous population of particles 
as the assay was able to differentiate a 5% difference in concentration in most cases with 
homogenous particles (Figure 3.4.11). Therefore, formulations should be as homogenous as 
























































































































Figure 3.4.11: Resolution of the DLS assay was analysed by measuring the count rate with 
small changes in concentration of 220 nm (top) or a mixture of 220 nm and 1 µm (bottom) 
polystyrene beads. Data are n=3 ± SD * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001, **** = 
p ≤ 0.0001. 
The major limitation of the assay was the time required to analyse samples, which is 
compounded by the requirement for all samples to be measured within the same day due to 
inter-day variability. Although faster results may be achieved by reducing the number of scans, 
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this comes at the cost of data quality. Therefore, only a limited number of samples may be used 
for each experiment. This is a concern due to the number of samples required for statistical 
significance. For samples with 95% and 97% relative concentration, 3 samples were sufficient 
for statistical power assuming the probability of a Type I error at 0.05 and a Type II error at 
0.2. However, for 99% relative concentration the number of samples required is 23, which may 
explain the difficulty in achieving statistical significance at 99% concentration (Figure 3.4.12) 
 
 
Figure 3.4.12: Calculation of sample size required to observe changes in relative 
concentration to a reference sample. The standard deviation is 1.20%, as measured in Table 
3.4.1. The alpha (probability of a Type I error) was 0.05 and the beta (probability of a Type 
II error) was 0.2. 
After validation of the assay, liposomes with PEI and varying concentrations of channels were 
incubated in fixed pH conditions and the DLS assay was used to determine if a pH dependent 
lysis effect could be seen (Figure 3.4.13). For this experiment OVA-PEI complexes or OVA 
was loaded into liposomes with varying concentrations of cyclodextrin (Table 3.4.3).  
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Table 3.4.3: Size and PDI of the formulations used for the lysis assay. Data are n=3 ± SD. 
 Z-average (nm) PDI 
Liposomes only 123.7 ± 2.0 0.342 ± 0.0003 
0.5% CHAN + PEI 140.0 ± 1.0 0.281 ± 0.009 
1% CHAN + PEI 90.1 ± 1.0 0.260 ± 0.006 
 
  
Figure 3.4.13: Percent lysis over neutral conditions as measured by the change in derived 
count rate when liposomes were incubated in acidic conditions (pH 5.5) compared to neutral 
conditions (pH 7.4). Data are n=3 ± SD, * = p ≤ 0.05. 
The results show the percentage lysis in acid of 4.82 ± 1.75% for 0.5% channel + PEI liposomes 
and 3.17 ± 1.01% for 1% channel + PEI liposomes (Figure 3.4.13). While ~4% lysis in acid 
may appear low fluorescence microscopy from Rehman et al. (306) demonstrates the number 
of endosomes that release PEI is very small. They observed release from up to five endosomes 
per cell, in comparison to approximately 200 total endosomes per HeLa cell (325), or 2.5%. In 
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addition, a calculation by Benjaminsen et al. (304) suggests less than 1% of endosomes are 
likely to lyse due to the proton sponge effect. Although this is lower than the ~4% lysis observed 
for this thesis, Benjaminsen et al. noted the endosomal membrane is more resistant to lysis, 
which may explain this discrepancy. Overall, the lysis observed in this experiment is consistent 
with literature. 
 
These experiments suggest lysis also occurs with cell-free systems, supporting a role for the 
proton sponge effect. This has two consequences. Firstly, an alternative theory to explain the 
transfection potential of PEI involves the electrostatic attraction between free PEI chains and 
negatively charged proteins embedded within the endosomal membrane. It is thought this 
causes disruption of the membrane to allow for endosomal escape (276). As negatively charged 
proteins are absent in liposomes, this theory is unlikely to explain the mechanism of action of 
PEI. Secondly, as the inhibition of the ATPase by bafilomycin has been shown to inhibit 
transfection (276, 299), it was assumed the symport of chloride ions by ATPase was necessary 
for this effect. However, this experiment shows the simple diffusion of chloride ions was 
sufficient in generating an osmotic pressure for lysis of liposomes. While these observations 
are not important for the delivery of actives, it gives an important insight into the mechanism 























































Figure 3.4.14: % Lysis in acidic conditions determined by DLS count rates for PEI + 1% 
CHAN liposomes (A) or unmodified liposomes (B). The inset table shows the results from 
statistical analysis (Two-way ANOVA with Sidak’s Multiple comparisons). Data are n=3 
measurements ± SD. ns = p > 0.05, * = p ≤ 0.05, ** = p ≤ 0.01. 
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Only liposomes with PEI and 0.5% channels showed a statistically significant decrease in count 
rate between control and acid exposed liposomes in this experiment. Attempts were made to 
reduce variability by producing homogenous liposomes with lower PDI values. However, as 
the proton sponge effect is subtle, it is difficult to detect. Data from individual experiments 
where the Zetasizer optic configuration was identical between measurements mirrors the data 
gathered from combined data from earlier experiments (Figure 3.4.14). Formulations with 1% 
channels and PEI showed a clear increase in lysis in acidic conditions in one experiment (Figure 
3.4.14A), with an overall trend showing increased lysis in acidic conditions. In contrast, 
unmodified liposomes do not show a clear trend towards lysis in acidic conditions, and no 
statistically significant results were recorded (Figure 3.4.14B). Therefore, these additional 
experiments supports the acid sensitivity of these formulations. 
 
3.4.2.4 Calcein release assay 
 
To visualise the ability of the formulations to deliver actives to the cytoplasm, calcein dye was 
used as it is self-quenching at high concentrations (326). Release of self-quenched dye from 
liposomes to the cytoplasm dilutes the dye causing the cell to fluoresce. Liposomes loaded with 
quenched calcein and Alexa Fluor 647 were incubated with murine dendritic cells and were 
analysed by florescence microscopy (Figure 3.4.15) and flow cytometry (Figure 3.4.16 and 
Figure 3.4.17) to investigate release into the endosomes and cytoplasm. The Alexa Fluor 647 




Figure 3.4.15: Florescence microscope image showing murine dendritic cells incubated with 
formulations containing Alexa-fluor 647 (red) and calcein (green). Alexa-fluor 647 shows 
cells that have taken up formulations, and calcein fluorescence shows release into endosomes 
or the cytoplasm. 
Fluorescence microscopy shows the formulation was internalised by dendritic cells as seen by 
the red fluorescence of Alexa-fluor 647 in Figure 3.4.15. Additionally, the green fluorescence 
of calcein may be seen in some cells, which was concentrated in small vesicles in some cells 
but more generalised in others. This suggests the dilution of calcein successfully occurred 
within the endosome and the cytoplasm of cells demonstrating release from liposomes. 
However, as this image is representative and is not intended to validate the assay, an example 
of the calcein dilution assay in literature to demonstrate cytoplasmic release may be found at 
this reference (327). 
 
The results from quantitative flow cytometry analysis (Figure 3.4.17, with the gating strategy 
in Figure 3.4.16) showed only the liposomes with PEI and 1% channels have significantly 
increased calcein fluorescence compared to brefeldin A (BFA) controls, while liposomes with 
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0% or 0.5% channels do not. Cells exposed to BFA were used as controls as BFA disrupts the 
transition of early to late endosomes (328), limiting the acidification and subsequent release of 
calcein from liposomes. Therefore, the background fluorescence of cells containing unreleased 
calcein liposomes may be measured, and calcein fluorescence may be normalised to controls 
as a ratio to account for quenching effects between calcein and PEI or channels. 
 
Liposomes modified with 1% channels and PEI are capable of releasing more actives into the 
cytoplasm compared to non-modified controls demonstrating the lysis observed with DLS 
(Section 3.4.2.3) translates to cytoplasmic release. In addition, at least 1% of channels were 
required in the formulation to show an effect, suggesting the concentration of channels is 
important for cytoplasmic release in cells. 
 
In order to examine the impact of PEI on release in this system, liposomes with half PEI 
concentration were produced. Halving the PEI reduced the calcein fluorescence (Figure 3.4.18). 
This suggests the PEI is likely to be important for the mechanism of action. However, more 
data is required to draw a stronger conclusion. Taken together with the data in Figure 3.4.17, 
both PEI and channels are required for cytoplasmic delivery. Therefore, the original hypothesis 
that the ion permeabilizing effects of the channels, and the proton sponge effect of the PEI are 








Figure 3.4.16: Gating strategy for FACS analysis. Data shows murine dendritic cells 
incubated with liposomes with 1% channels and PEI (top) and associated brefeldin A (BFA) 
control (middle). DCs were selected by gating on side and forward scatter, and live cells 
were stained low for V450 live/dead reagent. The cells of interest were APC+/FITC+ which 
represents liposome uptake of Alexa Fluor 647 and calcein fluorescence respectively. The 















































Figure 3.4.17: Fold increase of calcein MFI in murine dendritic cells incubated with 
formulation compared to brefeldin A (BFA) controls. Data are n=3 ± SD from 2 experiments 
**** = p ≤ 0.0001 
Fluorescence quenching of calcein by PEI is also demonstrable in this study (Figure 3.4.18) as 
the addition of PEI causes a decrease in MFI of calcein fluorescence compared to unmodified 
liposome controls. This is most apparent with liposomes with half PEI (MFIs of 5439, 4518, 
and 7904 for 0.5% channels with half PEI, 1% channels with half PEI and unmodified 
liposomes respectively). In addition, comparing 0.5% and 1% channel formulations shows a 
slight quenching effect with higher channel concentrations (9470 to 8153 from 0.5% channels 
to 1% channels in Figure 3.4.18). This quenching is consistent with previous sections in this 
chapter and the quenching has been controlled in this experiment through normalisation of 





Figure 3.4.18: MFI of calcein for MBDCs incubated with formulations bearing different 
concentrations of PEI and channels. 
 
Interestingly, incubating calcein loaded PEI + 1% channel liposomes in acidic conditions in the 
absence of cells could not replicate the increase in fluorescence with dendritic cells (Figure 
3.4.19). This result suggests the proton sponge effect is more effective in cells, likely owing to 
the active transport of chloride ions via the ATPase, compared to the passive influx of chloride 




Figure 3.4.19: Change in florescence of 1% channel + PEI + calcein liposomes incubated in 
pH 5.5 conditions over 4 hours. 
3.4.2.5 Cell viability assay 
 
As the calcein release experiment demonstrated the ability of the modified liposomes to release 
actives into the cytoplasm of cells, the formulations were loaded with DOX and incubated with 
B16.OVA murine melanoma cells. This is in contrast to experiments with the PDMAEMA 
nanoparticles in Section 3.3.1.2 whereby the nanoparticles were pre-incubated in acidic buffers 
in order to induce release before culture with cells. DOX-containing liposomes were produced 
by sonication and extrusion methods (Section 2.2). Dialysed formulations were incubated with 
B16.OVA melanoma cells, and a cell viability inhibition curve was plotted to determine the 












     IC50
DOX liposomes 2.896
PEI + DOX liposomes ~ 6969
PEI + 1% CHAN + DOX liposomes ~ 730.9
1% CHAN + DOX liposomes 2.684
DOX + PEI solution 1.048
DOX solution 0.7055
 
Figure 3.4.20: Cell viability curves for B16.OVA melanoma cells when incubated with DOX 
encapsulated liposomes produced by sonication. Unmodified DPPC liposomes (DOX 
liposomes), liposomes with channels only (1% CHAN + DOX), liposomes with PEI only (PEI 
+ DOX), liposomes with both PEI and channels (PEI + 1% CHAN + DOX), unformulated 
DOX-PEI solution (DOX + PEI) and DOX in PBS (DOX) were analysed. The inset table 
shows the IC50 (µg/mL). Data are n=3 ± SD, and is representative of two experiments. 
As seen in Figure 3.4.20, the liposomes produced with PEI demonstrated very poor cell killing 
compared to the liposomes without PEI. This was not expected as the inclusion of PEI was 
theorised to trigger the proton sponge effect, which would lead to improved cytotoxicity. One 
possible explanation is the process of sonication is known to release free-radicals (222) that 
may lead to a reaction between DOX and PEI preventing the release and activity of DOX. This 
is supported by the unusually high passive loading observed for sonicated liposomes in the last 
chapter (Section 2.11). Due to this interaction it was not possible to determine any effect of 




     IC50
DOX liposomes 1.57
PEI + DOX liposomes 5.982
PEI + 1% CHAN + DOX liposomes 1.205
1% CHAN + DOX liposomes 5.099
DOX + PEI solution 1.048
DOX solution 0.6838
 
Figure 3.4.21: Inhibition curves for B16.OVA melanoma cells when incubated with DOX 
encapsulated liposomes produced by extrusion. Unmodified DPPC liposomes, liposomes with 
channels only (no PEI), liposomes with PEI only (No channels), liposomes with both PEI and 
channels (Everything), unformulated DOX-PEI solution (DOX-PEI) and DOX in PBS (DOX-
PBS) were analysed. The inset table shows the IC50 (µg/mL). Data are n=3 ± SD, and is 
representative of two experiments. 
Repeating the inhibition studies with extruded liposomes (Figure 3.4.21) provides indirect 
support for a reaction between DOX and PEI. By producing liposomes without exposure to 
sonication, the PEI containing formulations were able to inhibit B16.OVA cells as the IC50 
decreased from an estimated 6969 µg/mL to 6 µg/mL for PEI liposomes and 730.9 µg/mL to 
1.2 µg/mL for PEI + 1% CHAN liposomes. Additional evidence of the reaction between PEI 
and DOX has been difficult to gather as the large molecular weight of the PEI (25 kDa) hinders 
analysis techniques, such as NMR and mass spectroscopy. For future studies IR spectroscopy 
or chromatography methods, such as size exclusion chromatography, may be used to study the 
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potential reaction between PEI and DOX. It is hypothesised that the product between PEI and 
DOX would have a molecular weight similar to PEI (i.e. 25 kDa), which would cause the PEI 
fraction to absorb or fluoresce similarly to DOX. 
 
With extruded liposomes, when comparing the efficacy of the liposomes containing PEI and 
channels (PEI+CHAN) with unmodified control liposomes (Figure 3.4.22), no enhanced cell 
killing was measured. However, as unmodified DOX-loaded liposomes were already very 
effective in killing the melanoma cells this result was expected. With DOX sensitive cell lines 
(such as B16.OVA) free DOX is as effective as formulations with endosomal escape (329). 
Therefore, a future study with DOX resistant B16 melanoma cells may reveal more about the 
efficacy of pH responsive formulations for drug delivery (329). 
 
Interestingly, formulations with PEI and without channels (+PEI) performed significantly 
worse compared to all conditions tested (Figure 3.4.22). This suggests the inclusion of channels 
is important to the mechanism of action of the formulation. Meanwhile, formulations 
containing PEI and 1% channels did not perform significantly better compared to formulations 
containing 1% channels only, suggesting the channels can impart minor improvement in 
endosomal escape, perhaps through the movement of protons across the liposomal membrane. 
 
This experiment exposes a potential flaw in PEI based delivery systems as incomplete release 
of actives from PEI complexes may limit the usability of the formulation. The issue is especially 
apparent with sonicated liposomes (Figure 3.4.20). However, given the restoration of cell 
inhibition with extruded liposomes (Figure 3.4.22), this flaw is limited to specific conditions 




Figure 3.4.22: IC50 values of extruded DOX loaded liposomal formulations incubated with 
B16.OVA cells. Data are means of two experiments ± range. 
In summary, improvement in cytoplasmic delivery with modified liposomes was demonstrated 
in cell-free and cell-based experiments. Improvement in DOX delivery was not detectable due 
to the high susceptibility of B16 melanoma cells to DOX. As many pH sensitive DOX loading 
formulations are already being developed (Section 1.2.1), the potential for these liposomes for 




Two formulations, PDMAEMA polymeric nanoparticles and modified DPPC liposomes were 
examined for pH responsive effects. In the case of PDMAEMA nanoparticles, the ability of the 
nanoparticles to release DOX in a pH sensitive manner was examined using cell viability 
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studies. DOX release from PDMAEMA nanoparticles was observed within endosomes only, 
and were unable to release DOX in ex vivo conditions at pH 5.5. 
 
For liposomes modified with PEI and channels a DLS based lysis assay was validated and 
utilised to demonstrate lysis of liposomes in acidic conditions. This finding was significant as 
the proton sponge effect has been demonstrated in a cell-free system, and the lysis was close to 
values predicted by literature. Additionally, the ability to release actives into the cytoplasm of 
cells was demonstrated with calcein delivery. However, the ability of the formulations in 
enhancing DOX delivery was not measurable due to the high susceptibility of the B16 
melanoma cell line to DOX, and further experiments with resistant cells are required. 
 
Lastly, this chapter demonstrates the need for robust assays for the measurement of actives. It 
is concerning as the fluorescence of actives is commonly used in literature to evaluate 
nanoparticles, with little emphasis placed on verifying the consistency of absorbance or 






Chapter 4 : PEI and Channel modified 




One of the major barriers to the development of a cancer vaccine is the processing of antigen. 
To summarise, as cancer vaccines deliver antigen to APCs they are recognised as ‘exogenous’. 
Therefore, the majority of this antigen is destined for the MHC-II pathway, as the MHC-I 
pathway is primarily reserved for the loading of endogenous antigen. To rectify this, APCs 
such as DCs, may present exogenous antigen on MHC-I via cross-presentation. However, 
cross-presentation occurs rarely and is yet to be fully understood. Thus, bypassing cross-
presentation via cytosolic delivery to DCs improves MHC-I loading and subsequently CD8+ T 
cell responses (Section 1.3.8.3). 
 
In the previous chapter, PEI + CHAN modified liposomes were shown to be capable of 
delivering actives to the cytoplasm of DCs. Therefore, modified liposomes may be capable of 
stimulating a strong CD8+ T cell response as a vaccine carrier. The aims of this chapter were 
to investigate the ability of the PEI + CHAN liposomes (with or without DMXAA) to stimulate 
an immune response in vitro with dendritic cells and T cells, and to verify the in vitro results 
with an in vivo murine melanoma model. 
 
 Use of polyethylenemine (PEI) in vaccines 
 
PEI has been explored for delivery of vaccine adjuvants and antigens, but PEI-based vaccines 
are yet to be approved for use. Early PEI-based vaccines focused on the delivery of adjuvants 
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such as tetanus toxoid (330) or were used to deliver DNA vaccines (302, 331) to enhance the 
immunogenicity of tumours, rather than to enhance the delivery of antigen. 
 
The earliest use of PEI to enhance antigen delivery and processing was reported by Chen et al. 
(274) where nanoparticles constructed of OVA and PEI demonstrated the ability to enhance 
cross-presentation. Subsequently, PEI was demonstrated to be effective in the delivery of viral 
glycoproteins by Wegmann et al. (315). Interestingly, the same article demonstrated the ability 
of PEI to improve cross-presentation. However, the adjuvant properties of PEI were found to 
prevent the formation of a robust CD8+ T cell response due to the mixed Th1/Th2 adjuvant 
properties of PEI. 
 
The adjuvant effects of PEI were realised earlier when Regnström et al. (332), reported PEI 
was capable of stimulating a mixed Th1/Th2 immune response, cautioning investigators 
pursuing PEI based gene therapies. This observation was also confirmed by Sheppard et 
al.(333)., who made a further observation that the addition of a Th1 polarising adjuvant, such 
as CpG, may be sufficient to allow CD8+ T cell responses to occur. 
 
Overall, it may be concluded that PEI is likely to provide beneficial effects for vaccine delivery 
and cross-presentation. However, its adjuvant properties are questionable with regards to the 
stimulation of CD8+ immune responses. Therefore, the addition of 5,6-dimethylxanthenone-4-
acetic acid  (DMXAA) to the formulation may sufficiently polarise the immune response 






 DMXAA and STimulator of INterferon Genes (STING) 
 
The synthesis of DMXAA was first reported by Atwell et al. (334) where it was reported to be 
effective for the treatment of C38 colon adenocarcinomas in mice. The synthesis of DMXAA 
was based upon the knowledge of flavoneacetic acid (FAA), which was capable of causing 
tumour rejection via vascular disruption of blood vessels at the tumour site (335). Thus, 
DMXAA was developed as a vascular disrupting agent (VDA) for human trials. It is reported 
that macrophages (336) or endothelial cells (337) may mediate the vascular disruption of 
tumours in response to DMXAA administration. 
 
In addition to its efficacy as a VDA it was also found to possess immunostimulatory properties, 
which is more pertinent for the function of the formulation in this chapter. In the original report 
by Atwell et al. (334) the enhanced activity of NK cells was cited as another factor by which 
DMXAA may exert its effects. Eventually, it was discovered that DMXAA binds to and 
activates an adaptor protein designated stimulator of interferon genes (STING) (338). 
 
STING is present in the endoplasmic reticulum (339) and is considered to be an adaptor protein 
for several DNA sensors, such as DDX41 (340) and IFI16 (341). Direct activation of STING 
by cyclic guanosine monophosphate–adenosine monophosphate (cGAMP) produced when 
intracellular DNA is processed by cyclic GMP-AMP synthase (cGAS) also occurs (342). 
Therefore, STING plays an important role in the detection of viral or pathogenic DNA and 
cyclic nucleotides during the innate immune response (343). Once activated STING signals 
through TANK-binding kinase 1 (TBK1) and interferon regulatory factor 3 (IRF3), which then 
leads to the upregulation of transcription and production of type-I interferons, such as IFN-β 




It is important to note human STING differs from murine STING preventing the binding and 
subsequent activation of human STING by DMXAA (345). This difference in affinity led to 
the failure of DMXAA in Phase III clinical trials (346). Therefore, new compounds targeting 
human STING are being investigated such as 8-methylxanthenone-4-acetic acid. In contrast to 
DMXAA’s 5,6-dimethylation, this single methylated xanthenone acetic acid demonstrated 
enhanced cytokine production from human leukocytes, but not murine leukocytes (347). 
 
The activation of STING has multiple effects on the immune system due to the secretion of 
IFN-β. Overall, a Th1 polarised response may be observed involving DC activation with 
subsequent CD4+ and CD8+ T cell proliferation (348, 349), which is supported by the secretion 
of cytokines such as IFN-γ (350) or TNF-α (351). These actions are then associated with tumour 
rejection (352), as discussed in Chapter 1 (Section 1.3.1). 
 
Interestingly, STING activation may also lead to Th2 responses (353). Ooi et al., suggested the 
activation of STING in this context may be similar to dsDNA release, triggering a Th2 response 
akin to alum. One explanation for this anomalous result may be due to the route of 
administration. DMXAA is frequently administered via the intraperitoneal (i.p.) route (349, 
351) or intratumorally (354), in contrast to the intradermal route reported by Ooi et al. 
Additionally, given the large volume of evidence demonstrating a Th1 immune response, it is 
unlikely that a Th2 response is the primary mechanism of action of DMXAA. 
 
While DMXAA is efficacious in mice, TNF-α dependent toxicity is dose limiting (347). This 
toxicity is theorised to occur due to TNF-α receptor activation in vascular endothelium outside 
the tumour, disrupting circulation to tissues and causing symptoms such as acute hypothermia 
(347, 355). Therefore, the delivery of DMXAA by liposomes to the tumour may be effective 
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Figure 4.1.1: Summary of STING activation and effects. 
 Synergy between DMXAA and PEI 
 
In addition to the Th1 polarising and immunostimulatory effects of DMXAA, an additive 
response between PEI and DMXAA may exist due to a shared signalling pathway. While the 
exact mechanism of action for the adjuvant properties of PEI is not yet known it is theorised 
the release of dsDNA occurs with cellular damage caused by PEI in a similar manner to alum 
(315) (Figure 4.1.2). The release of dsDNA by damaged cells may be detected by DCs through 
intracellular DNA sensors, or direct activation by cGAMP produced from tumour DNA by 
cGAS (344) leading to STING activation and type 1 IFN release (356). This is partially 
supported by the requirement of IRF3 that is downstream of STING for the adjuvant activity 






Figure 4.1.2: PEI and DMXAA may share a common pathway via STING. PEI has 
demonstrated the ability to release dsDNA which may be detected with intracellular DNA 
sensors in DCs. STING is a common adaptor to DNA sensors, and is also activated directly 
by DMXAA. Due to this common pathway additive effects may be possible between DMXAA 
and PEI. 
 Chapter aim 
 
The hypothesis being investigated in this chapter is the cytoplasmic delivery of antigen 
mediated by PEI + CHAN liposomes in conjunction with the adjuvant properties of DMXAA 
is capable of generating an immune response to prolong survival in a murine melanoma model.  
 
The most important component of the formulation is hypothesised to be PEI as it facilitates the 
delivery of antigen into DCs, bypassing cross-presentation to stimulate the production of a 
robust Th1 polarised immune response. Channels alone are not hypothesised to improve 
survival in mice as their role in the formulation is to potentiate the action of PEI by permitting 
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the transport of ions through the liposomal membrane. However, due to the Th2 polarising 
properties of PEI, DMXAA was included to induce a Th1 polarised response. 
 
Therefore, the aim of this chapter is to determine the efficacy of PEI + CHAN modified 
liposomes loaded with DMXAA and OVA as a vaccine in a murine melanoma model. To 
achieve this aim in vitro experiments such as DC stimulation and T cell division assays were 
performed, in addition to characterisation of liposomes with the addition of DMXAA. 
 
4.2 Materials and Methods 
 
 Production of modified liposomes 
 
Liposomes were produced using the thin film hydration and extrusion methods described in a 
previous chapter (Section 2.2). 50 mg DPPC and 1 mg cholesterol were added to an autoclaved 
50 mL round bottom flask using stock solutions in chloroform. 0.452 mg of channels as a 
methanol solution was then added to the flask, and a dry film was produced via rotary 
evaporation. For formulations where channels were not required, methanol was substituted. 
 
The film was hydrated with 1875 µL of 0.5 mg/mL OVA in PBS and 625 µL of 1 mg/mL PEI 
solution (2.5 mL total volume). All solutions were filtered with 0.22 µm filters, and the volumes 
were scaled to maintain a DPPC concentration of 20 mg/mL. OVA and PEI solutions were 
substituted with an equal volume of PBS if they were not required. Lastly, five autoclaved glass 
beads were added to the flask and the flask was transferred to a shaking water bath for at least 




The lipid films for DMXAA liposomes were identical to the liposomes described above. 
However, due to the low aqueous solubility of DMXAA the addition of 25% DMSO was 
required during hydration. Therefore, the lipid film was hydrated with 625 µL of 6 mg/mL 
DMXAA in DMSO solution, 625 µL of 1 mg/mL PEI solution, and 1250 µL of 0.5 mg/mL 
OVA solution (total volume of 2.5 mL, 20 mg/mL DPPC concentration). While the 
concentration of DMSO was high in the formulation (25%), it was diluted to 10% prior to 
administration to minimise the adverse effects of DMSO. As DMSO delivered i.p. in mice is 
well tolerated up to 10 mL/kg, 2.5 mL/kg was used for these experiments (357). 
 
Dispersions of hydrated lipids were then extruded through 800 nm, 400 nm and 200 nm 
polycarbonate membranes at least 10 times to produce liposomes. The interior of the extruder 
was flushed with 70% ethanol, and then with filtered PBS to minimise the potential for 
microbial contamination. Extruded liposomes were then stored at room temperature in dark 
conditions overnight prior to use. 
 
 In vitro DC stimulation and carboxyfluorescein succinimidyl ester (CFSE) cell 
proliferation assay with DMXAA-free formulations 
 
Ethical approval for this experiment was obtained from the Animal Ethics Committee at the 
University of Otago (Approval number: AEC 15/14). Murine BMDCs were pulsed with 
formulations and the stimulation was measured through the expression of the costimulatory 
markers CD80 and CD86. Additionally, formulation pulsed DCs were then co-cultured with 
carboxyfluorescein succinimidyl ester (CFSE) stained T cells from OT-I mice (section 4.2.5). 
OT-I mice are genetically engineered to produce OVA specific T cells (358). Therefore, DCs 
that are activated against OVA by the vaccine are capable of inducing clonal expansion of OT-




Figure 4.2.1: Timeline of events for the in vitro DC stimulation and T cell proliferation 
assays. 
 Preparation of liposomes 
 
Liposomes were prepared as described above with one modification, 0.2 mg/mL OVA solution 
was used for this experiment (substituting the 0.5 mg/mL solution) to give a final concentration 
of 10 µg/mL when diluted with culture medium, as DCs pulsed with OVA at this concentration 
are known to stimulate the division of lymphocytes (359). OVA-loaded unmodified, CHAN 
1% and PEI single modified, and CHAN 1% + PEI double modified liposomes were produced 
for this experiment. 
 
 Preparation and activation of dendritic cells (DCs) 
 
Dendritic cells were harvested from bone marrow from the hind legs of mice and cultured as 
described in the previous chapter (Section 4.2.4). Mature DCs were seeded in 900 µL in 10 
ng/mL GM-CSF supplemented RPMI at 5x105 cells per well in a 24 well plate. 100 µL of 
formulations (described in 4.2.3) were added to wells in triplicate. Additionally, PBS only, and 
0.2 mg/mL OVA solution controls were also included. After overnight pulse DCs were 
harvested, counted and seeded at 1x105 cells per well in a new 24 well plate in 1 mL of 10 
ng/mL GM-CSF supplemented RPMI in preparation for co-culturing with T cells. Remaining 
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cells were retained to measure the expression of CD80 and CD86 which will be described later 
in this section. 
 
 Preparation of T cells 
 
T cells were harvested from OT-I mice via the collection of the spleen, mesenteric, brachial, 
axial and inguinal lymph nodes. Lymph nodes and spleens were homogenised by gentle 
maceration with 5 mL syringe plungers and then filtered through 70 µm nylon mesh filters 
(Fisher Scientific, USA) to remove debris. Erythrocytes were removed from spleen 
homogenate by incubation of cells in RBC lysis buffer for 8 minutes (Appendix A.3). Cells 
were then washed with IMDM and strained through 70 µm nylon mesh filters to remove cell 
debris. Lymph node and spleen cells were then pooled and diluted to 2x107 cells/mL in PBS 
prior to CFSE staining. 
 
 CFSE staining and co-culture 
 
CFSE (Life Technologies, USA) solution was prepared at 5 mM in DMSO as a stock solution. 
This solution was diluted at 1 in 2000 in a volume of PBS which was equal to the volume of T 
cell dispersion prepared in the previous section. The two solutions were thoroughly mixed and 
incubated for 8 minutes. Unreacted CFSE was quenched with the addition of an equal volume 
of foetal calf serum (FCS). Cells were then washed 3 times with RPMI with a change in 
plasticware between each washing step. Washed cells were resuspended in 10 ng/mL GM-CSF 
supplemented RPMI to a concentration of 1×106 cells/mL. 1 mL (1×106 cells) was added to 
wells containing 1×105 cells/mL DCs (prepared earlier in the section). This gave a DC: T cell 
ratio of 1:10. Additionally, OVA pulsed T cells in the absence of DCs was included as a control 




Supernatant was collected from the plates, and centrifuged at 330 g for 10 minutes in 
microcentrifuge tubes. The supernatant was then collected and stored in -20°C to preserve the 
integrity of cytokines for future measurement. The cells were then harvested for FACS staining 
and analysis. 
 
 Flow cytometry and cell staining 
 
Antibodies and reagents for the labelling of cells were acquired from BD Biosciences (USA), 
with the exception of live-dead fixable violet reagent (Life Technologies, USA). Cells were 
kept on ice during staining to preserve cell viability. 
 
For dendritic cells, the supernatant was removed via pipetting, and 1mL of cold PBS was added 
to each well to detach cells. Cells were gently scraped and transferred to individual FACS tubes 
after straining through a 70 μm nylon mesh filter to remove large aggregates. Cells were then 
washed with 1 mL PBS and centrifuged at 330 g for 8 minutes. After dispersion of the pellet, 
cells were stained with 100 μL of an antibody solution consisting of FITC anti-CD11c, V450 
anti-CD80; and PE-Cy7 anti-CD86 antibodies diluted 1 in 200 with PBS. Single stain controls 
were also prepared at this time with 100 μL antibody diluted 1 in 200 with PBS, incubated with 
unstained cells. Cells were incubated in dark conditions for 25 minutes at room temperature 
with regular agitation using a platform mixer at 50 RPM (Ratek, Australia). After incubation, 
cells were washed with 1 mL PBS and centrifuged at 330 g for 8 minutes. Cells were then 
suspended in 100 μL of propidium iodide (PI) cell viability reagent diluted 1 in 100 in PBS. 
The cell dispersion was then analysed with a FACScanto II flow cytometer (BD, USA), and 




T cells were harvested from plates after the supernatant was carefully removed. The cells were 
strained through a 70 μm nylon mesh prior to transferring to individual FACS tubes. Cells were 
washed with 1 mL PBS and centrifuged at 330 g for 8 minutes. Resuspended cells were then 
stained with 100 μL of PE-Cy7 anti-CD8 antibodies for 25 minutes with gentle agitation in 
dark conditions at room temperature. After incubation, the cells were washed with 1 mL PBS 
and centrifugation at 330 g for 8 minutes. The cells were resuspended in 100 μL of PI live/dead 
reagent diluted 1 in 100 with PBS, and analysed as described above. 
 
 Measurement of cytokines 
 
Cytokines from the supernatant from the co-culture of DCs and T cells (Section 4.2.6) were 
analysed for IL-2, IFN-γ, and TNF-α to determine T cell stimulation and polarisation. 
Cytometric Bead Array (CBA) assay kits for IL-2, IFN- γ, and TNF-α were sourced from BD 
Biosciences (USA), and undiluted supernatants were assayed according to the instructions from 
the manufacturer. In brief, 100 μL of undiluted supernatant was incubated with multiplexed 
capture beads and was subsequently incubated with detection beads. The beads were detected 
using a FACScanto II flow cytometer and analysed with FlowJo, as described above. 
Concentrations of cytokines was calculated using a standard curve established using a reference 
sample provided by the manufacturer. 
 
 Characterisation of DMXAA liposomes 
 
Liposomes were characterised to determine the effects of the addition of DMXAA and 25% 
DMSO during hydration. DMXAA + OVA + PEI + 1% CHAN liposomes were characterised 





DMXAA loading was determined via fluorescence. Freshly prepared DMXAA + OVA + PEI 
+ 1% CHAN liposomes were dialysed overnight against PBS in 100 kDa dialysis tubing at a 
ratio of 1:300. Samples were then lysed using a final Triton X-100 concentration of 1%. As the 
fluorescence of DMXAA occurs at short wavelengths (345 nm excitation, 409 nm emission), 
quartz cuvettes were used due to concerns with absorbance from plastic-based consumables. 
This is in contrast to the measurement of FITC-OVA and DOX fluorescence, which utilised 
the plate reader with standard polycarbonate plates. Therefore, DMXAA fluorescence was 
measured using a F7000 fluorescence spectrophotometer (Hitachi, Japan) with matched quartz 
cuvettes. DMXAA concentration was calculated from standard curves prepared with DMXAA 
and DMXAA + PEI solutions (Appendix D). 
 
 In vitro DC stimulation with DMXAA formulations 
 
Liposomes containing DMXAA were produced as described in Section 4.2.1, with one 
substitution. The 0.5 mg/mL OVA solution included during hydration was substituted with a 
concentration of 0.2 mg/mL OVA to ensure an OVA concentration of 10µg/mL once diluted 
with cells. Additionally, a 1.5 mg/mL DMXAA in 25% DMSO and 75% PBS solution was 
produced as an unformulated control.  
 
Murine BMDCs were prepared as described in Section 4.2.4. DCs were then pulsed overnight 
with 100 μL of formulations, diluted in PBS to achieve 5 μg/mL, 50 μg/mL, and 120 μg/mL 
DMXAA concentrations when diluted 1 in 10 with cell medium. PBS and 50 μg/mL 
unformulated DMXAA was included as a control. BMDCs were then stained and analysed for 




 In vivo melanoma model 
 
A murine melanoma model was chosen as a model to assess the efficacy of the formulation as 
a therapeutic vaccine. Male C57BL/6 mice were obtained and housed in specific pathogen free 
conditions at the HTRU, University of Otago. Food and water were provided ad libitum. Ethical 
approval was obtained from the Animal Ethics Committee at the University of Otago (Approval 
number: AEC 15/14). 
 
Formulations were prepared as described in Section 4.2.1, and several variations of the 
formulation were produced as controls (Table 4.2.1) to determine the effects of each 
component. 
Table 4.2.1: Variations of vaccine formulations administered to mice. 
 Ovalbumin Channels DMXAA PEI 
DMXAA + PEI + OVA + CHAN liposomes Yes Yes Yes Yes 
DMXAA + PEI + CHAN liposomes No Yes Yes Yes 
OVA + CHAN + PEI liposomes Yes Yes No Yes 
DMXAA + OVA + CHAN liposomes  Yes Yes Yes No 
DMXAA + OVA + PEI liposomes Yes No Yes Yes 
DMSO/PBS control solution No No No No 
 
100 μL of 5 ×105 B16.OVA cells (total 5 ×104 cells) were injected s.c. into the flanks of mice. 
Mice were immunised via i.p. administration of formulations 6 days later with 200 μL of 
formulation, which was diluted to 500 μL with PBS to reduce the DMSO concentration to 10%. 
This volume of formulation corresponds to a dose of 50 μg of OVA, 2000 μg DPPC, and 300 




Mice were monitored daily for 6 days post-immunisation for physical signs of pain, such as 
changes in facial expression (360) and fluctuations in weight. After this period of intensive 
observation, the tumour was measured every two to three days with digital Vernier callipers 
and tumour size was calculated using the following equation: 
 = ℎ    × ℎ  ℎ   
Mice that reached a tumour area threshold of 150 mm2 were euthanized. Additionally, mice 
that developed haematomas were also euthanized on ethical grounds. The collected data was 
analysed as a survival curve with GraphPad Prism, where the Gehan-Breslow-Wilcoxon and 
log-rank tests were used for the calculation of statistical significance between groups. 
 
 SIINFEKL dextramer staining 
 
The OVA specific CD8+ T cell response was measured in vivo with a SIINFEKL dextramer. 
The dextramer contains multiple units that binds to T cells which possess TCRs against 
SIINFEKL, as SIINFEKL is the most loaded OVA peptide on MHC-I (361). The blood from 
mice immunised with DMXAA + PEI + CHAN + OVA liposomes, or PEI + CHAN + OVA, 
or DMXAA + PEI + CHAN liposomes, or PBS/DMSO control mice was collected 8 days post-
immunisation via tail tip excision. To prevent coagulation, blood was collected into 1 mL 
Alsever's solution and stored on ice prior to staining. Erythrocytes were lysed with RBC lysis 
buffer over 10 minutes, and the cells were washed with 1 mL PBS and centrifugation at 330 g 
for 8 minutes. Resuspended cells were then incubated for 20 minutes in the dark at room 
temperature with gentle agitation with 50 μL of PE SIINFEKL dextramer (Immudex, Denmark) 
diluted 1 in 5 in PBS. Cells were washed with 1 mL PBS and centrifuged at 330 g for 8 minutes. 
Resuspended cells were stained with 100 μL antibody solution containing FITC anti-CD8, 
APC-H7 anti-CD4, and APC-H7 anti-CD19, which were diluted 1 in 200 in PBS. After 25 
minutes of incubation with antibodies in dark conditions at room temperature, cells were 
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washed and stained with violet live/dead fixable reagent that was diluted 1 in 1000 with PBS. 
Cells were then measured for fluorescence with a FACScanto II flow cytometer and the data 
was analysed with FlowJo. 
 
4.3 Results and Discussion 
 
 In vitro DC stimulation  
 
The ability of PEI + CHAN modified liposomes in activating BMDCs was examined as the 
cytoplasmic delivery demonstrated in the previous chapter (Section 3.4.2.4) in conjunction with 
the adjuvant effects of PEI (333) may activate BMDCs. DMXAA was added later in the chapter 
to provide an additional immunostimulatory effect. 
 
 
Figure 4.3.1: Gating strategy to measure CD80/86 upregulation in dendritic cells. From left 
to right; gates were initially set on cells based on size and granularity (FCS-A versus SSC-A), 
then on single cells (FCS-A versus FCS-H). Live cells were selected by gating for cells with 
low PI fluorescence (FCS-A versus PI), and DCs were identified as FITC-CD11c positive 
cells (FITC versus FCS-A). Lastly, the MFI and frequency of CD80 or CD86 positive cells 
was calculated from a histogram (PE-Cy7-CD86 shown). 
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To evaluate the ability of the formulation to stimulate DCs, the upregulation of CD80 and CD86 
was measured in response to overnight pulse with formulations (flow cytometry gating strategy 
shown in Figure 4.3.1). These markers, formally the B7 molecules, are co-stimulatory 
activators of T cells following binding to CD28 (362).  
 
The results from Figure 4.3.2 indicates upregulation of CD80 (Figure 4.3.2A) and CD86 
(Figure 4.3.2B) in response to incubation with PEI and PEI + CHAN modified liposomes. The 
expression of CD80 and CD86 was found to be similar between the two PEI containing 
formulations (20703 ± 800 and 19710 ± 1005 for PEI liposomes and PEI + CHAN liposomes 
respectively for CD80 MFI). These results suggest that PEI is capable of stimulating DCs 
without additional adjuvants, which was not consistent with a previous experiment by 
Wegmann et al. (315) as no increase in CD80 and CD86 expression was observed. However, 
as their experiment used 2 µg/mL PEI, which was more than 10 fold less compared to this 
experiment (approximately 25 µg/mL PEI), stimulation of DCs by PEI may be concentration 
dependent. Additionally, the delivery of PEI within liposomes may have contributed towards 














































































































Figure 4.3.2: CD80 (A) and CD86 (B) expression in dendritic cells after overnight pulse with 
PBS, OVA solution, and modified and unmodified liposomes loaded with OVA. Formulations 
contained 25ug PEI and 10ug OVA. Data are n=4 ± SD, and is representative of two 
experiments. ns = p > 0.05, * = p ≤ 0.05, ** = p ≤ 0.01, **** = p ≤ 0.0001 
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The mechanism by which DCs are activated by PEI is unknown. Wegmann et al. demonstrated 
the effects of PEI occur via a TLR independent mechanism (315), and suggested the activation 
of the NLRP3 inflammasome is responsible for the immune effects of PEI. The NLRP3 
inflammasome is an intracellular complex which is formed upon detection of  a wide range of 
stimuli including nucleic acids and non-organic solids as a part of the innate immune response 
(363). However, it was demonstrated the NLRP3 inflammasome is not required for the immune 
effects of PEI, but its expression was required for Th2 polarising effects (315). Therefore, the 
mechanism of action of DC activation by PEI remains unknown. 
 
While PEI has a significant effect on CD80 and CD86, the presence of channels appears to 
have little effect as channel modified liposomes did not increase the expression of CD80 
compared to unmodified controls (1379 ± 175 for unmodified liposomes and 2140 ± 229 for 
1% CHAN liposomes, p=0.4518, Figure 4.3.2A). However, the addition of channels had a 
small, but significant improvement in CD86 expression (430.5 ± 94.2 for unmodified liposomes 
and 586.3 ± 41.03 for 1% CHAN liposomes, p=0.0457). The addition of channels in the 
presence of PEI did not improve CD80 or CD86 expression (p=0.1954 for CD80, p=0.9992 for 
CD86). This data supports the hypotheses that channels are unlikely to stimulate DCs. This 
may be beneficial in future applications of channel modified liposomes where immune 
stimulation is not desired. For example, for the production of theranostic liposomes described 
in Chapter 3 (Section 3.4.2.1). 
 
The reason for inclusion of channels into liposomes was not to induce DC activation but to 
facilitate the transfer of actives to the cytosol (Section 3.4.2.5), loading onto MHC-I and the 
activation of CD8+ T cells. This was then investigated by co-culturing formulation-pulsed DC 
with CD8+ T cells. 
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 In vitro T cell proliferation 
 
Formulation-pulsed DCs were co-cultured with CFSE stained naïve T cells to determine if T 
cell expansion could be induced (Figure 4.3.3). The CFSE proliferation assay is dependent on 
the daughter cells receiving a half of the CFSE labelled proteins from the parent cell during 
proliferation, which causes a dilution of CFSE in the daughter cells detectable by flow 
cytometry (359).  
 
Figure 4.3.3: Gating strategy to detect T cell division with CFSE.  From left to right; gates 
were initially set on cells based on size and granularity (FCS-A versus SSC-A), then on single 
cells (FCS-A versus FCS-H). Live cells were selected by gating for cells with low PI 
fluorescence (FCS-A versus PI). CD8+ cells were selected as PE-CY7 positive cells (PE-Cy7 
versus FCS-A), and their division was measured by the dilution of CFSE as FITC low cells 
(FITC versus count). 
The proliferation of CD8+ T cells (Figure 4.3.4) was low with less than 10% division. The low 
level of division could potentially be attributed to reduced interactions between DCs and T cells 
as flat bottom plates were used for this experiment. However, it is important to note the PEI 
containing formulations (PEI and 1% CHAN PEI liposomes) resulted in an increase in T cell 
proliferation, demonstrating that dendritic cells were primed in a manner that is consistent with 




Figure 4.3.4: OVA specific CD8+ division assay for T cells co-cultured with OVA pulsed-DCs 
for 48h (excluding OVA pulsed T cells only). The DCs were pulsed overnight with 
formulations prior to co-culturing. Data are n=4 ± SD and is representative of two 
experiments, **** = p ≤ 0.0001. 
There was a significant difference between the two PEI formulations (p<0.0001). The reduced 
CD8+ proliferation upon inclusion of channels in the liposomes does not support the hypothesis 
that the channels facilitate the presentation of antigen to CD8+ T cells. This unexpected result 
could potentially be due to disruption of the immune synapse. Methyl-beta-cyclodextrin 
(MBCD) has been used previously to remove cholesterol from the cholesterol-rich immune 
synapses to disrupt immune responses (364). Modelling shows the depletion of cholesterol is 
due to its high affinity for the hydrophobic cavity of beta-cyclodextrin (365), which gives a 
theoretical mechanism where channels may disrupt the immune synapse. This effect was not 
seen with 1% CHAN single modified liposomes compared to unmodified liposomes (p= 
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0.9871), but as the levels of proliferation for unmodified liposomes were not above background 
it is unlikely any negative effect on proliferation would have been detected.  
 
 Measurement of cytokines 
 
The concentrations of IFN-γ, TNF-α, and IL-2 were measured from the supernatants of the 
CFSE proliferation experiment with a CBA assay. Secretion of IFN-γ is widely considered to 
be the hallmark of a Th1 response. Therefore, measurement of IFN-γ represents the downstream 
effects of DC activation and polarisation. Additionally, secretion of TNF-α by activated T cells 
and DCs is also indicative of an immune response, while IL-2 is actively secreted and consumed 
by CD8+ T cells during clonal expansion to indicate a CTL response (176). 
 
The concentrations of IFN-γ were consistent with concentrations of TNF-α (Figure 4.3.5A and 
B), while concentrations of IL-2 were below detectable limits. Low concentrations of IL-2 can 
occur if the cytokine is being consumed as a growth factor by T cells. The concentrations of 
IFN-γ and TNF-α were found to be lower in both single (PEI or CHAN) or double (PEI and 
CHAN) modified liposomes compared to unmodified liposome controls.  It is interesting that 
while the unmodified liposomes did not induce measureable activation of DC activation 
(Section 4.3.1) or CD8+ T cell proliferation (Figure 4.3.4), they did stimulate significant 
cytokine production (p=0.0071 when compared to OVA solution).  The cytokine concentrations 
were unexpected as the unmodified liposomes did not contain any DC-activating adjuvants and 
were therefore not expected to activate DC.  It is possible that the unmodified liposomes 
stimulated CD4+ T cell activation rather than CD8+ T cell activation, which is more likely in 
liposomes not modified to induce cross-presentation.  The levels of cytokine stimulated by 
unmodified liposomes were higher than those induced by OVA solution, suggesting that it was 
either the liposome formulation or the increased uptake of formulation that was responsible 
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(366). As a control of empty liposomes was not included the precise cause of the increased 
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Figure 4.3.5: Concentrations of IFN- γ (A) and TNF- α (B) in supernatant after 72h when T 
cells were co-cultured with DCs that have been pulsed with formulations overnight. Data are 





However, the hypothesis being examined was that the inclusion of PEI and channels would 
increase DC activation and CD8+ T cell proliferation. Unexpectedly, the OVA + PEI + CHAN 
liposomes did not result in an increase the concentrations of IFN-γ (40705 ± 7939 fg/mL for 
OVA + PEI + CHAN liposomes, and 55872 ± 1954 fg/mL for OVA solution, p=0.8409) or 
TNF-α (12575 ± 904 fg/mL for OVA + PEI + CHAN liposomes, and 10523 ± 622 fg/mL for 
OVA solution, p=0.9555) compared to OVA in solution. This result was unexpected, as the 
OVA + PEI + CHAN liposome pulsed DCs were activated and were capable of stimulating T 
cell proliferation (Figure 4.3.4), yet the low cytokine concentrations are not consistent with this 
result. 
 
A theory to explain the lower levels of Th1 cytokines in modified liposomes is that a mixed 
Th1/Th2 response may be occurring to diminish the secretion of these cytokines. Prior evidence 
for this exists in literature, as PEI generated a Th2 polarised response (315). However, as PEI 
was administered via the nasal route for a Th2 polarised response these results may not be 
generalizable, as systemic administration produced a mixed Th1/Th2 response in the absence 
of a Th1 polarising adjuvant (332). Therefore, this combination of results with the proliferation 
of CD8+ T cells (Section 4.3.2), and the lack of Th1 cytokines may be indicative of a mixed 
Th1/Th2 response.  
 
Interestingly, DCs incubated with CHAN single modified liposomes was also associated with 
reduced TNF-α production (12221 ± 2210 fg/mL, p=0.0226), but not IFN-γ (59365 ± 12850 
fg/mL, p=0.3151) in comparison to unmodified liposomes, which may suggest CHAN may 
have slight Th2 polarising effects, but not adjuvant effects. However, future studies with the 
measurement of Th2 specific cytokines, such as IL-4, and the addition of Th1 and Th2 adjuvant 
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controls, such as MPL and aluminium hydroxide respectively may be carried out to determine 
the polarisation of the immune response in this experiment (367). 
 
 Incorporation of DMXAA and characterisation of DMXAA + PEI + CHAN 
liposomes 
 
As the PEI modified liposomes have demonstrated the ability to stimulate DCs, it was our 
hypothesis that the addition of DMXAA could improve DC activation, and perhaps polarise the 
immune system towards a Th1 response. The polarisation towards Th1 is an important function 
of DMXAA in this formulation, as PEI is known to possess mixed Th1/Th2 activity (333). 
 
In this section, PEI + OVA + 1% CHAN liposomes were characterised with the addition of 
DMXAA, as a major challenge with DMXAA was the low aqueous solubility. DMXAA is only 
freely soluble in very polar solvents such as DMSO. Thus, solubility in non-polar environments 
such as chloroform or lipid membranes are unlikely to aid in the manufacture or delivery of 
DMXAA. As the volume of liposomes that may be administered in vivo is limited, the 
concentration of DMXAA must be sufficiently high for dosing. Therefore, the solubility of 
DMXAA was improved with DMSO wherein 25% DMSO was used during formulation, which 
was diluted to 10% DMSO for in vitro and in vivo experiments to minimise adverse effects. 
 
 Size, size distribution and zeta potential 
 
During the production of liposomes with 25% DMSO and DMXAA, no issues were 
encountered during hydration and extrusion as the film was hydrated and extruded through the 
membranes without difficulty. However, solubility issues with DMXAA became apparent once 




The measurement of size and size distribution of DMXAA liposomes reflects the low solubility 
and the turbidity of DMXAA solutions. Figure 4.3.6 shows a change in size and size 
distribution over time. The initial measurement of size immediately after sample preparation 
(Run 1) shows a homogenous population of liposomes at 165.5 nm. However, subsequent 
measurements (Runs 2 and 3) show an increase in polydispersity, as an additional peak at 1106 
nm increases in intensity over 300 seconds. It is likely this large peak is due to precipitate 
formation, which also explains the turbidity of the solutions as micron sized particles are known 
to produce turbid solutions (368).  
 
 
Figure 4.3.6: Changes in particle size and distribution over time of DMXAA + PEI + CHAN 
1% liposomes as measured by DLS. Three subsequent measurements were recorded (100 
seconds per measurement), showing an increase in particle size and PDI over time. 
One concern with the formation of DMXAA precipitates upon dilution was the preservation of 
liposomal integrity. The TEM micrograph in Figure 4.3.7 shows the liposomes are intact and 
that DMXAA precipitates are formed (Figure 4.3.6). Interestingly, the liposomes dispersed in 
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is likely the DMXAA is ‘salting out’ of solution in PBS. The presence of ions in solution 




Figure 4.3.7: TEM image of DMXAA + PEI + OVA + 1% CHAN liposomes at 33,000× 
magnification, counterstained with phosphotungstic acid. The dark aggregates are likely to 
be stained DMXAA precipitates. 
For cell based in vitro and in vivo studies, formulations are suspended in PBS to prevent osmotic 
damage to tissues and cells. Therefore, the existence of micron sized aggregates of DMXAA 
in PBS may limit the available routes of administration. Fortunately, particles up to 5 µm in 
diameter have demonstrated low toxicity when administered i.v. (370). However, given the low 
aqueous solubility of DMXAA, i.v. administration is possible but not recommended as the 
volume required (500 µL) represents the maximum volume for a 20 g mouse (371). Therefore, 




The addition of DMXAA to PEI + OVA + 1% CHAN liposomes had a minor effect on particle 
characteristics (Table 4.3.1). While, the Z-average size did not change (250.0 ± 83.2 nm versus 
207.0 ± 20.0 nm, p=0.4332), the PDI decreased from 0.481 ± 0.042 to 0.179 ± 0.030 
(p=0.0005). This data suggests the addition of DMXAA resulted in more homogenous 
liposomes. However, given its low concentration (1.5 mg/mL or 5.3 µM) the addition of 25% 
DMSO is more likely to explain these results. As the higher polydispersity of PEI + OVA + 
CHAN liposomes is attributable to OVA induced aggregation (Section 2.10.1.2), perhaps the 
addition of DMSO prevented the interaction between OVA and liposomal membranes to avert 
aggregation. This is plausible as OVA is highly soluble (70%) in DMSO (372), hypothetically 
resulting in reduced interaction with liposomal membranes due to increased interactions with 
the solvent. 
 
The zeta potential increased from 10.3 ± 0.2 mV to 12.5 ± 0.2 mV (p=0.0002). It is highly 
unlikely these effects may be attributed to DMXAA as its ionised form is negatively charged 
due to the carboxylic acid group. The effects of DMSO may explain this anomalous result, as 
molecular modelling has shown the addition of DMSO to DPPC membranes causes the 
membrane potential to become more positive (373). Overall, given the small magnitude of the 
change, it is unlikely that this change in zeta potential would have any effect on the stability of 
the liposomes (Section 4.3.7). An alternative interpretation of this data is the overall magnitude 
of the change in zeta potential (2.2 mV) is a minor difference that may be within the margin of 
error of the Zetasizer. Therefore, the addition of DMXAA may not have affected the zeta 





Table 4.3.1: Size, PDI, and zeta potential of PEI+ OVA+ 1% CHAN and DMXAA + OVA + 
PEI + 1% CHAN liposomes.  
 Z-average (nm) PDI Zeta potential (mV) 
    
PEI + OVA + 1% 
CHAN 
250.0 ± 83.2 0.481 ± 0.042 10.3 ± 0.2 
    
DMXAA + OVA+ 
PEI + 1% CHAN 
207.0 ± 20.0 0.179 ± 0.030 12.5 ± 0.2 
 
 Loading of DMXAA and OVA 
 
The loading of OVA and DMXAA were measured for DMXAA + PEI + OVA + 1% CHAN 
liposomes, and the results are summarised in Table 4.3.2. The encapsulation efficiency of 
FTIC-OVA was not affected by the addition of DMXAA as 13.71 ± 3.05% encapsulation 
efficiency was observed in liposomes without DMXAA (Chapter 2, Section 2.11) in 
comparison to 11.9 ± 2.0% for liposomes with DMXAA. This is a positive result as it 
demonstrates that OVA was encapsulated successfully for formulations containing DMXAA, 
also providing further evidence the integrity of the liposomes was not compromised due to the 





Table 4.3.2: Loading and encapsulation efficiency for DMXAA + PEI + OVA + 1% CHAN 
liposomes. Data are n=3 ± SD  
 Loading (µg/mL) Encapsulation efficiency (%) 
 
       FITC-OVA 
 
119.3 ± 20.1 
 
11.9 ± 2.0 
       DMXAA 0.98 ± 0.05 0.08 ± 0.00 
 
While OVA loading was found to be acceptable, DMXAA loading was low with a loading of 
0.98 ± 0.05 µg/mL, representing an encapsulation efficiency of 0.08 ± 0.00% (Table 4.3.2). 
This is likely due to the low aqueous solubility of DMXAA hindering passive loading (374). 
This contrasts to the loading of DOX in Section 2.11 as no solubility issues were observed with 
DOX in comparison to DMXAA. Additionally, TEM images show aggregates of DMXAA 
outside liposomes (Figure 4.3.7), further contributing to the low encapsulation efficiency. 
 
A solution to improve the solubility and loading of DMXAA is to reformulate as a sodium salt 
as the carboxylic acid group of the DMXAA is a weak acid. One of the earliest reports for the 
synthesis of DMXAA includes a method to produce the sodium salt by the addition of DMXAA 
to a solution of sodium bicarbonate, which was purified by crystallisation in methanol/ethyl 
acetate (334). This may be examined in a future study. 
 
As DMXAA is not encapsulated within liposomes, the administration of the formulation will 
be akin to delivery of liposomes with a concurrent dose of DMXAA. To elaborate, the 
formulation was not dialysed prior to administration to maintain the consistency of doses of 
DMXAA and OVA for in vitro and in vivo experiments. Therefore, when the formulation is 
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administered, liposomes and aggregates of DMXAA will be deposited into the peritoneal cavity 
in mice (Figure 4.3.8).  
 
Figure 4.3.8: Absorption and transit of DMXAA and liposomes from the peritoneal cavity to 
lymph nodes. 
Once inside the peritoneal cavity, the liposomes and DMXAA must be absorbed into the body. 
Liposomes have been reported to reach lymphatic drainage within 5 hours (375). Whereas, 
suspensions of poorly soluble compounds such as DMXAA may take long periods of time for 
dissolution and absorption due to the limited volume of peritoneal fluid available for dissolution 
(376). In extreme cases, retention of compounds with low aqueous solubility, such as paclitaxel, 
was reported to be retained in the peritoneal cavity after two weeks (377). Therefore, the 
synchronicity between the delivery of antigen and adjuvant may be an issue with the 
formulation as simultaneous delivery of antigen and adjuvant is required to activate DCs 







The effect of DMXAA on the stability of liposomes for 14 days was observed with DLS. Figure 
4.3.9A shows the size is consistent regardless of the incubation temperature for 14 days. This 
is consistent with the results obtained in Chapter 2 as the inclusion of channels was shown to 
improve stability in all conditions, especially cold-induced fusion of liposomes (Section 2.13). 
The polydispersity (Figure 4.3.9B) is also similar between temperatures. However, a small 
decrease in size was noted for all conditions on day 7 (192.0 ± 1.4 nm to 174.5 ± 1.2 nm for 
room temperature), with a corresponding decrease in PDI (0.205 ± 0.006 to 0.165 ± 0.009 for 
room temperature).  
 
This result is interesting, as traditional sources of colloidal instability such as aggregation and 
Ostwald ripening predict an increase in particle size (247, 248). Additionally, DMSO is known 
to facilitate the fusion of liposomal membranes (378), which would exacerbate the increase in 
particle size. Using Israelachvili’s theory of packing (explained in Section 2.7.1.1), a decrease 
in liposome size is likely explained by an increase in head group size of the phospholipid. 
DMSO is unlikely to explain this decrease in size on day 7, as modelling shows the effects of 
DMSO occur at the membrane at the nanosecond scale (378). Although this reduction in size 
cannot be readily explained with conventional theories, it is important to note the change in 
size was small (approximately 25 nm) and the PDI decrease suggests an improvement in 
homogeneity. Therefore, the formulation may be considered to be physically stable for 14 days, 











Figure 4.3.9: Change in size (A) and polydispersity (B) over 14 days for DMXAA + PEI + 
OVA + 1% CHAN liposomes, incubated at room temperature (RT), 37°C, and 4°C. The inset 
figure shows the representative distribution of particle size for liposomes incubated at RT. 




















 In vitro DC stimulation with DMXAA formulations 
 
As the PEI and CHAN modified liposomes without the addition of DMXAA showed promising 
results with CD80 and CD86 upregulation in DCs earlier in this chapter (Section 4.3.1), the 
addition of DMXAA as an immunostimulant was briefly examined in vitro with BMDCs. 
Different concentrations of DMXAA were examined (5, 50 and 120 µg/mL) to determine if a 
dose-dependent effect occurs as DMXAA is known to stimulate DCs in this concentration 
range (349). 
 
With unformulated DMXAA solution, CD80 and CD86 expression (Figure 4.3.10) was 
significantly increased compared to the PBS control (p < 0.0001 for CD80 and CD86). This 
result is consistent with previous observations (349) and may be attributed to the activation of 
STING. Additionally, the unformulated DMXAA showed significantly higher CD80 and 86 
expression compared to OVA + PEI + 1% CHAN liposomes (p < 0.0001 for CD80 and CD86), 


































































































































Figure 4.3.10: CD80 (A) and CD86 (B) expression in MBDCs pulsed with OVA + PEI + 1% 
CHAN liposomes with increasing concentrations of DMXAA. Unformulated DMXAA solution 
was also examined. Data are n=4 ± SD.  **** = p ≤ 0.0001. 
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Despite the immunostimulatory results with unformulated DMXAA, the addition of DMXAA 
to OVA + PEI + 1% CHAN formulations did not further stimulate DCs (Figure 4.3.10) 
compared to DMXAA free control liposomes. Additionally, no dose-responsiveness between 
DMXAA concentrations (5-120 µg/mL) and CD80 or CD86 was observed. These results were 
unexpected, as the addition of DMXAA was predicted to improve the activation of DCs. 
Several theories may explain these results. 
 
The addition of channels is unlikely to have affected the activity of DMXAA. Although the 
hydrophobic cavity of the channels may potentially sequester DMXAA, the low concentrations 
at which the channel is present in the formulation does not support this theory. The channels 
were added at 1 mol% of DPPC (27.2 µM), in contrast to DMXAA that was present at 425 µM 
(15.6 equivalents) at 125 µg/mL DMXAA. Even with 100% occupancy, this concentration of 
channels is not sufficient to account for the complete removal of DMXAA activity. 
 
PEI is more likely to explain a physicochemical incompatibility of the formulation with 
DMXAA. The electrostatic interactions between positively charged PEI and negatively charged 
DMXAA ions may be too strong to allow the separation between the two compounds. However, 
this is also an unlikely explanation of results, as a strong interaction of DMXAA and PEI is not 
supported by the very low DMXAA loading observed earlier in this chapter (Section 4.2.9). In 
contrast, sonicated DOX and PEI liposomal loading was found to be abnormally high in the 
previous chapter, which is more consistent with an interaction between PEI and an active 
(Section 2.11). 
 
The most likely theory to explain the lack of synergy between DMXAA and the formulation is 
that both DMXAA and PEI share a common pathway through STING. Interestingly, the 
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activity of PEI appears to wholly dictate the stimulation of DCs as CD80 and CD86 expression 
was similar to DMXAA-free liposomes, which was lower compared to unformulated DMXAA 
controls (Figure 4.3.10). This suggests the activity from DNA sensors due to the effects of PEI 
are masking the effects of DMXAA. 
 
For future studies, the use of gene knockdown techniques, such as the use of siRNA (379) to 
prevent the transcription of STING in DCs, or STING knockout mice (339) to source STING 
knockout DCs would be valuable in determining the exact role of STING in the mechanism of 
action of PEI. 
 
 In vivo murine melanoma model 
 
The efficacy of the formulations were evaluated using a B16.OVA murine melanoma model as 
this cell line expresses ovalbumin that may be targeted by vaccines. Melanoma models in mice 
have been extensively studied, as it is a suitable model for human melanoma (380). 
 
 
Figure 4.3.11: Timeline of murine melanoma experiment. 
B16.OVA cells were implanted s.c. into the flanks of C57BL/6 mice, which were immunised 
6 days later (Figure 4.3.11). Mice were immunised with formulations containing OVA loaded 
single modified liposomes with DMXAA (DMXAA + PEI + OVA and DMXAA + OVA + 
CHAN) to determine the effects of PEI or CHAN; OVA loaded double modified liposomes 
without DMXAA to determine the effect of DMXAA (PEI + OVA + CHAN); and OVA loaded 
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double modified liposomes with DMXAA (DMXAA + PEI + OVA + CHAN), which is the 
complete formulation. Additionally, two controls were added, with an OVA-free formulation 
with DMXAA, PEI and CHAN to determine the non-antigen specific anti-tumour activity of 
DMXAA, and DMSO/PBS. 
 
Mice with implanted tumours were checked regularly for tumour size, and were sacrificed when 
the tumour exceeded an area of 150 mm2. Body weight was recorded to identify any adverse 
effects occurring in response to the formulation. Figure 4.3.12 shows the first day post-
immunisation was associated with a small decrease in weight for several groups. However, as 
the highest recorded individual weight loss was 3%, it may be assumed that administration of 
the formulations was not associated with severe adverse effects. 
 
Figure 4.3.12: Change in weight of mice in response to administration of formulations. The 







 Survival of mice 
 
Survival curves for each group of mice is shown in Figure 4.3.13 and the growth of tumours in 
each mouse are shown in Figure 4.3.14. One of the most important findings of this thesis is that 
the PEI + OVA + CHAN liposomes in the absence of DMXAA demonstrated the ability to 
improve the median survival from 20 days to 24 days with statistical significance (p= 0.0037), 
compared to OVA-free controls (DMXAA + PEI + CHAN) that did not show significance (21 
days, p= 0.1416). Therefore, the modified liposomes, even in the absence of DMXAA, are 
capable of stimulating a specific anti-OVA response against B16.OVA in C57BL/6 mice. 
 
The addition of DMXAA to PEI + OVA + CHAN liposomes (Figure 4.3.13) did not change 
median survival (23.5 days in double modified liposomes with DMXAA in contrast to 24 days 
without DMXAA, p = 0.8853), suggesting the addition of DMXAA was not effective as an 
immunostimulant when delivered in combination with PEI in liposomes. This observation 
mirrors the lack of synergy between PEI and DMXAA observed in the in vitro DC stimulation 
experiment (Section 4.3.8). However, a very interesting observation regarding survival and 
statistics was noted, as the Wilcoxon and log-rank methods for calculating statistical 
significance were inconsistent for DMXAA + OVA + PEI + CHAN liposomes (Figure 4.3.13, 
p= 0.0037 with Wilcoxon test, p= 0.0387 with log-rank test). While these statistics are generally 
similar (381) the Wilcoxon test is more sensitive to earlier deaths, while log-rank is more 
sensitive to later deaths (382). Therefore, this demonstrates that DMXAA + OVA + PEI + 
CHAN liposomes are producing a strong, but short-lived response.  
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Figure 4.3.13: Survival curves of C57BL/6 mice with s.c. implantation of B16.OVA murine 
melanoma cells (5×104 cells per mouse). The time is measured as post-implantation of 
tumour, and the median survival is listed in the inset table. Statistical significance was 
measured against DMSO solution controls by the Wilcoxon and Log-rank methods. Data are 
pooled from two experiments, n=10-12. ns = p > 0.05, * = p ≤ 0.05, ** = p ≤ 0.01. 
With regards to the role of channels in improving vaccine efficacy, DMXAA and PEI modified 
liposomes (DMXAA + PEI + OVA) showed a significant improvement in median survival 
compared to DMSO controls (24.5 days, p=0.0493) and did not show a significant difference 
compared to double modified (OVA + DMXAA + PEI + CHAN) liposomes (p=0.9075). This 
result indicates the addition of channels does not improve the efficacy of the formulation 
suggesting they are not necessary to permit the transport of ions and water across the liposomal 
membrane. This result is contrary to the in vitro calcein release experiment where 1% CHAN 
was required for cytoplasmic delivery (Section 3.4.2.4). One reason for the lack of in vivo and 
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in vitro correlation is perhaps the activity of PEI in vivo may also be attributed to pathways 
other than enhanced cytoplasmic delivery in DCs. For example, STING activation results in 
enhanced NK cell activity and IFN-β production (383) leading to an increase in Th1 activity 
(Section 4.1.2). 
 
Despite the lack of increased efficacy with the addition of channels, it is important to note the 
inclusion of channels was found to be beneficial for the stability of liposomes (Section 4.3.4), 
and the cyclodextrin cavities may allow for the delivery of additional actives or theranostic 
compounds, as discussed in a previous chapter (Section 3.3.2.2). 
 
Surprisingly, single modified liposomes with channels and DMXAA (DMXAA + 1% CHAN 
+ OVA) also demonstrated improved survival compared to DMSO controls (Figure 4.3.13, 23 
days, p=0.0286), which was not different from double modified liposomes (p= 0.9309). This 
was unexpected as in vitro data showed no stimulation of DCs with CHAN single modified 
liposomes without DMXAA (Section 4.3.1). Due to the absence of PEI to interfere with the 
action of DMXAA in this formulation, the survival benefits may be attributed to the action of 
DMXAA. Therefore, this result further demonstrates the incompatibility of DMXAA and PEI. 
DMXAA has been shown to have anti-tumour activity when administered  i.p. in mice with 
EG7 tumours (349), while intratumoural delivery of DMXAA was required to achieve a similar 
effect with B16 tumours (354). The lower efficacy of DMXAA in this experiment is likely due 
to differences in administration, as intratumoural delivery allows direct access of DMXAA to 
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Figure 4.3.14: B16.OVA tumour growth in C57BL6 mice with s.c. implantation of cells 
(5×104 cells per mouse). The time is measured as post-implantation of tumour. Data are 
pooled from two experiments, n=10-12. 
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 Mechanism of action 
 
To determine the mechanism of action of the formulation, OVA specific CD8+ T cells were 
measured in the blood of vaccinated mice by staining with a MHC-I SIINFEKL dextramer. 
Blood was collected from mice immunised with double modified liposomes with DMXAA or 
without DMXAA, OVA-free DMXAA + PEI + CHAN liposomes, and DMSO/PBS controls. 
Blood samples were obtained from mice 8 days post immunisation to coincide with peak 
activity of the adaptive immune response (384). Despite this timing, OVA specific CD8+ T 
cells were not able to be detected in any of the groups tested (data not shown). However, the 
survival data (Figure 4.3.13) provides indirect evidence that CD8+ responses were occurring.  
It is also noteworthy that only one dose of vaccine was given and multiple doses of non-living 
vaccines are often required to stimulate robust immune responses (385). 
 
The detection of antigen-specific T cells in blood using multimers (dimers, tetramers, 
pentamers, and dextramers) can be unpredictable.  The multimer used for staining  is composed 
of a fluorescent group, such as phycoerythrin conjugated to 2-10 MHC receptors loaded with 
the peptide of interest such as SIINFEKL to bind to the cognate TCR of OVA specific CTLs. 
While each individual interaction between MHC and TCR is weak, the cooperative binding 
between multiple TCRs and the multimer allows for a sufficiently strong interaction for cell 
staining (386).  The numbers of cells detected is often low, particularly when the vaccine used 
is peptide or protein based.  While live viral vaccines can result in up to 50 % of CD8+ T cells 
being antigen-specific (387), OVA tumour vaccines in mice stimulate around 5 % antigen-
specific CD8+ T cells (388). 
 
The lack of detectable antigen-specific CD8+ T cells may therefore be due to assay sensitivity 
combined with OVA being a weak antigen (389). This data is consistent with in vitro IFN-γ 
204 
 
and IL-2 cytokine release data earlier in this chapter (Section 4.3.3). Therefore, the use of 
DMXAA as an adjuvant to improve immune stimulation and polarisation towards a Th1 
response is not recommended for formulations containing PEI. For future studies, the addition 
of a TLR agonist, such as CpG may allow for a more robust CD8+ T cell response (333). 
Additionally, the use of a TLR agonist may be more likely to stimulate a synergistic response, 
as STING activation is independent of various TLR signalling pathways (349).  
 
As the observed CD8+ T cell response was weak, the improvement of median survival may 
have been augmented by an antibody response leading to ADCC as a part of a mixed Th1/Th2 
response (Figure 4.3.15). As PEI possesses alum-like adjuvant activity, the production of IgG 
in response to immunisation with PEI was noted by Sheppard et al. (333). Therefore, the 
delivery of OVA in conjunction with PEI is likely to have stimulated the production of anti-
OVA antibodies leading to the opsonisation of B16.OVA cells. Opsonised cells are then 
targeted for cytotoxic activity mediated by NKT cells (390). 
 
Interestingly, a similar experiment was carried out by Lee et al. where sub-micron sized PEI 
hydrogels were utilised to deliver cGAMP, an endogenous STING agonist in mice that then 
exhibited increased titres of anti-OVA IgG antibodies and IFN-β transcription in vivo. In their 
experiment a small synergistic effect between PEI hydrogels and cGAMP delivery was noted, 
which is not consistent with the observations of this experiment as DMXAA and PEI showed 
no additive activity. The likely explanation for this discrepancy is due to the PEI hydrogel was 
formed via conjugation of PEI to hyaluronic acid in their experiment. As the presence of free 
PEI chains is important to the activity of PEI (308) this conjugation may decrease the effect of 
PEI, allowing the effect of cGAMP to be detected as a synergistic effect. Alternatively, as their 
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experiment did not include a tumour model, the increase in anti-OVA antibodies and IFN-β 
may have been a clinically irrelevant effect. 
 
DMXAA also has non-T cell mediated effects, such as vascular disruption due to STING 
activation in macrophages (336) or endothelial cells (337). While the exact mechanism of 
vascular disruption is unknown, TNF-α mediated increase in tumour vasculature permeability 
leads to reduced tumour blood flow and haemorrhagic necrosis (391). However, it is important 
to note this unspecific action of DMXAA is unlikely to explain efficacy, as DMXAA + PEI + 
CHAN liposomes without antigen did not increase survival (Figure 4.3.13), suggesting the 
immune effects were more important in this experiment. 
 
A stronger conclusion for the mechanism of action may be drawn through additional 
experiments. Firstly, the use of STING knockout mice would provide strong evidence that the 
anti-tumour properties of PEI are attributable to STING. Secondly, as ADCC is likely 
occurring, selective depletion of NK cells via i.p. administration of anti-NK1.1 antibodies 
(392), or B cells via anti-CD20 antibodies (393) would provide strong evidence for ADCC 





Figure 4.3.15: Diagram demonstrating the potential immune responses in response to 
immunisation by modified liposomes. The effects of the formulation are mediated by the alum-
like effects of PEI resulting in an antibody response (lower left), as well as the CTL response 
(lower right). Where PEI is not present, the DMXAA causes vascular disruption via 
macrophage or endothelial cell activation.   
Additionally, as the polarisation of the immune response has not been measured in this 
experiment, measurement of the IgG1:IgG2a ratio would be valuable in determining the 
polarity of the immune response. These mechanistic studies would require a move away from 
the tumour therapy model into immunogenicity studies involving multiple injections of vaccine 
into healthy mice, which could potentially then be challenged with tumour (prophylactic 
model).  These studies could be used to examine not just antibody but also cellular responses 
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in more detail. However, it is important to note both Th1 and Th2 polarisation is capable of 
generating antibodies, while the former may also stimulate CD8+ T cell responses as seen with 
previous experiments with Quil A and CpG (394). Therefore, the search for a suitable Th1 
polarising adjuvant may further improve the efficacy of this formulation through an antibody 
and cell-mediated response. The inclusion of a Th1 adjuvant formulation as a control, such as 
monophosphoryl lipid A (395), in future experiments would allow for a comparison to a known 
CD8+ T cell response. Additionally, the stimulation of a strong CD8+ T cell response would aid 




PEI + CHAN modified liposomes were utilised as a vaccine delivery system as it was theorised 
that if the liposomes were capable of stimulating an immune response in vitro, this could  
translate to improved survival in an in vivo model. The in vitro DC stimulation and T cell 
proliferation assays demonstrated the modified liposomes were capable of activating DCs and 
subsequently, the proliferation of OVA specific OT-I T cells. Furthermore, PEI + CHAN 
liposomes demonstrated a statistically significant improvement of survival in an in vivo murine 
melanoma model. However, the original aim of the thesis must also be considered as it was 
hypothesised that a strong Th1 response could be generated by circumventing cross-
presentation by the cytoplasmic delivery of protein by PEI. 
 
Cytokine secretion in vitro and dextramer staining in vivo were unable to detect a CTL response 
with the formulation, possibly due to insufficient Th1 polarisation due to the activity of PEI. 
Therefore, a mixed Th1/Th2 response with ADCC via a humoral response in conjunction with 




Despite these results, it must be noted that PEI is capable of improving cross-presentation (274, 
315), thus the original intention of this thesis may be achieved in the future. However, an 





Chapter 5 : Conclusions and future 
directions 
 
5.1 General summary 
 
The overall aim of the thesis was to produce functionalised nanoparticles for pH sensitive 
delivery of DOX or improved cytoplasmic delivery of vaccines. To achieve this a pH sensitive 
polymer, PDMS-b-PDMAEMA was utilised to produce polymeric nanoparticles, while PEI 
and cyclodextrin ion channel modified liposomes were developed for cytoplasmic delivery. 
 
The first aim of this thesis was to evaluate PDMS-b-PDMAEMA as a potential pH responsive 
nanocarrier. DOX loaded PDMS-b-PDMAEMA micelles were produced and evaluated for pH 
sensitive release so that acid triggered release at the tumour bed could occur. Ex vivo release at 
pH 5.5 and 6.5 was not associated with improved cytotoxicity of DOX loaded formulations in 
comparison to pH 7.4 controls suggesting release at the tumour bed was unlikely. However, as 
the highly acidic endosomal conditions (as low as pH 4.5) were sufficient for DOX release the 
pH sensitivity of the formulation was demonstrated. Despite these initial positive results, 
further examination of this formulation was halted due to the micellar nature of the formulation 
limiting its use as a vaccine carrier. 
 
PEI + CHAN modified liposomes were hypothesised to stimulate improved cytotoxic CD8+ 
immune responses by improving antigen processing as the cytoplasmic delivery of antigen is 
associated with increased cross-presentation (188). Initial in vitro release in simulated 
endosomal acidic conditions was difficult to determine due to fluorescence quenching and 
antiquenching of FITC-OVA and DOX. Therefore, a fluorescence-free DLS assay was 
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validated and a link between PEI + CHAN modification and acid specific lysis was observed. 
Following cell-free experiments, in vitro uptake with murine BMDCs demonstrated improved 
cytoplasmic delivery with PEI + CHAN liposomes, which was also associated with increased 
BMDC activation and T cell proliferation. The in vitro results were validated with an in vivo 
melanoma experiment where PEI + CHAN liposomes with and without DMXAA demonstrated 
an improvement in median survival times. Interestingly, the mechanistic studies with the 
vaccine support the hypothesis that the Th2 polarising properties of PEI were impacting on the 
immunostimulatory actions of DMXAA attenuating the anti-cancer CTL response. 
 
5.2 Future directions: Delivery of chemotherapies by nanoparticles 
 
A common theme during the review of nanoparticle delivery systems in Section 1.2.1 was that 
functionalised nanoparticles have the capacity to improve therapies via tumour specific 
delivery. Even though much focus has been placed on the development of nanoparticle delivery 
systems, current therapies (such as Doxil) do not improve efficacy as only the adverse effects 
are minimised (396). The lack of improvement in efficacy of nanoparticle delivery systems 
may be explained by a recent meta-analysis by Wilhelm et al. (397) that revealed only 0.6% of 
the administered intravenous dose of passively targeted nanoparticles reaches the tumour, 
which was increased to 0.9% for actively targeted formulations. While this result may be 
alarming, Lammers et al. (398) emphasises these therapies remain clinically successful as the 
reduction of adverse effects allows for additional therapies to be administered to improve 
patient outcomes.  
 
One factor that was not identified by Wilhelm et al. is the development of treatment-resistant 
tumours as a result of the upregulation of efflux transporters. Resistant tumours are likely to 
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require higher dose of drugs which could be mitigated by improved cytoplasmic delivery (329), 
for example by the PDMAEMA (399) or PEI (275) based formulations in this thesis. This 
strategy is especially interesting for PDMAEMA which, although it was not triggered by 
extracellular pH, was triggered by endosomal pH. 
 
Regardless of the level of triggered release, an important finding reported by Wilhelm et al. is 
that active targeting improves the delivery of nanoparticles at the tumour, thus the formulations 
presented in this thesis may benefit from the addition of targeting ligands. However, this 
exposes a potential weakness in PEI + CHAN as the formulation is complex and further 
additions may destabilise the liposomal membrane, similar to the over-functionalised hybrid 
nanoparticles reported by Wu et al. (49) (Section 1.2.2). Another option would be to utilise the 
hydrophobic cavity of the channels as an anchor for targeting ligands linked to a guest 
molecule, such as amantadine. The major issue with this strategy is the release of amantadine 
from the channels was observed to be rapid (within 12 h, Section 2.10.3), thus the weak 
individual interactions may be consolidated with a multimeric amantadine linker (Figure 5.2.1). 
Similar to the anti-MHC dextramers used in this thesis (Section 4.3.11), multiple interactions 
between the targeting ligand and channels may allow for long lasting modification of 
liposomes. Additionally, the flexibility of the linker may be improved with the incorporation 
of a streptavidin group, allowing any biotin modified targeting antibody to be easily conjugated 





Figure 5.2.1: Simplified example of a multimeric amantadine linker (dimer pictured). 
As PDMS-b-PDMAEMA micelles do not require additional components for cytoplasmic 
release it is a more suitable formulation for the addition of active targeting ligands. However, 
an important challenge remains for PDMS-b-PDMAEMA as its micellar morphology limits the 
compatibility of actives due to the lack of an aqueous compartment. Discher’s theory (267) 
states the hydrophilic fraction dictates the morphology of polymeric nanoparticles, and an 
increase in length of the hydrophilic chain (PDMAEMA) is required to form vesicles (Section 
2.7.1.1). Although this strategy was attempted by Car et al. it did not lead to a change in 
morphology (2), and the issue was solved by Yildirim et al. (400) with a polymer where PDMS 
was substituted with ((tetrahydro-2H-pyran-2-yl)oxy)ethyl methacrylate (THP-HEMA). THP-
HEMA-b-PDMAEMA produced polymersomes that collapsed into micelles in low pH 
conditions and enhanced release was demonstrated by confocal microscopy. Due to this 
discovery, it is recommended that further development of PDMS-b-PDMAEMA be suspended 




5.3 Future directions: Therapeutic cancer vaccines 
 
The efficacy of cancer vaccines is concerning, as the only clinically available cancer vaccine, 
Sipuleucel-T (Provenge), results in very modest responses in patients (extension of 4.1 months 
in median survival) (173). Furthermore, the article “Therapeutic cancer vaccines: are we there 
yet?” by Klebanoff et al. (1) has been cited earlier in this thesis to demonstrate the low efficacy 
of current cancer vaccines where an overall response rate of 3.6% was reported. Since the 
publication of this paper, no further cancer vaccines have been approved and Stage III clinical 
trials, such as CIMAvax-EGF also resulted in only modest improvements in survival (12.43 
months versus 9.43 months) (401). Despite the low response rate, Klebanoff et al. remained 
optimistic in their report noting the large strides in immunotherapies, such as the introduction 
of checkpoint blockade inhibitors in clinical settings. Additionally, non-vaccine 
immunotherapies such as CAR T cell therapy have since further demonstrated the potential the 
immune system has in combating cancer (Section 1.3.7.2). The current lack of efficacy only 
reflects our limited understanding of the immune system (402), and the development of cancer 
vaccines remains important due to the astronomical costs of cellular therapies. 
 
One important question must still be considered, do vaccines present a viable treatment option? 
As a monotherapy, vaccines are unlikely to be successful as the extension in median survival 
time in this thesis (24 days in OVA + CHAN + PEI immunised mice versus 20 days in untreated 
mice) is similar to the modest improvements with Sipuleucel-T. This may be due to the tumour 
antigen-specific T cells are in an exhausted state due to unfavourable conditions of the TME, 
resulting in poor efficacy of cancer vaccines (Section 1.3.5.1). Therefore, vaccines alone are 
unlikely to yield effective cures, but may be effective in conjunction with other therapies, such 
as checkpoint blockade inhibitors (Section 1.3.7.1). Additionally, current small molecule 
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chemotherapies may continue to play a role with cancer vaccines.  The combination of these 
therapies may be beneficial as cancer vaccines may improve the sensitivity of cancer against 
chemotherapies, such as vaccination against TRP-2 on cancer cells (403), while 
chemotherapies are capable of changing the tumour microenvironment to be more favourable 
for anti-cancer immune responses due to the release of danger signals and antigen which 
accompanies immunogenic death of tumour cells (404). 
 
Turning now to the improvements that may be made to PEI + CHAN modified liposomes, the 
innate Th2 polarising activity of PEI was an issue due to the mixed Th1/Th2 response. Thus, a 
possible course of action to improve the Th1 immune response is to substitute another proton 
sponge, such as histidine modified polymers (405). However, as the adjuvant action of PEI is 
hypothesised to occur by DNA release as a consequence of cellular damage (333), Th2 
polarisation may be a trait of all proton sponges. Therefore, the selection of a Th1 polarising 
adjuvant such as CpG (333) may be a more practical solution in improving the vaccine in 
comparison to screening for alternative proton sponges. 
 
Another improvement that may be considered for PEI + CHAN liposomes is the removal of 
channels from the formulation. The main advantage of this is the reduction in complexity which 
improves the ease of manufacturing, and may allow alternative functionalisation such as the 
addition of targeting ligands such as anti-DEC205 for enhanced DC uptake (183). The loss of 
channels is unlikely to affect the stimulation of a CTL immune response as the median survival 





Lastly, PDMS-b-PDMAEMA micelles were incompatible with the use of the model protein 
antigen OVA. The lack of an aqueous interior in PDMS-b-PDMAEMA micelles may explain 
its incompatibility with OVA, as physical loading within the core is influenced by the strength 
of the interactions between the polymer and protein. For example, complementary acid-base 
interactions demonstrated an improvement in loading (406), while PDMS polymer does not 
have such favourable interactions with OVA. Furthermore, the electrostatic attraction between 
positively charged PDMAEMA in the corona and negatively charged OVA may result in 
vesicle aggregation and instability (281). As this interaction and instability is theoretical, 
further experiments will be required to assess the suitability of PDMAEMA based 
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Chapter 7 : Appendix 
 
A. Preparation of solutions 
 
1. Roswell Park Memorial Institute (RPMI) cell culture 
medium and supplementation 
 
RPMI medium sachet (Sigma-Aldrich, USA) 
4.5g D-glucose (Sigma-Aldrich, USA) 
1.5g Sodium bicarbonate (Sigma-Aldrich, USA) 
900mL MilliQ water 
 
RPMI powder, D-glucose, and sodium bicarbonate was added to a 1L volumetric flask with a 
magnetic stir bar. 800mL of MilliQ water was added to the flask, and the remaining 100mL 
was used to rinse the sachet and the sides of the flask. The medium was stirred until complete 
dissolution (approximately 15 minutes). Prepared medium was filtered with a 0.22µm vacuum 
filter, and stored at 4°C prior to supplementation with the following solutions: 
 
100mL Foetal calf serum (Sigma-Aldrich, USA) 
10mL 100x Penicillin-streptomycin (Thermo Fisher, USA) 
10mL 100x Glutamax (Thermo Fisher, USA) 
10mL 100x Sodium pyruvate (Thermo Fisher, USA) 
1mL 1000x 2-mercaptoethanol (Thermo Fisher, USA) 
 
Supplemented medium was stored at 4°C in the dark. 
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2. Iscove's Modified Dulbecco's Medium (IMDM) cell culture 
medium and supplementation 
 
IMDM medium sachet (Thermo Fisher, USA) 
3.024g Sodium bicarbonate (Sigma-Aldrich, USA) 
900mL MilliQ water 
 
IMDM powder and sodium bicarbonate was added to a 1L volumetric flask with a magnetic 
stir bar. 800mL of MilliQ water was added to the flask, and the remaining 100mL was used to 
rinse the sachet and the sides of the flask. The medium was stirred until complete dissolution 
(approximately 15 minutes). Prepared medium was filtered with a 0.22µm vacuum filter, and 
stored at 4°C prior to supplementation with the following solutions: 
 
50mL Foetal calf serum (Sigma-Aldrich, USA) 
10mL 100x Penicillin-streptomycin (Thermo Fisher, USA) 
10mL 100x Glutamax (Thermo Fisher, USA) 
1mL 1000x 2-mercaptoethanol (Thermo Fisher, USA) 
 
Supplemented medium was stored at 4°C in the dark. 
 
3. RBC lysis buffer 
 
Part A 
8.56g Ammonium chloride 




Ammonium chloride was added to MilliQ water in a 1L bottle and stirred until complete 
dissolution. The solution was stored at room temperature. 
 
Part B 
20.6g Tris.HCl  
1L MilliQ water 
 
Tris.HCl was added to 950mL MilliQ water and stirred until complete dissolution. The pH of 
this solution was fixed to pH 7.85. The solution was stored at room temperature. 
 
Immediately prior to use, 9 parts of Part A was added to 1 part of Part B, and the resulting 
solution was filtered through a 0.22µm syringe filter. 
 
4. PEI solution 
 
50mL MilliQ water 
50mg PEI (25kDa, linear) 
 
MilliQ water and PEI were added to a 50mL borosilicate glass bottle, and the PEI was dispersed 
by shaking. The bottle was then placed in a bath sonicator set to 60°C, and was sonicated for 
approximately 1-2 hours, until the PEI was fully solubilised. The bottle was then removed and 
allowed to cool at room temperature for 2 hours, where a precipitate of excess PEI was seen. 
The solution was then filtered with a 0.22µm syringe filter and stored in 10mL aliquots at -








50mL carbonate buffer (220mmol, pH 9.5) 
 
FITC and OVA were dispersed within 50mL of carbonate buffer in a beaker with a stir bar. The 
solution was allowed to stir in the dark at 4°C overnight. Excess FITC was removed by pressure 
ultrafiltration with a 10kDa membrane, while the ultrafiltration cell was protected from heat 
and light. The solution was washed with excess MilliQ water and the ultrafiltration was 
repeated until the filtrate demonstrated no FITC fluorescence. The resulting FITC-OVA 
solution was dried by lyophilisation, and stored at 4°C, protected from light. 
 
C. 1H NMR spectra 
 
 





Figure 5.3.2: 1H NMR spectrum for compound (2) in DMSO. 
 
Figure 5.3.3: 1H NMR spectrum for compound (3) in DMSO. 
 
D. Representative standard curves 
 
 
Figure 5.3.4: Absorbance standard curve of DOX in PBS at pH 7.4, data are n=2 ± SD. 



















Figure 5.3.5: Fluorescence standard curve of DOX in PBS at pH 7.4, data are 
n=2 ± SD. 
  
Figure 5.3.6: Fluorescence standard curve of DOX + PEI in PBS at pH 7.4, data 
are n=2 ± SD. 








































Figure 5.3.7: Fluorescence standard curve of DOX + PEI in PBS at pH 4.5, data 
are n=2 ± SD. 
 
 
Figure 5.3.8: Fluorescence standard curve of DOX in PBS at pH 4.5, data are 
n=2 ± SD. 






































Figure 5.3.9: Standard curve of FITC-OVA + PEI in PBS at pH 4.5, data are 
n=2 ± SD. 
 
Figure 5.3.10: Standard curve of FITC-OVA in PBS at pH 7.4, data are n=2 ± 
SD. 






































Figure 5.3.11: Standard curve of FITC-OVA + PEI in PBS at pH 7.4, data are 
n=2 ± SD. 
 
Figure 5.3.12 Standard curve of FITC-OVA in PBS at pH 7.4, data are n=2 ± SD. 
 







































Figure 5.3.13: Standard curve of DMXAA in PBS, data are n=3 ± SD. 
 
Figure 5.3.14: Standard curve of DMXAA + PEI in PBS, data are n=3 ± SD. 
 
E. Calculation of channels per liposome 
 
Assuming 200 nm diameter spherical liposomes, where the average thickness of the membrane 
is 4 nm and the average area per DPPC molecule is 0.0616 nm2, which has been previously 
reported (407). Additionally, the length of the alkyne tail of the channels is expected to be 











































similar to that of nonane (9 carbons long, similar to the alkyne tail), which was calculated to be 
1 nm long (408). 
 
Calculating the surface area of the liposome as both the inner and outer leaflets (radius of 98 
nm and 100 nm respectively) results in a total surface area of 2.42 × 105 nm2. Assuming that 
the tails of the channels have spread into the membrane, the total area which may be covered 
by each channel is 28 nm2 (assuming maximum spread and taking the 1.5nm diameter of the 
cyclodextrin into consideration). Therefore, to achieve coverage of both leaflets of the 
liposome, 8643 channels are required (2.42 × 105 nm2 / 28 nm2). The number of channels can 
then be compared to the number of DPPC molecules within the liposome, which is 
approximately 4 × 106 molecules (2.42 × 105 nm2 / 0.0616 nm2). 8643 channels in comparison 
to 4 × 106 DPPC molecules is 0.22%. 
 
